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The current thesis was guided by three principal research objectives.  The first 
objective was to identify target genes responsive to indispensable amino acid 
deprivation with the goal of identifying potential components of the Integrated Stress 
Response as well as possibly identifying some genes that are differentially expressed 
in response to amino acid deprivation but not other stress conditions. The second 
objective was to determine whether the previously identified targets and eIF2α-kinase-
mediated responses would be induced in animals fed a diet that was marginal in 
essential amino acid composition. The third objective was to elucidate the role of 
elevated 4E-BP1 expression in regulating translation initiation during nutrient 
deficiency. 
To assess the role of amino acid deprivation on eIF2α phosphorylation and 
downstream transcriptional responses, we conducted additional microarray studies for 
leucine-depleted HepG2/C3A cells and compared these with results for cysteine-
depleted cells. The comparison of cells exposed to deficiencies of two different amino 
acids was done to facilitate selection of genes whose expression is more likely to be 
altered specifically in response to GCN2-induced eIF2α phosphorylation. In addition, 
we assessed the effects of both cysteine and leucine deprivation on the 
phosphorylation of eIF2α and on the protein expression patterns of ATF4 and other 
ISR-related proteins.  We have compiled a list of 120 genes whose expression was 
   
differentially expressed in HepG2/C3A cells cultured in either cysteine- or leucine-
deficient medium, and this list contains many of the genes known to respond to eIF2α 
kinase activation and to be components of the ISR. Clearly, amino acid deficiency, 
including cysteine deficiency in the absence of oxidative stress, induces eIF2α 
phosphorylation, presumably by activation of GCN2, leading to changes in expression 
of ATF4 and stress-related target genes. 
To answer whether eIF2α-kinase–mediated responses would be induced in 
animals fed a sulfur amino acid (SAA) deficient diet not as imbalanced as one in 
which a single essential amino acid is totally absent, we fed rats soy protein-based 
diets that were either adequate or limiting in SAA. Rats fed a SAA-deficient diet grew 
more slowly than rats fed the control diet. Analysis of liver from rats fed these diets 
for 7 days showed that the SAA-deficient rats had higher levels of eIF2α 
phosphorylation and higher levels of activating transcription factor (ATF) 4, ATF3, 
asparagine synthetase, solute carrier 7A11, cysteinyl-tRNA synthetase, and 
cystathionine γ-lyase. On the other hand, components of the integrated stress response 
(ISR) known to promote apoptosis or translational recovery were not induced. These 
results indicate that rats fed the SAA-deficient diet had a prolonged activation of an 
eIF2α kinase that leads to upregulation of adaptive components of the ISR. 
To assess the role of elevated 4E-BP1 expression in regulating translation 
initiation during nutrient deficiency, we fed rats various protein/amino acid-deficient 
diets with a varying degree of deficiency and achieved amino acid deficiency and 
reduction of growth. In these experiments we consistently observed a significant 
induction of total 4E-BP1 protein levels that did not parallel a reduction in 4E-BP1 
phosphorylation and was independent of energy restriction or feed intake. Further, the 
induction of total 4E-BP1 appeared independent of eIF2α phosphorylation.
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CHAPTER 1 
AN INTRODUCTION 
 
 Cellular growth repression can mediate positive health outcomes and 
ameliorate the manifestation, while decelerating the progression, of chronic diseases.  
Protein synthesis and growth regulation are known to be regulated by essential amino 
acids through a variety of pathways.  The lack of amino acids leads to suppression of 
global protein synthesis.  There are two major systems that sense and respond to 
amino acid limitation by reducing protein synthesis, the GCN2 system and the mTOR 
system. 
 Amino acid availability is sensed via GCN2 (General Control 
Nonderepressible kinase 2, also known as eukaryotic Initiation Factor 2α kinase 4), 
which functions by sensing the increase of non-aminoacylated tRNAs that occurs 
when essential amino acids are limiting.  Sensing of “uncharged” tRNAs activates 
GCN2 which phosphorylates eIF2α which in turn leads to reduction of global 
translation due to inhibition of ternary complex formation and subsequent suppression 
of translation initiation. Another way translation initiation is regulated is through the 
action of eukaryotic Initiation Factor 4E – Binding Protein 1 (4E-BP1).  When amino 
acids, glucose or energy substrates are limiting, there is less phosphorylation of 4E-
BP1, rendering the protein available to competitively bind to eIF4E displacing eIF4G 
and subsequently suppressing translation initiation.  
 In addition to reduction of global translation, the eIF2α phosphorylation 
response in particular regulates expression of a variety of genes that are involved in 
cellular repair and defense. For this reason, the response is considered beneficial.  
Other stresses can activate other eIF2α kinases that in turn phosphorylate eIF2α 
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leading to outcomes /responses that are similar to those induced by amino acid 
deprivation (Figure 1.1).  The downstream response of eIF2α phosphorylation is 
termed the Integrated Stress Response (ISR) and is associated with cell survival and 
stress resistance since it leads to the selective upregulation of genes that promote 
adaptation to stress and survival.   
 Thus, a modest restriction of protein or essential amino acid intake may, via 
the ISR pathway activation, extend a variety of beneficial physiological effects, such 
as slowing the aging process and/or preventing age-related diseases (e.g., coronary 
heart disease, cancer, and type II diabetes mellitus) (Salminen and Kaarniranta, 2010). 
Other beneficial effects could include the promotion of hormesis prior to a known 
stress (e.g., treatment with a toxic drug); inhibition of osteoclast formation and activity 
and thus suppression of bone resorption (osteoporosis); and suppression of 
hypertrophic/hyperplastic conditions (e.g., cancer) (Calabrese et al., 2010; Rattan SI, 
2008).  Consequently, understanding the relationship between amino acid intake and 
the regulation of the ISR could reveal health strategies for manipulating ISR in a way 
that would improve health outcomes pertinent to the aforementioned health conditions. 
 3
 
Figure 1.1.  The diagram shows a potential link between eIF2α phosphorylation and 
the levels of 4E-BP. A potential link between Activating Transcription Factor 4 
(ATF4) and the levels of 4E-BP is also illustrated.  4E-BP mRNA levels have been 
shown increased when eIF2α is phosphorylated (Lu et al., 2004) suggesting a potential 
link between the ISR and the induction of 4E-BP.  Another potential link depicted in 
the diagram is the one between eIF2α phosphorylation and the mammalian Target of 
Rapamycin (mTOR) pathway. Finally, as seen in the diagram, the ISR is eIF2α 
phosphorylation-dependent but not all components of the ISR are necessarily ATF4 or 
Amino Acid Response Elements (AARE)-dependent. 1 
 
                                                            
1 Phosphoryation of eIF2α leads to the global reduction of translation of most mRNAs. However, the 
translation of a few specific mRNAs with inhibiting uORFs or other structural features is actually 
increased.  ATF4 is the best-understood example. 
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Overall, exposure to stress (as long as severe cell injury does not occur) has 
been considered a beneficial strategy in building resistance and tolerance towards 
more severe stressful conditions that may arise in the future (preconditioning) (Lu et 
al., 2004; Harding et al., 2000).   Pathways, such as the ISR, that couple diverse 
stressful conditions to a common signaling event (such as eIF2α phosphorylation) 
leading to a common downstream program are likely candidates for playing a role in 
preconditioning.  This postulation holding a key role for eIF2α and its phosphorylation 
has been supported by a variety of in vitro (Lu et al., 2004; Harding et al., 2000) and 
in vivo (Raffaghello et al., 2008) studies.  The evidence that subjecting an organism to 
a mild stress facilitates the organism’s ability to subsequently withstand a second more 
severe or different stress has important clinical implications.  For example, short-term 
starvation has been associated with protection of mice against a high dose of the 
chemotherapy drug/pro-oxidant cyclophosphamide (Raffaghello et al., 2008). 
Induction of the ISR may be particularly useful in circumstances where acute tissue 
injury by Reactive Oxygen Species (ROS) can be anticipated, such as in organ 
procurement for transplantation and vascular surgery, and in circumstances where 
potentially cytotoxic drugs are administered. 
Caloric restriction (or dietary restriction), defined as reduced dietary intake 
without malnutrition, has been proposed to be a mild stress with hormetic effects 
(Masoro EJ, 2007; Masoro EJ, 1998).  Dietary restriction has been long shown to 
drastically improve health parameters and increase longevity in a variety of species 
including worms (Caenorhabditis elegans), flies (Drosophila melanogaster), yeast 
(Saccharomyces cerevisiae), rats (McCay et al., 1939; McCay et al., 1935) and mice 
(McCarty et al., 2008; Martin et al., 2007).  Although the data for humans are not 
direct it is likely that the basic biological mechanisms via which caloric restriction 
exerts its beneficial effects are conserved in humans.  Even though the exact 
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mechanism via which caloric restriction induces health benefits is not clear it appears 
that in general, when caloric restriction is applied, cells turn to a maintenance/repair 
phase as opposed to a growth one.  Whether the benefit of caloric restriction should be 
attributed to the restriction of energy (calories) per se or to the restriction of protein, 
which often occurs when caloric restriction regiments are applied, is not fully 
resolved.  Some studies have tried to disentangle these two arms and it seems that at 
least part of the beneficial response of caloric restriction is due to protein restriction 
(Lee et al., 2008; Yamaguchi et al., 2008; Sanz et al., 2006; Zimmerman et al., 2003; 
Ooka et al., 1988; De Marte and Enesco, 1986).  The evidence for a role of amino acid 
or protein deficiency in extending lifespan in mice and fruit flies suggest that GCN2 
plays a role in this process by mediating eIF2α phosphorylation, leading both to 
depression of global protein synthesis/growth and to activation of the downstream 
ISR.   
The long-term overall objective of this work was to increase understanding of 
the protein and essential amino acid contribution to the regulation of protein 
translation and the induction of the ISR by investigating cellular and animal responses 
to indispensable amino acid deficiency.  In this context we aimed to assess the effect 
of dietary protein and essential amino acid adequacy on induction of the ISR and the 
expression/regulation of proteins involved in translation inhibition in the liver. In 
addition, we investigated whether dietary restriction has a similar or different effect 
than protein/essential amino acid restriction on the induction of the ISR and the 
expression/regulation of proteins involved in translation inhibition in the liver of rats. 
Additionally, we attempted to determine whether eIF2α phosphorylation by GCN2 is 
essential for the induction of 4E-BP1. Further, we investigated the time-course for the 
induction of the ISR and the expression/regulation of proteins involved in translation 
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inhibition in the liver of rats when they are switched from an adequate diet to one 
limiting in protein and/or essential amino acids.  
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CHAPTER 2 
LITERATURE REVIEW 
 
Significance of indispensable amino acids in optimizing health and survival  
 A question fundamental in biology is how cells sense and respond to changes 
in their nutrient supply.  The ability to synthesize protein and other nitrogenous 
compounds is essential for growth, maintenance, healing, and survival.  Of the 20 
common amino acids required for protein synthesis, nine are considered indispensable 
(Leu, Ile, Val, Lys, Thr, Trp, Phe, Met and His) for humans and rats, while cysteine 
and tyrosine are considered semi-indispensable because they can be synthesized if 
intake of their indispensable amino acid precursors (Met and Phe respectively) is 
adequate, via transulfuration and transamination reactions, respectively.  A continuous 
supply of all amino acids is necessary for protein synthesis to proceed at a maximal 
rate.  Insufficient intake of protein or of indispensable amino acids may occur in 
individuals with restricted dietary intakes due to choice, illness, or low caloric 
expenditure/intake as well as in individuals consuming diets consisting of foods that 
provide low amounts of protein or a protein mixture deficient in one or more 
indispensable amino acid.  Because excess amino acids are not stored in the body, 
tissues tend to respond quickly to amino acid limitation by reducing their amino 
acid/protein catabolism, slowing rates of protein synthesis, and upregulating amino 
acid transporters.  In general, scientific advisory committees (e.g., Institute of 
Medicine/National Academies; USDA) have recommended the intake of diets that 
provide protein and essential amino acids at levels well above the average requirement 
in order to provide a safety allowance for all age groups except infants for whom 
human milk is used as the standard.  On the other hand, intake of largely plant-based 
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diets has been associated with health in industrialized and industrializing populations, 
and these plant-based diets typically provide lower intakes of protein and essential 
amino acids (Milward and Jackson, 2003).  Although not fully explored, it is possible 
that some health benefits of plant-based diets may relate to the content and 
composition of proteins in these diets.  The consequences of marginal intakes of 
protein on overall health have not yet been fully assessed, but these could relate both 
to lower rates of protein synthesis and growth and to generation of a physiological 
state of increased stress-resistance.  
How mammalian cells respond to changes in the availability of essential amino 
acids has been a major interest of research in the past decade, particularly in the 
context of the regulation of nutrient sensing by the mammalian target of rapamycin 
(mTOR) pathway and of cellular sensing of essential amino acid levels by GCN2 
[general control nonderepressible 2, or eukaryotic initiation factor (eIF) 2 alpha kinase 
4].  Amino acids and energy are necessary for synthesis of proteins, which are needed 
for cells to grow and proliferate.  When fuels or amino acids become limiting, protein 
production needs to be carefully regulated, both in terms of total protein synthesis as 
well as which specific proteins are synthesized, so that cells can optimally utilize their 
limited resources to survive.  
A greater capacity of an organism to adapt to and cope with stress in order to 
defend homeostasis constitutes a critical advantage and can determine survival over 
death.  In this context, the study of stress response mechanisms is of great interest in 
terms of possible applications to health promotion and disease prevention or treatment.  
Nutrient deprivation and other situations of stress require a rapid response as an early 
line of defense against the stressful environment that ultimately allows organisms to 
adapt to their changing environment by controlling cell growth, proliferation, and 
optimize survival.  
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How amino acid availability regulates translation initiation  
 The regulation of protein synthesis in mammalian tissues has been 
demonstrated to occur largely at the translation initiation phase (i.e., at steps involved 
in the formation of a ribosome binding site/translation start site, rather than in the 
elongation phase).  Regulation occurs at two parts of the translation initiation process: 
(1) formation of a functional eIF4F complex at the 5′-cap and (2) formation of ternary 
complex (Met-tRNAiMet · eIF2 – GTP) needed to form the 43S pre-initiation complex 
containing the 40S ribosomal subunit (Wek et al., 2006; Tettweiler et al., 2005; 
Hinnebusch, 2000).   
The eIF4F complex comprises the 5′-cap-binding protein eIF4E that binds the 
m7GTP cap present at the 5′-end (cap structure) of the mature mRNA, the RNA 
helicase eIF4A, and the scaffolding protein eIF4G (Gabauer, 2004; Prévôt et al., 
2003).  This eIF4F complex recruits the 43S pre-initiation complex.  The 43S pre-
initiation complex is the result of the association of the ternary complex (Met-
tRNAiMet · eIF2 – GTP) with the 40S ribosomal subunit and a variety of other initiator 
factors (eIF1A, eIF3).  The recruitment of the 43S pre-initiation complex to eIF4F 
yields a translation-competent 48S complex, which begins to scan for the AUG start 
codon to initiate translation.  Stable binding of the 48S complex to the AUG codon 
triggers the joining of the 60S ribosomal subunit, which, along with the hydrolysis of 
eIF2-bound GTP and subsequent release of eIF2-GDP, forms the 80S complex (Figure 
2.1).  To begin another round of initiation, eIF2-GDP is recycled back to eIF2-GTP 
(eIF2-GTP regeneration) via a reaction catalyzed by eIF2B, the guanine nucleotide 
exchange factor for eIF2 (Kubica et al., 2006).  The ability of eIF4E to bind eIF4G to 
form a functional eIF4F complex has been shown to be regulated by the mTOR 
pathway (Avruch et al., 2009; Schmelzle, 2000), while the regeneration of eIF2-GTP 
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for the formation of ternary complex has been shown to be regulated by stress-
activated eIF2α kinases, including GCN2 (Wek et al., 2006; Holcik et al., 2005). 
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Figure 2.1.  Formation of the 43S pre-initiation complex and its regulation by 
phosphorylation of eIF2’s alpha subunit by an eIF2α kinase (e.g., GCN2). 
The mammalian target of rapamycin (mTOR) pathway regulates translation 
initiation through phosphorylation of eIF4E binding protein (4E-BP).  eIF4E-binding 
proteins (4E-BPs) are a family of three small (10-12 kDa) acidic proteins that act as 
repressors of translation initiation (Gingras et al., 1999).  The three members of the 
4E-BP family, 4E-BP1, 4E-BP2, and 4E-BP3, interact with eIF4E, the cap-binding 
component of the eIF4F complex, which recruits mRNA to the polysomes (Poulin et 
al., 1998).  eIF4E is present in rate-limiting amounts, so the binding of eIF4E by 4E-
BPs inhibits complex assembly and represses cap-dependent translation (Mader et al., 
1995).  The binding of eIF4E is reversible and is dependent on the phosphorylation 
state of 4E-BP.  Hypophosphorylated 4E-BP interacts with eIF4E whereas 
hyperphosphorylated 4E-BP does not (Gingras et al., 1999).  The three members of the 
4E-BP family are homologous to one another, with most striking homology found in 
the middle region of the protein which contains the eIF4E binding motif and the 
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residues that are phosphorylated.  Such redundancy in translational control mechanism 
emphasizes the importance of eIF4E binding hence its need for regulation (Poulin et 
al., 1998) (Figure 2.2).  
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Figure 2.2.  Formation of the 5′-cap binding complex eIF4F (eIF4E, 4G, 4A complex) 
and its regulation by association of eIF4E with 4E-BP. 
Phosphorylation of 4E-BP1 by mTOR complex 1 (mTORC1) is positively regulated 
by insulin and other growth factors, availability of fuels, and the presence of amino 
acids, especially leucine (Choo and Blenis, 2009; Schmelzle and Hall, 2000).  
Mechanisms for insulin and growth factor signaling and sensing of cellular energy 
status have been at least partially elucidated but the mechanism for amino acid or 
leucine sensing is still unknown (Avruch et al., 2009).  The hyperphosphorylation of 
4E-BP by mTORC1 blocks the binding protein’s ability to bind eIF4E and allows 
eIF4E to associate with eIF4G to promote formation of functional eIF4F complex.  In 
contrast, low energy or low amino acid status in cells or a lack of insulin or IGF-1 can 
reduce the activation state of mTORC1.  Inactive mTORC1 is unable to 
hyperphosphorylate its downstream target 4E-BP, making 4E-BP available to bind to 
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eIF4E and displace eIF4G.  With the eIF4F complex unable to be assembled, 
recruitment of the 43S complex and subsequent translation initiation are inhibited 
(Tettweiler et al., 2005; Gingras et al., 1999; Haghighat et al., 1995; Mader et al., 
1995).   
 
The Integrated Stress Response (ISR) pathway  
 The eIF2α kinases regulate eIF2-GTP availability for ternary complex 
formation, and hence 43S pre-initiation complex formation, by phosphorylation of the 
Ser51 residue of the alpha subunit of the eIF2 heterotrimeric complex (i.e., eIF2α).  
Although there are four mammalian eIF2α kinases, with each responding to different 
types of cellular stress, it is only GCN2 that specifically responds to a lack of amino 
acids (Figure 2.3).  In contrast to the mTORC1 pathway, which appears to show 
specificity for leucine and secondarily other branched-chain amino acids in terms of 
its activation by the presence of amino acids, GCN2 responds to deprivation of any 
essential amino acid (Avruch et al., 2009) (Figure 2.3).  An increase in the abundance 
of non-aminoacylated tRNAs (“uncharged” tRNAs) is sensed by a histidyl-tRNA 
synthetase homologous domain of GCN2 (Wek et al., 2006; Padyana et al., 2005; Hao 
et al., 2005; Hinnebusch, 2000; Wek et al., 1995).   Binding of uncharged tRNAs to 
this domain activates the juxtaposed protein kinase (PK) domain of GCN2 rendering 
the PK domain component of GCN2 active and leading to subsequent phosphorylation 
of eIF2α (Padyana et al., 2005; Hao et al., 2005; Wek et al., 1995).  The 
phosphorylation of eIF2α reduces the dissociation rate of the eIF2 complex from 
eIF2B, thereby sequestering eIF2B (in fact, eIF2α-P binds eIF2B very tightly) and 
inhibiting its GDP-GTP exchange activity.  This results in less eIF2-GTP and 
consequently less formation of the ternary complex needed for 43S pre-initiation 
complex formation/translation initiation and ultimately suppression of global protein 
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synthesis (Guo and Cavener, 2007; Padyana et al., 2005; Hao et al., 2005; Gabauer 
and Hentze, 2004; Harding et al., 2000; Hinnebusch, 2000; Wek et al., 1995; Kimball 
et al., 1991; Wek et al., 1989) (Figure 2.3).  
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Figure 2.3.  Conceptual scheme presenting the sensing mechanisms for amino acids 
and their responses to amino acid availability and limitation.  Dashed arrows indicate 
lower vs. solid arrows higher, activation of the pathway.   
Although both mechanisms of regulation of translation initiation regulate the 
rate of translation initiation (for general/global translation), eIF2α phosphorylation 
also, somewhat paradoxically, increases the translation of a subset of mRNAs, most 
notably of activating transcription factor 4 (ATF4).  The presence of inhibitory up-
stream open reading frame (ORF) that overlaps the ATF4 ORF, promotes read-
through of the ATF4 translational start codon, thus preventing ATF4 translation under 
normal conditions in which ternary complex is abundant (Wek et al., 2006; Lu et al., 
2004a).  In amino acid deprivation or other stress conditions in which an eIF2α kinase  
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is activated and ternary complex formation is reduced, delayed initiation or re-
initiation (i.e., ribosomal scanning through the inhibitory up-stream ORF start codon) 
is favored so that initiation occurs at the ATF4 ORF start codon, therefore allowing 
ATF4 to be translated (Figures 2.4 & 2.5).   
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Figure 2.4.  Conceptual scheme of the amino acid deprivation response which leads to 
reduction of global protein synthesis and the selective upregulation of the ATF4 gene 
and its downstream targets. 
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Figure 2.5.  Model for ATF4 translational control by its leader sequences (Vattem and 
Wek, 2004).  The ATF4 mRNA is illustrated as a straight line that has uORFs 1 and 2 
which are presented as boxes.  The shading of the small ribosomal subunit indicates its 
association with eIF2-GTP bound Met-tRNAiMet.  After translation of the positive-
acting uORF1, ribosomes retain the capacity to resume translation initiation at a 
downstream ORF.  The basis for this re-initiation capacity is currently not clear.  In 
the related GCN4 translation mechanism, in yeast, the termination context of the 
analogous uORF1 is thought to facilitate the retention of the small ribosomal subunit 
with the GCN4 mRNA (Hinnebusch 2000, Hinnebusch 1997, Grant and Hinnebusch 
1994).  After translation of the ATF4 uORF1, the 40S ribosomal subunits are proposed 
to resume scanning in a 5′ to 3′ direction along the ATF4 transcript.  When eIF2-GTP 
bound Met-tRNAiMet is plentiful during nonstressed conditions, the small ribosomal 
subunits quickly acquire the eIF2 ternary complex and, coupled with the 60S 
ribosome, re-initiate translation at uORF2.  After translation of this inhibitory uORF2, 
ribosomes dissociate from the ATF4 mRNA, thereby reducing expression of the 
ATF4-coding region.  When cells are subjected to ER stress or to nutrient deprivation, 
the levels of eIF2 phosphorylation are enhanced leading to reduced eIF2-GTP levels.  
After translation of uORF1, there is an increased time required for reacquisition of 
eIF2-GTP coupled Met-tRNAiMet that allows a portion of the scanning 40S ribosomal 
subunits to scan through the negative-acting uORF2.  While scanning the mRNA-
leader region from beginning of uORF2 to the initiation codon of the ATF4-coding 
region, ribosomes reacquire the eIF2 ternary complex, facilitating translational 
expression of ATF4.  If uORF1 is mutated, ribosomes scanning from the 5′-end of the 
ATF4 mRNA will initiate translation at uORF2.  After translation of the inhibitory 
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Figure 2.5 (Continued)  uORF2, ribosomes dissociate from the ATF4 mRNA, thus 
lowering translation of the ATF4-coding region even when eIF2-GTP levels are 
reduced in response to cellular stress.  When the distance between uORF1 and uORF2 
is increased compared to WT, most ribosomes are competent for re-initiation before 
reaching uORF2, thereby reducing ATF4 translation independent of eIF2-GTP 
availability. (Figure and legend from Vattem and Wek, 2004.) 
ATF4 is a member of the ATF subfamily of the basic leucine zipper (bZIP) 
transcription factor super-family. ATF4 is involved in upregulation of expression of a 
subset of genes, including the ATF4 gene, at the transcriptional level.  ATF family 
members heterodimerize within the ATF family as well as with members of another 
bZIP subgroup, the CCAAT/enhancer-binding protein (C/EBP) family. Many of the 
genes known to be transcriptionally upregulated by amino acid deprivation or the 
eIF2α-P/ATF4-mediated stress response pathway, contain C/EBP-ATF composite 
sites that are also known as amino acid response elements (AAREs) or CCAAT-
enhancer binding protein-activating transcription factor response elements (CAREs) 
(Kilberg et al., 2009; Shan et al., 2009; Harding et al., 2000).  The ATF4 half-site 
within these composite sites is highly conserved, which is consistent with the central 
role of ATF4 in the transcriptional program that follows activation of an eIF2α kinase.  
The AARE sites have a 9bp core element (NTTNCATCA) but differ by several 
nucleotides among genes (Harding et al., 2003).  Genes that have been clearly 
established to contain a functional AARE and to be transcriptionally induced by the 
eIF2α-P/ATF4 pathway include those encoding several transcription factors [ATF4, 
ATF3, C/EBPβ, and CHOP (C/EBP-homologous protein)]; several members of the 
solute carrier (SLC) family including amino acid transporters [SNAT2 (sodium-
coupled neutral amino acid transporter 2 or SLC38A2); CAT1 (high affinity cationic 
amino acid transporter 1 or SLC7A1); and xCT (the transporter subunit of the cystine-
glutamate exchanger XC- or SLC7A11)]; an enzyme for amino acid biosynthesis 
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[ASNS (asparagine synthetase)]; and a putative protein kinase [TRIB3 (tribbles 
homolog 3)].   
 GCN2 is the only known eIF2α kinase in yeast.  Activation of GCN2 in yeast 
results in increased translation of GCN4, the functional counterpart to mammalian 
ATF4, and GCN4 acts to induce expression of an array of genes that encode amino 
acid biosynthetic enzymes (Hinnebusch, 2005).  Unlike yeast, mammalian cells are 
unable to synthesize a subset of amino acids, the so-termed essential or indispensable 
amino acids, and must obtain them from the environment.  Not surprisingly, in 
mammalian cells, ATF4 induces the expression of a somewhat different array of 
genes, which includes other transcriptional regulators, solute carrier family 
transporters, and genes involved in cell cycle and DNA repair as well as amino acid 
uptake and amino-acyl tRNA synthetases (Lee et al., 2008; Sato et al., 2004; Lu et al., 
2004b; Harding et al., 2003, 2000).  This selection of upregulated genes assists the cell 
in coping with the amino acid limitation by increasing the efficiency of the uptake and 
utilization of the available amino acids, while minimizing the requirement.  The 
downstream response of eIF2α phosphorylation in mammalian cells has been termed 
the integrated stress response (ISR) and shown to be associated with cell survival and 
stress resistance.  The ISR was so-named because various kinases, activated by 
different types of stress situations, phosphorylate eIF2α to activate the ISR, hence 
eIF2α can be viewed as a molecule that integrates stress-related signaling and initiates 
a response to the induced stress.  Other kinases that phosphorylate eIF2α, besides 
GCN2, are the heme-regulated inhibitor kinase (HRI), which is stimulated by heme 
depletion; protein kinase activated by double-stranded RNA (PKR), which is 
stimulated by viral infection; and PKR-like endoplasmic reticulum kinase (PERK), 
which is activated under endoplasmic reticulum (ER) stress (Lu et al., 2004a; Harding 
et al., 2003, 2000) (Figure 2.6). 
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Figure 2.6.  In mammals there are four eIF2α kinases that are capable of promoting 
eIF2α phosphorylation and the consequent downstream effects. 
 
Although many of the responses to different stresses are similar, the responses 
also differ due to eIF2α phosphorylation-independent induction of other transcription 
factors or signaling pathways by the specific stress condition.  These auxiliary 
pathways are best understood for ER stress responses in which PERK and ATF6 are 
also key factors.  So even though amino acid deprivation and other stresses that 
activate mammalian eIF2α kinases commonly trigger increased ATF4 synthesis, a 
somewhat distinct subset of genes is activated in response to different types of cellular 
stress, perhaps due to eIF2α kinase-independent signaling, which, among other things, 
may lead to induction of different C/EBP family members (Dang et al., 2009; Shan et 
al., 2009; Wek et al., 1995).  It is also likely that some of the longer-term responses to 
sustained induction of eIF2α may simply be consequences of the global repression of 
translation and/or of stress granule formation.  
It has been shown that mammalian cells respond to a deficiency of one or more 
essential amino acids by induction of the eIF2α-P/ATF4-mediated ISR (Kilberg et al., 
2009; Sato et al., 2004; Harding et al., 2000; Wek et al., 1995).  Studies in GCN2 
knockout mice and murine cells have shown that the GCN2 pathway is the major 
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signaling pathway involved in the up- and down-regulation of gene expression in 
response to amino acid starvation.  Studies in murine embryonic stem cells and 
immortalized embryonic fibroblasts showed that eIF2α phosphorylation was not 
activated in GCN2-/- cells cultured in leucine-devoid medium (Deval et al., 2009; 
Zhang et al., 2002).  Zhang et al. (2002) further showed that perfused livers of GCN2-/- 
mice did not display either induction of eIF2α-P or repression of eIF2B activity in 
response to histidine deprivation as occurred in wild-type mice.  Anthony et al. (2004) 
reported that GCN2-/- mice fed a leucine-free diet for 1 h or 6 days did not show 
increased phosphorylation of hepatic eIF2α or restriction of liver protein synthesis, 
whereas increased phosphorylation of eIF2α and concomitant decreased protein 
synthesis were observed in liver of wild-type mice. Also the GCN2-/- mice maintained 
their liver mass but lost muscle mass and lost more body mass than the wild-type 
mice.  Similarly, asparaginase treatment of GCN2-/- mice to lower asparagine levels 
did not lead to increased phosphorylation of eIF2α, whereas asparaginase treatment 
induced hepatic eIF2α-P levels in wild-type mice and in mice with a liver-specific 
eIF2α kinase 3 (PERK) deletion (Bunpo et al., 2009).   
Although the mTOR pathway clearly plays a substantial role in regulation of 
protein synthesis and growth in response to nutrient availability, the eIF2α 
phosphorylation pathway may be better suited to respond to diets limiting in specific 
indispensable amino acids.  Normal diets or food proteins are rarely, if ever, limiting 
in leucine but are commonly limiting in sulfur-containing amino acids (SAAs), lysine, 
threonine or tryptophan (Milward and Jackson, 2003).   
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Suppression of general protein synthesis and induction of the ISR by SAA 
restriction may lead to stress-resistance and/or increased lifespan 
 The evidence that protein or amino acid restriction can play a critical role in 
extending lifespan in model organisms, as well as the possible relation of this to 
induction of a stress-resistant physiological state, has wide-ranging implications for 
human nutrition and health.  Zimmerman et al. (2003) reported that lowering the 
content of SAAs in the diet by removing cysteine and restricting the concentration of 
methionine extended all measured survival parameters in various rat strains, and pair-
feeding of control rats with a SAA-supplemented diet demonstrated that the increase 
in survival was not simply due to caloric restriction.  Although methionine restriction 
led to a decrease in levels of hepatic glutathione and cysteine, glutathione levels in 
most extrahepatic tissues did not decline while cysteine levels did (Richie et al., 2004).  
Methionine restriction was further shown to decrease mitochondrial oxygen radical 
production, as well as to decrease oxidative damage to mitochondrial DNA and 
cellular proteins (Sanz et al., 2006).   
 A number of studies have shown an association of eIF2α phosphorylation with 
induction of a state of stress resistance in cells.  Studies in murine hippocampal 
(HT22) cells involving stable genetic mutations that resulted in reduced activity of the 
eIF2 complex (Tan et al., 2001) and subsequent studies employing a genetic system 
for inducing rapid reversible phosphorylation of eIF2α independent of cell stress (Lu 
et al., 2004b) demonstrated that reduced translational activity of the eIF2 complex 
induced resistance to subsequent oxidative glutamate toxicity in HT22 cells.  Lu et al. 
(2004b) showed that eIF2α phosphorylation, or loss of functional eIF2 complex, 
resulted in translational inhibition, reduced incorporation of [35S]-methionine into 
newly synthesized protein, and increased mRNA expression of many genes encoding 
enzymes involved in amino acid uptake and utilization, thiol-metabolism and 
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sufficiency, as well as resistance to oxidative and other cellular stresses.  Knockdown 
of GADD34 (i.e., a decrease in eIF2α phosphatase activity) enhanced eIF2α 
phosphorylation, activated the ISR, and strongly protected mammalian cells against 
oxidative stress, peroxynitrite stress, and more modestly against ER stress induced by 
thapsigargin (Jousse et al., 2007).  In addition, Ranganathan et al. (2008) reported that 
the activation of eIF2α kinase signaling in highly malignant squamous T-HEp3 cells 
or SW620 colorectal carcinoma cells induced both survival and tumor growth 
suppression, which was associated with a loss of tumorgenicity.  The activation of 
eIF2α kinase inhibited T-HEp3 and SW620 carcinoma growth in vivo, suggesting that 
the growth-inhibitory function of eIF2α phosphorylation dominated in the tumor cells.  
This hypothesis was further supported by the observation that reduction of eIF2α 
kinase activity in a spontaneously arising in vivo quiescent variant of HEp3 cells, 
which displays strong basal PERK (eIF2α kinase 3) activation, led to reversion of the 
quiescent phenotype and restored tumor growth.  These observations suggested a key 
and protective, pro-survival role for eIF2α-P.  With our work we aimed to explore 
whether a mild, nutritional stress can lead to increased eIF2α-P and the associated 
events both in vitro and in vivo. 
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CHAPTER 3 
GENE EXPRESSION AND INTEGRATED STRESS RESPONSE IN 
HepG2/C3A CELLS CULTURED IN AMINO ACID DEFICIENT MEDIUM 
 
INTRODUCTION 
A fundamental question in biology is how cells sense and respond to changes 
in their nutrient supply.  How mammalian cells respond to changes in the availability 
of essential amino acids has been a major research focus in recent years due to 
evidence for various roles of essential amino acids in the regulation of protein 
translation and growth as well as regulation of stress response pathways. 
In our studies of cysteine metabolism in mammalian cells, we discovered that 
cysteine deprivation does not necessarily induce an oxidative state in unstressed cells 
(Lee et al., 2008) but, rather, the data suggested that expression of genes for cyst(e)ine 
uptake and GSH synthesis may be induced as part of the cell’s normal response to 
amino acid deficiency.  In particular, we observed highly significant upregulation of 
expression of a group of genes (ASNS, ATF3, C/EBPβ, SLC7A11, TRIB3, ATF4, and 
SLC7A1) that are known to contain an amino acid response element (AARE) and to 
respond to amino acid deprivation via the binding of activating transcription factor 4 
(ATF4).   
ATF4 is translationally, as well as transcriptionally, upregulated in response to 
activation of stress response eIF2α kinases which then phosphorylate Ser51 of the 
alpha subunit of eukaryotic initiation factor 2 (eIF2).  One of the four mammalian 
eIF2α kinases is GCN2 (protein kinase general control nonderepressible 2, or eIF2α 
kinase 4) which is activated specifically in response to amino acid deprivation (Wek et 
al., 2006).  The GCN2 kinase senses an increase in the abundance of non-
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aminoacylated tRNAs via its histidyl-tRNA synthetase homologous domain (Wek et 
al. 1995; Padyana et al. 2005; Hao et al. 2005).  Binding of uncharged tRNAs to this 
domain activates the juxtaposed protein kinase domain of GCN2, rendering the kinase 
active and leading to phosphorylation of Ser51 of eIF2α.  As shown in Figure 3.1A, the 
phosphorylation of eIF2 subsequently leads to inhibition of the GTP-GDP exchange 
activity of eIF2B, and this in turn leads to diminished formation of the ternary 
complex (Met-tRNAiMet · eIF2 – GTP) that is needed for all cytoplasmic translation 
initiation events (Gabauer and Hentze 2004; Hinnebusch 2000; Kubica et al., 2006; 
Kimball et al., 1991).  In addition to globally reducing translation initiation events and 
hence the overall rate of protein synthesis, reduced ternary complex formation 
paradoxically results in increases in the translation of some specific mRNAs, most 
notably that for ATF4 (Dang Do et al., 2009), as illustrated in Figure 3.1B. The 
presence of an inhibitory upstream open reading frame (ORF) that overlaps the ATF4 
ORF promotes read-through of the ATF4 translational start codon, preventing ATF4 
translation under normal conditions in which ternary complex is abundant (Lu et al., 
2004a, b; Wek et al., 2006). In amino acid deprivation, in which eIF2B is inhibited 
and ternary complex formation is reduced, ribosomal scanning through the inhibitory 
upstream ORF start codon is favored so that initiation occurs at the downstream ATF4 
ORF start codon, allowing an increase in ATF4 mRNA translation. 
This translationally mediated increase in ATF4 leads to a transcriptional 
response that involves the upregulation of a number of genes including that for ATF4 
itself (Lu et al., 2004a, b; Harding et al., 2000, 2003).  GCN2 is the only eIF2α kinase 
in yeast, and activation of GCN2 in yeast results in increased translation of GCN4, the 
functional counterpart to mammalian ATF4, and GCN4 acts to induce expression of 
an array of genes that encode amino acid biosynthetic enzymes (Hinnebusch 2005).  
Unlike yeast, mammalian cells express several different eIF2α kinases, which are 
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activated by various kinds of stress including accumulation of unfolded proteins, heme 
deficiency, and viral infection, in addition to amino acid deprivation (Wek et al., 
2006).  Because mammalian cells, unlike yeast, are unable to synthesize a subset of 
amino acids, the so-called essential or indispensable amino acids, they must obtain 
them from the environment.  Not surprisingly, the phospho-eIF2α/ATF4 signaling 
cascade induces the expression of a somewhat different array of genes in mammalian 
cells compared with those induced by the GCN2/GCN4 pathway in yeast.  The genes 
induced in mammalian cells include those encoding transcriptional regulators, solute 
carrier family transporters, aminoacyl-tRNA synthetases, and proteins involved in cell 
cycle and DNA repair (Harding et al., 2000, 2003; Lee et al., 2008; Lu et al., 2004b; 
Sato et al., 2004).  Because the mammalian response to eIF2α phosphorylation is 
induced by kinases that respond to a variety of stressors, the downstream 
translational/transcriptional response is often termed the integrated stress response 
(ISR). 
Although amino acid deprivation and other stresses that activate mammalian 
eIF2α kinases commonly trigger increased ATF4 synthesis, a somewhat distinct subset 
of genes is activated in response to different types of cellular stress, perhaps due to 
eIF2α kinase-independent signaling, which, among other things, may lead to induction 
of different C/EBP family members (Wek et al., 1995; Dang Do et al., 2009; Shan et 
al., 2009).  Gene expression surveys have been conducted with cells lacking ATF4 
(Harding et al., 2003), in cells with ER-stress induced by tunicamycin  (Harding et al., 
2003; Lu et al., 2004b), with drug-induced activity of an artificial eIF2α kinase, Fv2E-
PERK (Lu et al., 2004b), and in cells lacking GCN2 (Deval et al., 2009).  All of these 
studies have been done using immortalized murine fibroblasts. To our knowledge, no 
large gene expression surveys have been reported for mammalian cells exposed to 
amino acid deprivation other than our studies in cysteine-deficient HepG2/C3A cells 
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(Lee et al., 2008).  Results could vary with both the type of stress and with the type of 
cell that is used for the gene expression studies. 
 
 
 
Figure 3.1. Mechanisms by which eIF2α kinases downregulate formation of ternary 
complex (Met-tRNAiMet · eIF2 – GTP) formation (A) and by which the reduced 
availability of ternary complex suppresses global protein translation while selectively 
increasing ATF4 mRNA translation (B). The increase in ATF4 translation leads to 
induction of genes containing amino acid response elements (AARE). The collective 
consequences of eIF2α phosphorylation are termed the integrated stress response 
(ISR).  
 
Thus, to further assess the role of amino acid deprivation on eIF2α 
phosphorylation and downstream transcriptional responses, we conducted additional 
microarray studies for leucine-depleted HepG2/C3A cells and compared these with 
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results for cysteine-depleted cells.  The comparison of cells exposed to deficiencies of 
two different amino acids was done to facilitate selection of genes whose expression is 
more likely to be altered specifically in response to GCN2-induced eIF2α 
phosphorylation.  In addition, we assessed the effects of both cysteine and leucine 
deprivation on the phosphorylation of eIF2α and on the protein expression patterns of 
ATF4 and other ISR-related proteins.  The results of this study add to our 
understanding of how gene expression changes in response to amino acid deprivation 
in a human-derived cell line. Amino acid deprivation frequently induces a milder 
degree of stress than the agents used to induce ER stress (e.g., tunicamycin, 
thapsigargin), and the human HepG2/C3A cell line represents a more-differentiated 
cell line than the immortalized murine embryonic fibroblasts used in the studies 
mentioned above.  The HepG2/C3A cell line is a derivative of the human 
hepatocarcinoma HepG2 cell line, with the C3A derivative being selected for its more 
liver-specific phenotype. HepG2 cells have been used in other studies of the amino 
acid deprivation response (Jousse et al., 2000; Thiaville et al., 2008; Palii et al., 2009). 
 
 
MATERIALS AND METHODS 
 
Experimental treatment of HepG2/C3A cells  
HepG2/C3A cells (ATCC CRL-10741) were cultured in a humidified incubator 
at 37oC and 5% CO2 in complete medium prepared using sulfur amino acid (SAA)- 
and leucine-free Dulbecco’s modified Eagle’s medium (DMEM; from Gibco/ 
Invitrogen) supplemented with 0.8 mM L-leucine, 0.2 mM L-methionine, 0.2 mM L-
cysteine, 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 
1×MEM nonessential amino acid solution and 0.05 mM bathocuproine disulfonate.  
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All cells were plated in complete medium at a density of 1×106 cells per 100 mm 
diameter culture dish.  After 24 h of culture in complete medium to allow cells to 
reach 50-60% confluence, the medium was replaced with experimental medium, 
which was the same complete medium (+Leu, +Cys) or medium prepared without 
leucine (-Leu) or without cysteine (-Cys). Cells were cultured with a medium change 
at 18 h and harvested at the indicated time-points. 
 
RNA extraction, microarray analysis, and selection of differentially expressed genes  
HepG2/C3A cells cultured in complete or Leu-free treatment medium for 36 h 
as described above were washed twice with ice-cold PBS and then directly lysed into 
denaturation solution.  Total RNA was extracted from three separate plates of cells 
grown under each treatment with an RNeasy Micro kit (Qiagen).  Microarray analysis 
was performed on each of the three samples for each treatment using Affymetrix 
GeneChip Human plus 2.0 Arrays, a GeneChip Scanner 3000, and Affymetrix GCOS 
software, as described previously (Lee et al., 2008).  To look for differential gene 
expression between the two treatment conditions, the Student’s t test was applied on 
the normalized signals for each probe set.  To select the differential gene set, a 
significance level cutoff was empirically established at P < 0.0001, based on the 
number of genes passing the cutoff, the magnitude of fold changes, and the 
relationship between fold changes and P values. The complete set of microarray data 
has been deposited in the NCBI Gene Expression Omnibus (accession no. GSE13142, 
on-line: http://www.ncbi.nlm.nih.gov/geo/). 
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Comparison of gene expression array results for HepG2/C3A cells cultured in 
leucine-free medium versus complete medium with those for HepG2/C3A cells 
cultured in cysteine-free medium versus complete medium 
Using a dataset generated earlier for HepG2/C3A cells cultured in cysteine-
free (-Cys) medium (SAA-free DMEM supplemented with 0.1 mM L-methionine) 
versus cells cultured in cysteine-supplemented (+Cys) medium (SAA-free DMEM 
supplemented with 0.1 mM L-methionine plus 0.1 mM L-cysteine) (GEO, accession 
no. GSE9517), we similarly selected differentially expressed genes (P ≤ 0.0001).  The 
two sets of selected genes were then compared to each other to select those that were 
differentially expressed (P ≤ 0.0001) in both Cys-deficient and Leu-deficient 
HepG2/C3A cells.  It should be noted that HepG2/C3A cells are readily depleted of 
cysteine, even when cultured in methionine-containing medium, due to the lack of the 
high Km isoform of methionine adenosyltransferase (Lee et al., 2008; Lu and Huang 
1994).  
 
Western blot analysis of protein levels in HepG2/C3A cells cultured in -Leu, -Cys, or 
complete medium 
Dishes of HepG2/C3A cells were cultured in complete, -Leu, or -Cys medium 
as described earlier.  After 6, 12, 24, or 30 hours of culture, treatment medium was 
aspirated and cells were washed with ice-cold PBS containing 10 mM NaF.  
Monolayers were then harvested into TNESV lysis solution (50 mM Tris, pH 7.5, 1% 
(v/v) Nonidet P-40, 2 mM EDTA, 150 mM NaCl, and 10 mM sodium ortho-vanadate) 
supplemented with 1×PhosSTOP phosphatase inhibitor cocktail (Roche Applied 
Science) and 1×Complete Protease Inhibitor Cocktail (Roche).  Cell lysates were 
centrifuged at 17,000×g for 30 min, and the protein concentration of the supernatants 
was determined using the bicinchonic acid assay (Pierce).  For western blotting, 60 μg 
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of total supernatant protein from each sample were separated by one-dimensional 
SDS-PAGE (12% w/v acrylamide) and electroblotted overnight onto 0.45 μm (pore 
size) Immobilon-P PVDF membranes (Millipore).  Membranes were immunoblotted 
for proteins of interest using the following antibodies: anti-pS51-eIF2α and anti-eIF2α 
(total) from Cell Signaling Technology; anti-ATF4 (gift from M.S. Kilberg, 
University of Florida, Gainesville, FL); antiATF3 (C-19), anti-ASNS (C-14), anti-
CHOP, and antiHSP5A from Santa Cruz Biotechnology; and anti-GCLC from 
Neomarkers (Freemont, CA).  Bands were visualized using horseradish peroxidase-
coupled secondary antibodies and chemiluminescent substrates (West Dura, Pierce) 
and autoradiography. The cell culture studies were repeated three or more times for 
designated time-points to assure the repeatability of the results.  
 
 
RESULTS 
Effect of amino acid deficiency on gene expression in HepG2/C3A cells 
A total of 670 genes were identified as differentially expressed with a P ≤ 
0.0001 in cells cultured in leucine deficient (-Leu) versus complete (+Leu) medium, 
with 301 being upregulated and 369 being downregulated (Tables S1 and S2 in 
supplemental materials, see appendix 5).  Similarly, 807 genes were identified as 
differentially expressed with a P ≤ 0.0001 in cells cultured in cysteine deficient (-Cys) 
versus complete (+Cys) medium (GSE13142 data set; Tables S3 and S4 in 
supplemental materials, see appendix 5); 407 genes were upregulated and 400 were 
downregulated.  To obtain a list of genes that are potential targets of regulated 
expression in response to essential amino acid deprivation, genes that met the 
following conditions were selected: (1) the gene was differentially expressed at P ≤ 
0.0001 in both the -Leu and the -Cys conditions; (2) the differential expression of the 
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gene was at least twofold; and (3) the differential expression of the gene was detected 
with the same probe set in both series of studies.  Application of these criteria yielded 
the list of 120 genes that are listed in Table 3.1.  Of these genes that were differentially 
expressed in response to both leucine and cysteine deprivation, 67 were 
downregulated.  This downregulated group includes many genes involved in cell 
cycle/cell division, fatty acid and sterol metabolism/synthesis, and nucleotide 
metabolism/synthesis, as shown in Table 3.1.  The remaining 53 genes were 
upregulated, and this upregulated group of genes includes a number of genes involved 
in amino acid uptake, aminoacyl-tRNA synthesis, transcriptional regulation, and 
growth inhibition.  Most notably, many of the genes known to contain AAREs and to 
be induced in response to eIF2α (Ser51) phosphorylation and ATF4 heterodimer 
binding (i.e., ATF3, C/EBPβ, SLC7A1, SLC7A11, and TRIB3), as well as others 
shown to be induced downstream of eIF2α (Ser51) phosphorylation (C/EBPγ, CARS, 
SARS, CLCN3, CBX4, and PPP1R15A, which is also known as GADD34, were 
among these 53 genes (Lee et al., 2008; Lu et al., 2004b) (see Table 3.1 for names of 
gene products).  Expression of ASNS, another AARE-dependent gene, met all criteria 
except one in that the fold increase for expression in the -Cys medium was only 1.6.  
Two other well-characterized AARE-containing genes, ATF4 and (also known as 
DDIT3 or GADD153) were also identified as significantly differentially expressed in 
cells cultured in both -Leu and -Cys medium using a lower statistical significance 
cutoff of P ≤ 0.001.   
Confirmation that the amino acid deprivation response was actually initiated in 
HepG2/C3A cells cultured in -Leu or -Cys medium was obtained by western blot 
analysis of total and phosphorylated eIF2α, ATF4, activating transcription factor 3 
(ATF3), and asparagine synthase (ASNS) proteins in the cells. Glutamate-cysteine 
ligase catalytic subunit (GCLC) and heat shock 70-kDa protein 5 (HSPA5) were also 
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assayed to confirm that proteins that are not part of the amino acid deprivation 
response were not upregulated.  As shown in Figure 3.2, the amount of phosphorylated 
eIF2α increased between 6 and 24 hours of culture in cells cultured in -Leu or -Cys, as 
well as in control medium.  However, the increases were greater in cells cultured in -
Leu or -Cys medium than in cells cultured in control medium, such that the amount of 
phosphorylated eIF2α in cells cultured for 24 to 30 hours in amino-acid-deficient 
medium was double that in cells cultured in control medium (2.0-times for -Leu and 
2.2times for -Cys).  The amount of total eIF2α did not change significantly across time 
or culture conditions.  A significant increase in total ATF4 levels in the cells was 
noted only at the 24 h time-point at which time ATF4 in cells cultured in the -Leu 
medium was 1.3-times and that in cells cultured in -Cys medium was 1.2-times that in 
control cells.  Expression of ATF3 and ASNS, whose genes are well-established 
targets for upregulation in response to amino acid deprivation or eIF2α phosphory-
lation, paralleled the increases in eIF2α phosphorylation.  ATF3 levels in cells 
cultured in amino acid-deficient medium for 24 h/30 h were 8.0-and 9.8-times for -Leu 
and -Cys cells, respectively, and ASNS levels were 2.7- and 1.9-times, respectively, 
those in cells cultured in complete medium.  CHOP was strongly induced in cells 
cultured in -Leu medium but only weakly detected in cells cultured in -Cys medium at 
the longest time-point (30 h).  The amount of GCLC, which served as a loading 
control, did not change with time or treatment.  As a control on the specificity of the 
amino acid deprivation/GCN2-mediated response, a chaperone protein that is strongly 
induced in response to activation of a different eIF2α kinase (i.e., PERK, or eIF2α 
kinase 3) by a different type of stress (endoplasmic reticulum stress, or ER stress) was 
measured.  The ER chaperone HSPA5 was not increased over time or with amino acid 
deprivation of the medium and, in fact, was consistently lower in cells cultured in -Leu 
medium than in those cultured in control medium.  Similar results were obtained for  
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Table 3.1. Genes differentially upregulated and downregulated in amino acid-deficient 
G2/C3A cells.  
 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title 
Fold 
Difference 
-Cys/ 
+Cys 
-Leu/
+Leu 
Genes with known functional AAREs 
202672_s_at ATF3 activating transcription factor 3 10.3 4.0 
212501_at CEBPB CCAAT/enhancer binding protein (C/EBP), beta 4.6 3.3 
209921_at 
SLC7A11 solute carrier family 7, (cationic amino acid transporter, y+ system) member 11 
13.8 4.2 
217678_at 9.9 3.2 
1555788_a_at 
TRIB3 
 
tribbles homolog 3 (Drosophila) 
5.8 4.0 
218145_at 4.0 3.2 
212295_s_at SLC7A1 solute carrier family 7 (cationic amino acid transporter, y+ system), member 1 3.3 2.6 
Amino Acid Metabolism 
212971_at CARS cysteinyl-tRNA synthetase 2.7 2.3 
206085_s_at CTH cystathionase (cystathionine gamma-lyase) 2.9 3.1 
202014_at PPP1R15A  
(GADD34) 
protein phosphatase 1, regulatory (inhibitor) 
subunit 15A 
8.6 2.2 
37028_at 6.2 2.9 
231894_at SARS seryl-tRNA synthetase 4.4 3.5 
200629_at WARS tryptophanyl-tRNA synthetase 2.6 4.5 
 33
Table 3.1 (Continued) 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title 
Fold 
Difference 
-Cys/
+Cys 
-Leu/ 
+Leu 
Endosomal/lysosomal system 
201734_at 
CLCN3 chloride channel 3 
2.1 2.4 
201735_s_at 2.0 2.4 
205569_at LAMP3 lysosomal-associated membrane protein 3 3.0 5.9 
208786_s_at 
MAP1LC3
B 
microtubule-associated protein 1 light chain 
3 beta 
3.7 2.9 
209822_s_at VLDLR Very low density lipoprotein receptor 3.5 3.0 
GAPs and GEFs 
209435_s_at ARHGEF2 
rho/rac guanine nucleotide exchange factor 
(GEF) 2 
5.5 4.4 
224822_at DLC1 deleted in liver cancer 1 2.6 2.0 
Growth regulation  
209409_at GRB10 growth factor receptor-bound protein 10 3.1 2.8 
210587_at INHBE inhibin, beta E 6.8 4.6 
202393_s_at KLF10 kruppel-like factor 10 3.5 3.1 
226275_at 
MXD1 MAX dimerization protein 1 
4.4 2.1 
228846_at 4.2 3.3 
203373_at SOCS2 suppressor of cytokine signaling 2 3.5 2.4 
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Table 3.1 (Continued) 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title 
Fold 
Difference 
-Cys/ 
+Cys 
-Leu/ 
+Leu 
Cytoskeleton  
226084_at MAP1B microtubule-associated protein 1B 3.5 2.9 
226342_at SPTBN1 spectrin, beta, non-erythrocytic 1 3.5 4.6 
Other  
209993_at ABCB1 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
2.3 2.0 
210517_s_at AKAP12 
A kinase (PRKA) anchor protein 
(gravin) 12 
6.1 3.0 
220088_at C5R1 
complement component 5 receptor 1 
(C5a ligand) 
9.4 2.1 
201925_s_at DAF 
decay accelerating factor for complement 
(CD55, Cromer blood group system) 
4.2 5.5 
235296_at EIF5A2 
eukaryotic translation initiation factor 
5A2 
3.5 2.3 
209098_s_at JAG1 jagged 1 (Alagille syndrome) 5.9 2.1 
201010_s_at TXNIP thioredoxin interacting protein 3.1 3.2 
Transcriptional regulators  
227558_at CBX4 
chromobox homolog 4 (Pc class 
homolog, Drosophila) 
2.5 2.8 
204203_at 
CEBPG 
CCAAT/enhancer binding protein 
(C/EBP), gamma 
2.6 2.2 
225527_at 3.3 2.4 
223287_s_at FOXP1 forkhead box P1 3.5 2.2 
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Table 3.1 (Continued) 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title 
Fold 
Difference 
-Cys/ 
+Cys 
-Leu/ 
+Leu 
 
Unknown functions 
225283_at ARRDC4 arrestin domain containing 4 3.8 5.3 
226398_s_at C10orf4 chromosome 10 open reading frame 4 2.4 2.2 
227443_at C9orf150 chromosome 9 open reading frame 150 5.0 2.3 
201919_at FLJ10618 Hypothetical protein FLJ10618 2.7 2.2 
222953_at GPR83 G protein-coupled receptor 83 10.0 6.4 
202147_s_at IFRD1 interferon-related developmental regulator 1 5.5 2.7 
236565_s_at LARP6 
La ribonucleoprotein domain family, 
member 6 
3.5 3.4 
209205_s_at LMO4 LIM domain only 4 3.5 2.1 
221501_x_at LOC339047 hypothetical protein LOC339047 3.0 2.27 
220437_at LOC55908 
hepatocellular carcinoma-associated gene 
TD26 
2.4 5.26 
236285_at MGC16635 hypothetical protein BC009980 11.3 7.04 
204538_x_at 
NPIP /// 
LOC339047 
/// 
LOC440341 
nuclear pore complex interacting protein /// 
hypothetical protein LOC339047 /// similar 
to hypothetical protein LOC339047 
2.8 2.38 
215707_s_at PRNP 
prion protein (p27-30) (Creutzfeld-Jakob 
disease, Gerstmann-Strausler-Scheinker 
syndrome, fatal familial insomnia) 
2.1 2.04 
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Table 3.1 (Continued) 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title 
Fold 
Difference 
-Cys/ 
+Cys 
-Leu/ 
+Leu 
209568_s_at RGL1 
ral guanine nucleotide dissociation 
stimulator-like 1 
2.2 2.52 
202130_at RIOK3 
RIO kinase 3 (yeast) /// RIO kinase 3 
(yeast) 
2.8 2.04 
202241_at TRIB1 tribbles homolog 1 (Drosophila) 2.4 2.08 
222408_s_at YPEL5 yippee-like 5 (Drosophila) 2.9 2.13 
223506_at ZC3H8 Zinc finger CCCH-type containing 8 2.2 3.23 
225522_at  similar to BMP2 inducible kinase 2.6 3.13 
227755_at  
cDNA clone IMAGE:4077090, partial 
cds 
5.9 5.26 
Cell Cycle/Cell Division 
222608_s_at ANLN 
anillin, actin binding protein (scraps 
homolog, Drosophila) 
0.33 0.32 
209642_at BUB1 
BUB1 budding uninhibited by 
benzimidazoles 1 homolog (yeast) 
0.36 0.33 
203418_at CCNA2 cyclin A2 0.27 0.27 
213226_at   0.31 0.34 
214710_s_at CCNB1 cyclin B1 0.35 0.35 
228729_at   0.33 0.35 
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Table 3.1 (Cotinued) 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title 
Fold Difference 
-Cys/ 
+Cys 
-Leu/ 
+Leu 
     
203214_x_at 
CDC2 
cell division cycle 2, G1 to S and G2 to 
M 
0.32 0.30 
210559_s_at 0.27 0.29 
203967_at CDC6 
 
CDC6 cell division cycle 6 homolog (S. 
cerevisiae) 
0.19 0.27 
203968_s_at 0.27 0.30 
204159_at CDKN2C 
cyclin-dependent kinase inhibitor 2C 
(p18, inhibits CDK4) 
0.20 0.27 
209714_s_at 
CDKN3 
 
cyclin-dependent kinase inhibitor 3 
(CDK2-associated dual specificity 
phosphatase) 
0.28 0.34 
204962_s_at CENPA centromere protein A, 17kDa 0.36 0.38 
209194_at CETN2 centrin, EF-hand protein, 2 0.41 0.38 
205394_at CHEK1 CHK1 checkpoint homolog (S. pombe) 0.23 0.42 
210416_s_at CHEK2 CHK2 checkpoint homolog (S. pombe) 0.45 0.38 
203764_at DLG7 discs, large homolog 7 (Drosophila) 0.31 0.37 
223556_at HELLS helicase, lymphoid-specific 0.29 0.35 
201555_at MCM3 
MCM3 minichromosome maintenance 
deficient 3 (S. cerevisiae) 
0.19 0.39 
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Table 3.1 (Cotinued) 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title Fold Difference 
   
-Cys/ 
+Cys 
-Leu/ 
+Leu 
219978_s_at NUSAP1 nucleolar and spindle associated protein 1 0.34 0.37 
219148_at PBK PDZ binding kinase 0.21 0.26 
221521_s_at Pfs2 
DNA replication complex GINS protein 
PSF2 
0.14 0.23 
205909_at POLE2 
polymerase (DNA directed), epsilon 2 
(p59 subunit) 
0.29 0.34 
203554_x_at PTTG1 pituitary tumor-transforming 1 0.26 0.40 
203696_s_at RFC2 
replication factor C (activator 1) 2, 
40kDa 
0.34 0.45 
204127_at 
RFC3 
 
replication factor C (activator 1) 3, 
38kDa 
 
0.21 0.33 
204128_s_at 0.19 0.26 
204023_at RFC4 
replication factor C (activator 1) 4, 
37kDa 
0.25 0.37 
209891_at SPBC25 
spindle pole body component 25 
homolog (S. cerevisiae) 
0.24 0.23 
204026_s_at ZWINT ZW10 interactor 0.17 0.34 
Calcium signaling  
1554483_at 
TMEM37 
 
transmembrane protein 37 
 
0.22 0.34 
1554485_s_
at 
0.20 0.36 
203797_at VSNL1 visinin-like 1 0.17 0.33 
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Table 3.1 (Cotinued) 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title 
Fold Difference 
-Cys/ 
+Cys 
-Leu/ 
+Leu 
Cytoskeleton  
212320_at TUBB tubulin, beta polypeptide 0.34 0.46 
Fatty acid and sterol metabolism 
209608_s_at ACAT2 
acetyl-Coenzyme A acetyltransferase 2 
(acetoacetyl Coenzyme A thiolase) 
0.23 0.27 
209389_x_at DBI 
diazepam binding inhibitor (GABA 
receptor modulator, acyl-Coenzyme A 
binding protein) 
0.21 0.25 
202735 _at EBP 
 
 
emopamil binding protein (sterol 
isomerase) 
0.38 0.32 
   
213787_s_at 0.31 0.29 
208962_s_at FADS1 
 
fatty acid desaturase 1 
 
0.39 0.29 
208964_s_at 0.42 0.33 
210950_s_at FDFT1 
farnesyl-diphosphate farnesyltransferase 
1 
0.24 0.30 
201036_s_at 
HADH
SC 
L-3-hydroxyacyl-Coenzyme A 
dehydrogenase, short chain 
0.22 0.43 
204615_x_at IDI1 
isopentenyl-diphosphate delta isomerase 
1 
0.32 0.24 
202245_at LSS 
lanosterol synthase (2,3-oxidosqualene-
lanosterol cyclase) 
0.36 0.25 
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Table 3.1 (Cotinued) 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title Fold Difference 
209146_at SC4MOL sterol-C4-methyl oxidase-like 0.31 0.28 
Nucleotide synthesis/metabolism 
202534_x_at DHFR 
 
dihydrofolate reductase 
 
0.30 0.43 
48808_at 0.29 0.36 
1553984_s_at 
DTYMK 
 
deoxythymidylate kinase (thymidylate 
kinase) 
 
0.24 0.43 
203270_at 0.30 0.39 
209932_s_at DUT dUTP pyrophosphatase 0.35 0.40 
201476_s_at RRM1 
ribonucleotide reductase M1 
polypeptide 
0.33 0.49 
209773_s_at RRM2 
ribonucleotide reductase M2 
polypeptide 
0.10 0.28 
209980_s_at SHMT1 
serine hydroxymethyltransferase 1 
(soluble) 
0.26 0.38 
1554408_a_at TK1 
 
thymidine kinase 1, soluble 
 
0.27 0.21 
202338_at 0.23 0.24 
202330_s_at UNG uracil-DNA glycosylase 0.19 0.42 
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Table 3.1 (Cotinued) 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title Fold Difference 
   
-Cys/ 
+Cys 
-Leu/ 
+Leu 
Other 
208951_at ALDH7A1 aldehyde dehydrogenase 7 family, member A1 0.18 0.47 
206651_s_at CPB2 
Carboxypeptidase B2 (plasma, 
carboxypeptidase U) 
0.07 0.30 
226980_at DEPDC1B DEP domain containing 1B 0.28 0.36 
228033_at E2F7 E2F transcription factor 7 0.41 0.45 
219990_at E2F8 E2F transcription factor 8 0.26 0.36 
201341_at ENC1 
ectodermal-neural cortex (with BTB-
like domain) 
0.41 0.49 
203564_at FANCG 
Fanconi anemia, complementation 
group G 
0.35 0.45 
202503_s_at KIAA0101 KIAA0101 0.14 0.39 
221952_x_at KIAA1393 KIAA1393 0.38 0.48 
218755_at KIF20A kinesin family member 20A 0.35 0.29 
207256_at MBL2 
mannose-binding lectin (protein C) 2, 
soluble (opsonic defect) 
0.43 0.46 
213599_at OIP5 Opa interacting protein 5 0.26 0.31 
235113_at PPIL5 
peptidylprolyl isomerase (cyclophilin)-
like 5 
0.34 0.37 
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Table 3.1 (Cotinued) 
GENES UPREGULATED  IN AMINO ACID DEFICIENT CELLS 
Probe ID Gene Symbol Gene Title Fold Difference 
   
-Cys/ 
+Cys 
-Leu/ 
+Leu 
203824_at TSPAN8 tetraspanin 8 0.17 0.34 
223229_at UBE2T 
ubiquitin-conjugating enzyme E2T 
(putative) 
0.33 0.27 
Unknown  
225687_at C20orf129 
chromosome 20 open reading frame 
129 
0.33 0.37 
 
212279_at MAC30 
 
hypothetical protein MAC30 
 
0.17 0.31 
212282_at 0.13 0.40 
226456_at MGC24665 hypothetical protein MGC24665 0.21 0.27 
 
HepG2/C3A cells cultured in medium deficient in L-methionine (but containing 0.2 
mM L-cysteine) (data not shown).  
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Figure 3.2.  Western blot of protein levels in cells cultured for 6, 12, 24 or 30 hours in 
complete control medium (C), leucine-free (-L) or cysteine-free (-C). For each sample, 
60 μg of total soluble protein was loaded in each lane.  
 
Comparison of results for genes induced in response to amino acid deficiency with 
lists of upregulated genes previously generated for eIF2a phosphorylation/ATF4-
mediated changes in gene expression 
To further explore the list of 53 upregulated genes that met stringent criteria 
for designation as differentially expressed (P ≤ 0.0001) in HepG2/C3A cells cultured 
in amino acid deficient medium, this list of genes was compared with lists of 
upregulated genes previously generated for eIF2α phosphorylation/ATF4-mediated 
changes in gene expression (Figure 3.3). These comparison lists include (1) that for 
murine fibroblasts that was generated by Harding et al. (2003) by selecting genes 
whose expression was at least twofold lower in tunicamycin-treated ATF4-/- cells 
compared with tunicamycin-treated wild-type cells (i.e., genes upregulated by 
tunicamycin in an ATF4-dependent fashion) and (2) that for murine fibroblasts that 
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was generated by Lu et al. (2004b) by selecting genes whose expression was induced 
at least twofold in both drug-induced Fv2E-PERK cells and 1.5-fold in tunicamycin-
treated wild-type cells (i.e., genes upregulated by both drug-induced eIF2α 
phosphorylation and by induction of ER stress). Interestingly, only two genes appear 
on all three lists: C/EBPβ and C/EBPγ (CCAAT/enhancer binding protein, β and γ, 
respectively).  These two genes represent the only overlap with the selected list of 
Harding et al. (2003).  Comparison of our list with that of Lu et al. (2004b) yields 
seven additional overlapping genes: ATF3, SARS (seryl-tRNA synthetase), CARS 
(cysteinyl-tRNA synthetase), CBX4 (chromobox homolog 4), CLCN3 (chloride 
channel 3), LMO4 (LIM domain only 4), and TXNIP (thioredoxin interacting protein).   
 
 
Figure 3.3.  Comparison of genes proposed to be induced in response to eIF2α 
phosphorylation and/or ATF4 induction.  Lists of upregulated genes generated by 
Harding et al. (2003) by selecting genes whose expression was at least two-fold lower 
than tunicamycin-treated ATF4-/- murine fibroblasts compared to tunicamycin-treated 
wild-type cells; Lu et al. (2004b) by selecting genes whose expression was induced at 
least two-fold in both drug-induced Fv2E-PERK murine fibroblasts and 1.5-fold in 
tunicamycin-treated wild-type cells; and in our work by selecting genes that were 
induced at least twofold in HepG2/C3A cells when cultured in either cysteine-
deficient medium or leucine-deficient medium.      
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ASNS (asparagine synthetase), SLC1A7 (glutamate/neutral amino acid transporter), 
NARS (asparaginyl-tRNA synthetase), and ERO1L (endoplasmic reticulum 1-like 
oxidoreductase) made the lists of both Harding et al. (2003) and Lu et al. (2004a, b) 
but not our list of genes induced by amino acid deprivation in HepG2/C3A cells.  
 
DISCUSSION 
Amino acid deprivation leads to downregulation of genes involved in amino acid 
uptake, aminoacyl-tRNA synthesis, transcriptional regulation, and growth 
inhibition 
The 120 genes that met stringent criteria for designation as differentially 
expressed (P ≤ 0.0001) in HepG2/C3A cells cultured in amino acid deficient medium 
should all be considered potential targets for regulation by amino acids in HepG2/C3A 
cells. 
The upregulated group of 53 genes includes a number of genes involved in 
amino acid uptake, aminoacyl-tRNA synthesis, transcriptional regulation, and growth 
inhibition; comparison of this group of upregulated genes with the groups of 
upregulated genes identified by other investigators as potential downstream targets of 
eIF2α phosphorylation and ATF4 induction, amino acyl-tRNA synthetases and amino 
acid transporters stand out as consistently upregulated although the specific ones 
varied among studies.  The cystine-glutamate exchanger, SLC7A11, was the most 
highly induced amino acid transporter gene in HepG2/C3A cells in both -Cys and    -
Leu medium.  Several amino acyl-tRNA synthetases, CARS, SARS, and WARS, were 
induced under conditions of both Cys and Leu deficiency. 
Another striking observation from our comparison of various studies to 
identify common genes induced by various stresses that induce eIF2α phosphorylation 
and ATF4 expression is that a number of genes that are known to contain AAREs and 
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to be induced by ATF4 binding were identified, as would be anticipated.  These 
include C/EBPβ, ATF3, and ASNS.  Other genes induced in the amino acid deficient 
HepG2/C3A cells that are known to contain AAREs and to be induced by ATF4 
binding include SLC7A1, SLC7A11, and TRIB3.  The identification of these AARE-
containing genes is consistent with transcriptional responses to amino acid deprivation 
being mediated by ATF4 binding to AARE and with phosphoeIF2α/ATF4-dependent 
gene expression being a key component of the ISR.  
Further support for the induction of the ISR in HepG2/ C3A cells cultured in 
amino acid deficient medium was obtained from the eIF2α phosphorylation and 
protein expression patterns in the HepG2/C3A cells. Increases in eIF2α 
phosphorylation were apparent by 12 h after the removal of leucine or cysteine from 
the medium as were increases in ATF3 protein levels, and increases in ATF4 and 
ASNS protein levels were apparent in both cysteine-and leucine-depleted cells by 24 
h.  Whereas ATF3 protein was strongly induced by either leucine deprivation or 
cysteine deprivation, ASNS protein was consistently more strongly induced in the 
cysteine-depleted cells.  On the other hand, CHOP protein was strongly induced in the 
leucine-depleted cells whereas induction was not evident in the cysteine-depleted cells 
until the 30-h time-point. The stronger induction of CHOP by leucine depletion is con-
sistent with our microarray results that showed a 6.7-fold induction (significant at P ≤ 
0.0001) of CHOP mRNA in -Leu-treated cells but only a 4.1-fold, less significant (P ≤ 
0.001) induction in -Cys-treated cells.  Jousse et al. (2000) previously reported a 
similar finding for both HeLa and HepG2 cells, finding that CHOP protein induction 
was greater in cells incubated for 16 h in -Leu medium than in cells incubated in -Cys 
medium.  Thus, a robust upregulation of components of the amino acid deprivation 
pathway or ISR was observed, although not all downstream responses were highly 
correlated with the degree of eIF2α phosphorylation or with cellular ATF4 levels.  
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There are several possible reasons for the lack of apparent correlation of all 
upstream responses with activation or expression of early components of the ISR 
pathway or of mRNA and protein expression levels for individual genes.  First of all, 
the time-course for changes in levels of various mRNAs and proteins is highly 
dependent upon the turnover rate of the individual mRNAs and proteins.  Second, the 
levels of ATF4 in the nucleus may not parallel the amount of total ATF4 in the cell.  
Third, other transcriptional regulators including ATF4’s heterodimerization partners 
may also play an important role in gene activation.  ATF4 forms heterodimers with 
members of another bZIP family, which consists of C/EBP α, β, γ, δ, ε, and CHOP.  
ATF4-C/EBP complexes have been detected at the C/EBP-ATF composite sites 
(functional AAREs) on promoters of genes induced by amino acid deprivation.  ATF4 
activity is subjected to regulation (activation or repression) by its various binding 
partners, with some of these dimerization partners (e.g., ATF3, TRIB3, C/EBPβ, and 
CHOP), as well as the ATF4 gene itself, being transcriptionally induced by ATF4 
heterodimers (Shan et al., 2009; Mungrue et al., 2009; Pan et al., 2007).  Fourth, some 
of the effects of amino acid deprivation are undoubtedly mediated by GCN2-
independent pathways and these may vary for different amino acids (Jousse et al., 
2000; Su et al., 2009; Deval et al., 2009; Thiaville et al., 2008; Palii et al., 2009).  
Finally, regulation of gene expression and/or protein level may involve the integration 
of a number of regulators and points of regulation, with these additional signaling 
pathways either enhancing or suppressing the GCN2/ phospho-eIF2α/ATF4 signaling 
pathway (Shan et al., 2009; Ishikawa et al., 2009; Vesely et al., 2009).  
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Amino acid deprivation leads to downregulation of genes involved in the cell cycle, 
fatty acid desaturation, sterol synthesis, and nucleotide synthesis  
The group of genes that were downregulated in cells cultured in either -Leu or 
-Cys medium included a number of genes involved in cell cycle/cell division, fatty 
acid and sterol metabolism/synthesis, and nucleotide metabolism/synthesis (Table 
3.1).  Genes that are downregulated in response to eIF2α phosphorylation/ATF4 
induction have generally received much less attention, although one would expect that 
DNA synthesis and cell proliferation and growth would be restricted under conditions 
of cell stress so that resources can be diverted to deal with the imposed stress.  
Downregulation of the expression of genes involved in cell division and nucleotide 
synthesis, along with the eIF2α phospho-mediated reduction in protein synthesis, 
would seem to be synergistic in facilitating the cell’s survival during times of nutrient 
deprivation or other stress.  We observed downregulation of expression of a cluster of 
genes in the folate/deoxythymidine nucleotide synthetic pathway as well as 
downregulation of genes involved in all phases of the cell cycle.  
Guo and Cavener (2007) speculated that GCN2 may act as a master regulator 
of metabolic adaptation to nutrient deprivation, because an essential amino acid 
limitation in nature would almost always be correlated with the deprivation of other 
nutrients as well.  Using   GCN2-/- and wild-type mice, they found that triglyceride 
synthesis was repressed in the livers of wild-type mice that were fed a leucine-devoid 
diet for 7 or 17 days but continued unabated in the livers of GCN2-/- mice.  In the 
GCN2-/- mice, consumption of a leucine-deficient diet was accompanied by 
accumulation of hepatic triglyceride as well as impaired lipolysis of adipose stores.  
Guo and Cavener (2007), using quantitative RT-PCR and western blotting, showed 
that the -Leu diet resulted in diminished fatty acid synthase (FAS) expression in wild-
type but not GCN2-/- mice.  Similarly, hepatic mRNA levels for stearoyl-CoA 
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desaturase (SCD) and other enzymes involved in fatty acid synthesis were diminished 
in GCN2-/- mice fed the –Leu diet but remained the same or even increased in wild-
type mice.  Furthermore, they showed that the mRNA levels for enzymes involved in 
β-oxidation (e.g., fatty acyl-CoA oxidase, long-and medium-chain acyl-CoA 
dehydrogenases) were not affected by leucine deprivation in wild-type mice, whereas 
the expression of these genes was markedly increased in GCN2-/- mice fed a leucine-
devoid diet.  Our gene expression studies in HepG2/C3A cells cultured in medium 
deficient in either Cys or Leu also showed the consistent downregulation of a group of 
genes involved in fatty acid and sterol metabolism, although the particular genes 
showing high fold induction in our microarray study were somewhat different than 
those observed by Guo and Cavener.  The genes whose mRNA levels were 
significantly reduced (P ≤ 0.0001, ≤0.5-fold) in our analysis included genes involved 
in fatty acid desaturation (FADS1 and SCD), in isoprenoid and sterol synthesis 
(FDFT1, IDI1, LSS, EBP, SQLE, and SC4MOL), and in cholesterol ester synthesis 
(ACAT2).  The only gene in this repressed group that was also included in the       
more-limited screen done by Guo and Cavener (2007) is SCD, and they found that 
SCD mRNA level was reduced to < 20% of control in liver of wild-type mice fed the 
leucine-devoid diet. Furthermore, Guo and Cavener (2007) showed that this reduction 
was strictly dependent on GCN2 because SCD mRNA levels were not different in 
GCN2-/- mice suggesting that regulation of SREBP-1c may underlie some of the other 
transcriptional changes in genes involved in fatty acid synthesis.  They did not, 
however, pursue the role of SREBP-2 in the regulation of sterol synthesis in their 
study which focused on regulation of triglyceride synthesis.  Nevertheless, our 
findings support their hypothesis that amino acid deficiency has effects on overall 
macronutrient metabolism and, in particular, leads to a restriction of lipid synthesis.  
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Deprivation of a single amino acid likely results in amino acid-specific changes in 
gene expression in addition to those mediated by the ISR 
In the previously reported analysis of -Cys/+Cys microarray results, we 
selected genes that were differentially expressed under conditions of both 6-and 42-h 
culture in treatment medium.  Of the 24 genes significantly differentially expressed (P 
≤ 0.0001) after both 6-and 42-h culture in -Cys/+Cys medium (Table 2 of Lee et al., 
2008, see appendix 3), 16 remained on the list of genes differentially expressed in both 
the -Leu/+Leu and -Cys/+Cys conditions reported here.  All of the genes known to 
contain functional AAREs that were differentially expressed in response to both short-
and long-term culture in -Cys medium (ATF3, C/EBPβ, SLC7A11, SLC7A1, and 
TRIB3), along with CARS, MAP1LC3B, VLDLR, ARHGEF2, INHBE, DAF, CBX4. 
C/EBPc, FLJ10618, MGC16635, and NPIP///LOC339047// LOC440341, were also 
significantly upregulated in response to leucine deprivation in this study.  ASNS, 
FOXO3A, GADD45A, GCLM, LNK, STC2, TUBE1, TXNRD1, and ZFAND1, 
which were significantly upregulated in response to both 6- and 42-h culture in -Cys 
medium were not detected as significantly upregulated in response to -Leu.  These 
genes might be more responsive to cysteine depletion than to depletion of leucine or 
possibly other amino acids.  GLCM and TXNRD1 contain known EpREs and may 
have been responding to glutathione depletion caused by cysteine deprivation.  
 
Identification of transcriptionally regulated targets of the phospho-eIF2a/ATF4 
pathway 
Comparison of the genes identified in this study with those previously 
identified in different studies also aimed at identification of genes that respond to 
eIF2α phosphorylation and ATF4 induction yielded a limited number of genes that 
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were identified in more than one study (Figure 3.3).  These include C/EBPβ, C/EBPγ, 
ATF3, SARS, CARS, CBX4, CLCN3, LMO4, and TXNIP, which were identified in 
this study, as well as ASNS, SLC1A7, NARS, and ERO1L, which were identified in 
two studies of murine fibroblasts but not in our study with HepG2/C3A cells.  It is 
quite interesting that only three of these 13 genes (C/EBPβ, ATF3, and ASNS) have 
been extensively studied as ISR target genes.  C/EBPγ, CBX4, and LMO4 may also be 
important transcriptional regulators of the ISR.  Amino acyl-tRNA synthetases, 
including CARS and SARS, are likely targets and would serve to preserve synthesis of 
critical stress-response proteins in the face of amino acid deprivation.  The roles of 
induction of CLCN3 and TXNIP expression are less clear, and confirmation that levels 
of these proteins increase is still needed.  TXNIP binds reduced thioredoxin and 
inhibits the ability of thioredoxin to reduce other proteins, thus increasing redox stress, 
inhibiting growth and hypertrophy, and causing increased apoptosis (Patwari et al., 
2006).  CLCN3 has been localized to late endosomes/lysosomes where it apparently is 
involved in organelle acidification (Li et al., 2002; Okamoto et al., 2008), and this 
would be consistent with the increase in macroautophagy observed in nutrient-
depleted cells (Tallóczy et al., 2002; Kuma et al., 2004; Komatsu et al., 2005).  
 
SUMMARY 
The ISR is generally viewed to be adaptive and to promote cell survival in the 
face of stress.  The downregulation of expression of genes involved in cell growth and 
division, as well as the global reduction in protein synthesis that is a consequence of 
eIF2α phosphorylation, is consistent with cell survival under conditions of nutrient 
limitation.  At the same time, the induction of expression of genes involved in amino 
acid uptake and aminoacyl-tRNA synthesis and reduced expression of lipogenic genes 
suggest that eukaryotic cells may attempt to adapt to an amino acid-or nutrient-limited 
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environment by facilitating more efficient utilization of the limited resources (i.e., 
amino acids, other nutrients) and upregulating stress response genes, while at the same 
time suppressing overall protein synthesis, cell proliferation, and growth.  All of these 
responses can be seen as consistent with cell survival under conditions of nutrient 
limitation.  We have compiled a list of 120 genes whose expression was differentially 
expressed in HepG2/C3A cells cultured in either cysteine-or leucine-deficient 
medium, and this list contains many of the genes known to respond to eIF2α kinase 
activation and to be components of the ISR.  Clearly, amino acid deficiency, including 
cysteine deficiency in the absence of oxidative stress, induces eIF2α phosphorylation, 
presumably by activation of GCN2, leading to changes in expression of ATF4 and 
stress-related target genes.  This list of target genes should be useful, as an initial step, 
in identifying potential components of the ISR as well as possibly identifying some 
genes that are differentially expressed in response to amino acid deprivation but not 
other stress conditions.  Comparison of genes that were highly upregulated in 
HepG2/C3A cells cultured in -Cys and also in -Leu medium with lists generated by 
other investigators for genes induced in murine fibroblasts in response to eIF2α 
phosphorylation yielded a small list of only nine common genes (C/EBPβ, C/EBPγ, 
ATF3, SARS, CARS, CBX4, CLCN3, LMO4, and TXNIP).  These nine genes are 
likely to be robust targets of the phospho-eIF2α/ATF4-mediated pathway of 
transcriptional regulation, although only two of them (C/EBPβ and ATF3) have so far 
been well characterized as target genes. 
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CHAPTER 4 
GROWING RATS RESPOND TO A SULFUR AMINO ACID-DEFICIENT 
DIET BY PHOSPHORYLATION OF THE ALPHA SUBUNIT OF 
EUKARYOTIC INITIATION FACTOR 2 HETEROTRIMERIC COMPLEX 
AND INDUCTION OF ADAPTIVE COMPONENTS OF THE INTEGRATED 
STRESS RESPONSE 
 
INTRODUCTION 
The ability of an organism to adapt to and cope with stress constitutes a crucial 
survival advantage, and the study of stress response mechanisms is of great interest in 
terms of possible applications to health promotion and disease prevention or treatment. 
Mammalian cells respond to various kinds of stress, including nutritional stress, via 
pathways that are initiated by phosphorylation of the α subunit of the eukaryotic 
initiation factor 2 heterotrimeric complex (eIF2α).  Mammalian eIF2α kinase 4, which 
is usually called general control of amino acid biosynthesis, nonderepressing 2 
(GCN2) after its yeast ortholog, is responsible for the cellular response to a lack of 
essential amino acids (Wek et al., 1995). Phosphorylation of eIF2α leads to 
simultaneous control of global and gene-specific translation, a response that is 
collectively referred to as the integrated stress response (ISR) (Harding et al., 2003; 
Harding et al., 2000; Kimball et al., 1991). 
A key component of the ISR is an increase in translation of activating 
transcription factor (ATF) 4 (Kilberg et al., 2009; Shan et al., 2009; Wek et al., 2006; 
Lu et al., 2004a; Harding et al., 2000).  The presence of inhibitory upstream open 
reading frames (ORF) promotes read-through of the ATF4 translational start codon, 
preventing ATF4 translation under normal conditions in which ternary complex is 
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abundant. Under stress conditions in which eIF2B is inhibited by eIF2α-P and ternary 
complex formation is reduced, ribosomal scanning through the inhibitory upstream 
ORF start codon is favored so that initiation occurs at the downstream ATF4 ORF 
start codon, allowing ATF4 to be translated.  ATF4 then is involved in upregulation of 
expression of a subset of genes, including the ATF4 gene at the transcriptional level. 
Many of the genes known to be transcriptionally upregulated by the eIF2α-
P/ATF4-mediated stress response pathway contain C/EBP-ATF composite sites that 
are also known as amino acid response elements (AARE) or CCAAT-enhancer 
binding protein activation transcription factor response elements (Kilberg et al., 2009; 
Shan et al., 2009; Harding et al., 2000).  Genes that have been clearly established to 
contain a functional AARE and to be transcriptionally induced by the eIF2α-P/ATF4 
pathway include those encoding several transcription factors [ATF4, ATF3, C/EBPβ, 
and C/EBP-homologous protein (CHOP)]; several members of the solute carrier 
(SLC) family amino acid transporters (sodium-coupled neutral amino acid transporter 
20 or SLC38A2); high affinity cationic amino acid transporter 1 (CATl ) or SLC7A1; 
and the transporter subunit of the cystineglutamate exchanger Xc- (xCT) or SLC7A11; 
an enzyme for amino acid biosynthesis [asparagine synthetase (ASNS)]; and a putative 
protein kinase [nibbles homolog 3 (TRIB3)] (Shang et al., 2010; Kilberg et al., 2009; 
Shan et al., 2009; Pan et al., 2007; Palii et al., 2006; Ohoca et al., 2005; Sato et al., 
2004; Harding et al., 2000). 
Studies in GCN2 knockout mice and murine cells have shown that the GCN2 
pathway is the major signaling pathway involved in the up- and down-regulation of 
gene expression in response to amino acid starvation.  Studies in murine embryonic 
stem cells and immortalized embryonic fibroblasts showed that eIF2α phosphorylation 
was not activated in GCN2-/- cells exposed to leucine-devoid medium (Deval et al., 
2009; Zhang et al., 2002). Zhang et al. (2002), further showed that perfused livers of 
 55
GCN2-/- mice did not display induction of eIF2α phosphorylation in response to 
histidine deprivation as occurred in wild-type mice.  Anthony et al. (2004) reported 
that GCN2-/- mice fed a leucine-free diet for 1 h or 6 days did not show increased 
phosphorylation of hepatic eIF2α or restriction of liver protein synthesis, whereas 
increased phosphorylation of eIF2α and concomitant decreased protein synthesis were 
observed in liver of wild-type mice.  Similarly, asparaginase treatment of GCN2-/- 
mice lowered asparagine levels but did not lead to increased phosphorylation of eIF2α, 
whereas hepatic   eIF2α-P levels were increased in wild-type mice and in mice with a 
liver-specific deletion of a different eIF2α kinase (i.e. eIF2α kinase 3, also known as 
PERK) (Bunpo et al., 2009). 
Because the models used to study eIF2α-kinase-mediated responses to amino 
acid deficiency have commonly used media or diets devoid of one or more essential 
amino acids, we asked whether eIF2α-kinase-mediated responses would be induced in 
animals fed a more typical diet that was marginal in essential amino acid composition 
but not as imbalanced as one in which a single essential amino acid is totally absent.  
To answer this question, we fed rats soy protein-based diets that were either adequate 
(+SAA) or limiting in sulfur-containing amino acids (-SAA) and evaluated eIF2α 
phosphorylation and protein expression levels for ATF4 and other ISR-target genes in 
the livers of these rats. 
 
 
 
 
 
 
 
 56
MATERIALS AND METHODS 
Diets 
Rats were fed a semipurified diet that contained 100 g of soy protein isolate 
plus 3.4 g L-methionine/kg diet (+SAA) or that contained 100 g of soy protein-isolate 
but no supplemental SAA (-SAA) (Table 4.1).  L-Threonine and L-lysine were added 
to both diets to ensure that the      -SAA diet would be limiting only in SAA.  These 
experimental diets were mixed with an equal volume of a hot 0.003% (wt:v) agar 
solution, cooled, refrigerated, and cut into cubes for feeding. The -SAA diet provided 
1.1 g of methionine plus 1.1 g of cyst(e)ine, or a total of 2.46 g of methionine 
equivalents (1.24 g cystine = 1.0 g methionine)/kg diet.  With the addition of L-
methionine, the +SAA diet provided a total of 5.86 methionine equivalents. 
 
Table 4.1.  Composition of experimental diets 
Ingredient +SAA -SAA 
 g/kg diet 
Soy protein isolate (86% 
purity) 
100 100 
L-Methionine 3.40 0 
L-Threonine 1.82 1.82 
L-Lysine 0.58 0.58 
Cornstarch 497.5 497.5 
Dextrinized cornstarch 165 165 
Sucrose 94.2 97.2 
Cellulose 50 50 
Soybean oil 40 40 
AIN-93-M vitamin mix 35 35 
AIN-93-M mineral mix 10 10 
Choline bitartrate 2.5 2.5 
Tetra-butylhydroquinone 0.008 0.008 
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Rats, treatments, and sample collection 
Male Sprague-Dawley rats (N = 24) that were ∼5 weeks old and weighed ∼120 
g were purchased from Harlan Sprague Dawley and housed in individual 
polycarbonate cages with corncob bedding at 20°C and 60-70% humidity with light 
from 2100 to 0900 h.  Rats were allowed free access to diet and water at all times.  All 
rats were fed the +SAA diet for 1 week prior to experimental group assignment.  At 
the end of the acclimation week, the rats were distributed among 4 treatment groups 
using a random block design to ensure an even distribution of larger and smaller rats.  
Rats were fed the assigned experimental diets, with fresh diet given at the beginning of 
each dark cycle each day.  Feed intake and body weight were measured at intervals. 
On day 8, 1 group of rats fed each diet was killed between 0800 and 0900 h (feed-
deprived) and the other group fed each diet was killed between 1400 to 1500 h (fed).  
Rats were anesthetized with CO2 and quickly decapitated.  The liver was rapidly 
removed, rinsed with ice-cold saline, blotted, weighed, and quickly frozen in liquid 
nitrogen.  Frozen tissues were stored at -80°C until analysis.  Rats were killed and 
samples were collected in the order of assigned blocks, but rats within each block were 
killed randomly.  All animal procedures were approved by the Cornell University 
Institutional Animal Care and Use Committee. 
 
Analysis of protein expression levels  
Rat liver was homogenized in TNESV lysis buffer supplemented with protease 
and phosphatase inhibitors [50 mmol/L Tris, pH 7.5, 1% (v:v) Nonidet P-40, 2 
mmol/L EDTA, 150 mmol/L NaCl, and 10 mmol/L sodium orthovanadate] 
supplemented with 1 × PhosSTOP phosphatase inhibitor cocktail (Roche Applied 
Science) and 1 × Complete Protease Inhibitor Cocktail (Roche), to form 20% (wt:v) 
homogenates.  Homogenates were centrifuged at 4°C at 18,000×g for 20 min to obtain 
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the soluble fraction.  Nuclear extracts of liver were obtained by the method of Sha et 
al. (Sha et al., 2009).  Protein concentration was determined using the bicinchonic acid 
assay (Pierce) and equal amounts of total protein were loaded for western blotting.  
For western blotting, 50 µg of total supernatant protein from each sample was 
separated by one-dimensional SDS-PAGE (12% wt:v acrylamide) and electroblotted 
overnight onto 0.45-µm (pore size) Immobilon-P PVDF membranes (Millipore).  
Membranes were immunoblotted for proteins of interest using the following 
antibodies: anti-pS51-eIF2α, anti-eIF2α (total), and anti-β-actin from Cell Signaling 
Technology; antiATF4 (gift from M.S. Kilberg, University of Florida, Gainesville, 
FL); anti-ATF3 (C-1 9), anti-ASNS (C-14), anti-CHOP, anti-heat shock protein 5A 
(HSP5A), anti-TRIB3, and anti-growth arrest and DNAdamage-inducible protein 34 
(GADD34) (H-1 93) from Santa Cruz Biotechnology; anti-SLC7All (xCT) and anti-
cysteinyl-tRNA synthetase (CARS) from Abcam Inc; and anti-cystathionine γ-lyase 
(CTH) from Abnova.  Bands were visualized using horseradish peroxidase-coupled 
secondary antibodies and chemiluminescent substrates (West Dura, Pierce) and 
autoradiography.  Visualization, normalization, and analysis of the bands were done as 
described by Dominy et al. (2007). 
 
Measurement of hepatic glutathione and cysteine levels  
Total intracellular cyst(e)ine levels were measured by a modified acid ninhydrin 
method of Gaitonde (1967) as described by Dominy et al. (2007).  Total glutathione 
levels were measured by the method of Cereser et al. (2001) (for more detailed 
methodological procedures see appendix 1). 
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Statistical analysis 
Results for the 2 dietary treatment groups and 2 time points were compared by 
2-way ANOVA.  Liver GSH values were transformed to log10 prior to ANOVA.  
Results for all variables except nuclear CHOP levels were similar for both time points.  
Thus, except for the nuclear CHOP results, data for both time-points were collapsed.  
Results for the 2 dietary treatments were analyzed by Student's t test.  Significance 
was accepted at P ≤ 0.05. 
 
RESULTS 
Upon switching from the +SAA diet to the -SAA diet at the beginning of the 
experimental period, feed intake of the -SAA group over the first 4 days was less (P ≤ 
0.01) than that of rats that continued to consume the +SAA diet and weight gain over 
the same 4 days was only 10% that for +SAA rats (Figure 4.1A).  Rats appeared to 
adapt to the -SAA diet, however, as both feed intake and weight gain of the -SAA rats 
were much greater during days 5-7 of the diet treatment period.  In fact, the feed 
intake of the -SAA rats for the last 3 days of the diet treatment period did not differ 
from that of +SAA for control rats and mean weight gain was 66% of that for the 
+SAA rats.  Although the -SAA rats were smaller than the +SAA rats (152 ± 3 vs. 181 
± 2 g after 7 days of treatment), the differences in feed intake and weight gain 
remained when data were expressed relative to body weight (Figure 4.1B). 
Hepatic thiol levels, measured at the end of the 7-day dietary treatment period, 
were markedly lower in the -SAA rats than in the +SAA rats.  Total cysteine in the -
SAA rats was 49% of that in +SAA rats, whereas total glutathione was only 17% of 
the level in +SAA rats (Figure 4.2). 
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Figure 4.1.  Absolute (A) and relative (B) daily weight gain and daily feed intake of 
rats fed the  -SAA and +SAA diets for 7 days. Gains and intakes were determined over 
2 periods, days: 1–4 (mean of 4 days) and days: 5–7 (mean of 3 days). In B, data are 
expressed relative to body weight at days 0 or 4, as appropriate. Values are means ± 
SEM, N=12. Asterisks indicate different from +SAA: **P ≤ 0.001, *P ≤ 0.05.  
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Figure 4.2. Total cysteine and total glutathione levels in liver of rats fed the -SAA and 
+SAA diets for 7 days. Values are means ± SEM, N=12. Asterisks indicate different 
from +SAA: **P ≤ 0.001, *P ≤ 0.01. 
 
Phosphorylation of eIF2α (Ser51) was induced in rats fed the -SAA diet (Figure 
4.3A & B). Values for eIF2α-P and total eIF2α did not differ for rats killed at the 2 
different time-points (feed-deprived vs. fed).  The amount of eIF2α-P in liver of the -
SAA rats was 1.6 times that of the +SAA rats, whereas total eIF2α levels did not differ 
for livers of the -SAA and +SAA rats. 
 
 
 62
 
 
 
Figure 4.3.  Western blots (A) and mean fold values (B) for phosphorylation of Ser51 
of eIF2α in liver of rats fed the -SAA vs. +SAA diet. (A) Examples of western blots 
for rats killed at either the end of the light period (feed-deprived) or at the mid-point of 
the dark period (fed). Equal amounts of total protein were loaded per lane. (B) Mean 
fold values for phospho-eIF2α and total eIF2α relative to the mean density for the 
+SAA rats. Values are means ± SEM, N=12. Asterisks indicate different from +SAA: 
*P ≤ 0.05.  
 
Protein levels for ATF4 in liver of the -SAA rats was 4.5 times that in liver of 
the +SAA rats (Figure 4.4).  Expression of several other proteins whose genes contain 
a functional AARE and are induced by ATF4 was also higher in the -SAA rats than in 
the +SAA rats.  ATF3, ASNS and SLC7A11 protein levels in liver of the -SAA rats 
were 2.4, 1 .6, and 2.5 times, respectively, those for +SAA rats.  Similarly, the level of 
CARS and CTH, 2 proteins involved in SAA metabolism whose gene expression 
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(mRNA) levels were upregulated (>2-fold difference; P < 0.0001) in our previous 
studies of cysteine and leucine deprivation in HepG2 cells (Lee et al., 2008; A.K. 
Sikalidis, J-I. Lee, and M.H. Stipanuk, unpublished data), were also induced in liver of 
-SAA rats to 1.6 and 2.1 times, respectively, the levels in liver of +SAA rats.   
On the other hand, expression of CHOP was not detectable in liver 
homogenates from either group of rats and protein expression levels for TRIB3 (a 
direct ATF4 target) and growth arrest and DNA damage protein 34 [GADD34; also 
known as PPP1R15A for protein phosphatase 1, regulatory (inhibitor) subunit 15A, 
which is a downstream target], were not increased.  Because CHOP was not detectable 
in the whole tissue preparations, we also assessed CHOP expression in nuclear 
extracts.  Only basal low levels of CHOP were measured in the nuclear extracts and 
these levels did not differ for the 2 dietary groups, although they did differ for the fed 
and feed-deprived states in both diet groups (Figure 4.4A), with expression levels 
being lower (P ≤ 0.05) in feed-deprived rats than in fed rats. 
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Figure 4.4.  Western blots (A) and mean fold values (B) for protein expression levels 
of ATF4 and its transcriptional targets in liver of rats fed the -SAA and +SAA diets. 
(A) See Figure 3A legend for details. (B) Mean fold values for protein levels relative 
to the mean density for the +SAA rats. Values are means ± SEM, N=12, except for 
values for CHOP. For CHOP, values are reported only for rats killed in the fed state 
(N=6), because values were different, P < 0.05, for rats killed in the feed-deprived 
state and values are for nuclear extracts instead of total soluble protein. Nuclear CHOP 
in -SAA rats was 0.44-fold that of the +SAA rats. Asterisks indicate different from 
+SAA: **P ≤ 0.001, *P ≤ 0.01.  
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DISCUSSION 
Rats fed the -SAA diet displayed reduced growth and low cysteine and 
glutathione levels. Rats in this study were fed a -SAA diet that provided ~70% of the 
mean SAA requirement for growing rats but was adequate in all other amino acids 
(Bella et al., 1999; Bella et al., 1996; Stockland et al., 1973).  The diminished levels of 
hepatic cysteine and glutathione in rats fed the         -SAA diet demonstrated that the 
rats were indeed deficient in SAA.  Hepatic glutathione levels were reduced to a 
greater extent (17% of control levels) than hepatic cysteine levels (49% of control), 
suggesting that body cysteine levels were sustained at the expense of the glutathione 
pools and most likely that SAA were used preferentially for protein synthesis 
compared with glutathione synthesis under conditions of dietary SAA limitation.  This 
is consistent with previous reports that glutathione levels become depleted at SAA 
intakes that are marginal but adequate for sustaining protein synthesis and growth (Lee 
et al., 2004; Stipanuk et al., 1992). 
Consistent with the inadequate level of dietary SAA and with the well-
established effects of essential amino acid-deficient diets on growth of rats, rats fed 
the -SAA diet grew more slowly throughout the 7-day experimental period.  Over the 
first 4 days of the dietary treatment period, -SAA rats gained only 10% as much 
weight as did rats fed the +SAA diet.  This difference was reduced markedly over the 
subsequent 3 days of treatment, however, with rats fed the -SAA diet gaining 66% as 
much weight as did rats fed the +SAA diet. During the first 4 days of the experimental 
period, the -SAA rats consumed only 76% as much diet as the rats that continued to be 
fed the +SAA diet and the reduced food intake undoubtedly contributed to their low 
weight gain over this period.  However, food intake for the subsequent 3 days did not 
differ between rats fed the -SAA and +SAA diets.  Although food intake of the -SAA 
rats increased by only 1.3 g/d (7.8%) between the first and second halves of the 
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experimental period, mean daily weight gain increased by 3.8 g (633%).  Thus, the 
increase in food intake cannot explain the much better growth of rats during the 
second part of the dietary treatment period.  This suggests that the more adequate rate 
of growth during the latter time-period may have mainly been due to metabolic 
adaptations of the rats to allow growth when consuming the nutrient-limited diet.  
Such a metabolic adaptation could relate to a suppression of SAA degradation and/or 
to a more efficient utilization of the limited amounts of SAA available.  Nevertheless, 
despite an apparent adaptation to the diet, the mean daily weight gain during the 
period from day 4 to 7 (expressed relative to day 4 weight) remained less (P ≤ 0.05) 
for -SAA rats (3.2 ± 0.3 g/100 g body weight) than for +SAA control rats (4.3 ± 0.2 
g/100 g body weight), which is consistent with the fact that animals cannot completely 
adapt to a diet lacking in an essential nutrient that they are not able to synthesize. 
We did not include a pair-fed control group in this study, because we did not 
anticipate a difference in food intake between the 2 groups.  In previous studies in 
which rats were fed a SAA-deficient diet that contained 100 g casein/kg, food intake 
was the same or slightly greater than that of rats fed an adequate diet that contained 
either 100 g casein/kg diet supplemented with methionine or 200 g casein/kg without 
SAA supplementation (Bella et al., 1999; Bella et al., 1996).  Nevertheless, because 
we collected samples on day 8, several days after food intake of the -SAA rats had 
returned to levels not significantly different from those for +SAA rats, a major effect 
of food intake on our results seems unlikely.  Some of the consequences of the         -
SAA dietary treatment in this study could have been due to the modest early 
restriction of food intake rather than to the lack of SAA and a pair-fed group or a 
longer feeding period would be appropriate for any future studies using the -SAA diet 
prepared with 100 g soy protein isolate/kg. 
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Rats fed the -SAA diet displayed increased phosphorylation of eIF2α  
Phosphorylation of eIF2α was clearly induced in liver of intact rats fed the -
SAA diet for 7 days, which is consistent with the activation of a stress-induced eIF2α 
kinase, presumably GCN2, in response to SAA deprivation.  In contrast to previous 
studies of the role of GCN2 and/or eIF2α phosphorylation in the response of intact 
animals to amino acid deprivation (Guo et al., 2007; Anthony et al., 2004; Anthony et 
al., 2001), the diet used in this study was limiting in, but not devoid of, an essential 
amino acid.  Thus, our results extend the observations in mice to the situation in which 
the diet is only partially deficient in an essential amino acid (i.e. SAA), to an amino 
acid pattern that is more representative of that in diets consumed by humans and 
animals, and to a diet that has been shown to support both growth and longevity 
(Zimmerman et al., 2003; Orentreich et al., 1993; Hosokawa et al., 1988). 
One of the consequences of eIF2α phosphorylation is a reduction in the rate of 
protein synthesis.  Both absolute liver weight and relative liver weight were lower in 
rats fed the -SAA diet than in rats fed the +SAA diet, with the relative liver weights 
being 3.5 ± 0.3 and 4.6 ± 0.5 g/100 g body weight for the -SAA and +SAA groups, 
respectively.  The lower relative liver weight in -SAA rats is consistent with 
diminished protein synthesis in liver in response to eIF2α phosphorylation, although, 
of course, we cannot exclude an effect of protein turnover, because we did not 
measure synthesis rates directly in this study.  Suppression of hepatic protein synthesis 
might facilitate increased utilization of the limiting amino acid for muscle protein 
synthesis and growth and this interpretation would be consistent with the observation 
of no difference in the relative weights of the gastrocnemius and planteris muscles and 
epididymal adipose depot between rats fed the -SAA and +SAA diets (data not 
shown).  This interpretation of our data is supported by the earlier work of Anthony et 
al. (2004) with GCN2 knockout mice.  Wild-type control mice fed a leucine-free diet 
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for 6 days lost liver mass while preserving muscle mass, whereas GCN2-/- mice fed the 
same leucine-free diet maintained their liver mass but lost muscle mass and lost more 
body mass than the wild-type mice.  Furthermore, the rate of hepatic protein 
translation was reduced in wild-type but not in GCN2-/- mice fed the leucine-free diet, 
suggesting that translational repression in the liver of rats fed diets limiting in essential 
amino acids may play an important role in conserving muscle and body mass. 
 
Rats fed the -SAA diet displayed increased expression of proadaptive proteins that 
are known components of the ISR 
Our protein expression data indicate that the eIF2α-P/ATF4-mediated ISR was 
induced in liver of the -SAA rats compared with the +SAA rats.  In particular, we saw 
large increases in the relative abundance (amount per g total soluble protein) of ATF4, 
ATF3, SLC7A11, and CTH, along with smaller fold-increases in ASNS and CARS.  
ATF4 and ATF3 are important transcription factors that initiate and regulate the ISR, 
whereas the other proteins are involved in amino acid transport and metabolism and 
have been reported to be induced under stress conditions that initiate eIF2α 
phosphorylation (Lee et al., 2008; Lu et al., 2004a; Lu et al., 2004b; Harding et al., 
2003) (A.K. Sikalidis, J-I. Lee, and M.H. Stipanuk, unpublished data). Induction of 
genes involved in amino acid uptake and aminoacyl-tRNA synthesis may play an 
important role in the adaptation of rats to diets limiting in essential amino acids. In the 
case of SAA deprivation, the strong induction of SLC7A11 (xCT), which is the 
transporter subunit of the cystineglutamate exchanger Xc-, of CARS, the cysteinyl-
tRNA synthetase, and of CTH, which is involved in cysteine synthesis from 
homocysteine and serine as well as in desulfhydration of cysteine, suggests that 
cysteine utilization is highly regulated under conditions of SAA deficiency. 
 
 69
Rats fed the -SAA diet did not display increased expression of pro-apoptotic proteins 
that are known components of the ISR 
Despite the clear induction of eIF2α phosphorylation and increased expression 
of ATF4, ATF3, ASNS, SLC7A11, CARS, and CTH in liver of the -SAA rats, several 
other downstream targets of the eIF2α-P/ATF4 signaling pathway were not induced.  
Expression of CHOP, which has a well-established role in the induction of apoptosis 
(Su and Kilberg, 2008; Tamaki et al., 2008; Marciniak et al., 2004; Oyadomari et al., 
2004), was clearly not induced in liver of -SAA rats, being nearly undetectable, even 
in nuclear extracts.  Consistent with the lack of upregulation of CHOP in liver of rats 
fed the -SAA diet, levels of TRIB3 and GADD34 proteins, whose transcriptional 
induction is dependent upon CHOP (Shang et al., 2010; Ohoka et al., 2005), were not 
elevated.  The lack of increased expression of CHOP, TRIB3, or GADD34 proteins 
suggests that activation of the GCN2/eIF2α-P/ATF4 signaling pathway does not 
necessarily result in induction of all downstream target genes and is consistent with 
the variable induction of mRNA and/or protein levels for ISR genes reported 
previously for HepG2 cells (Palii et al., 2006; Zimmerman et al., 2003) (A. K. 
Sikalidis, J-I. Lee, and M. H. Stipanuk, unpublished data). Induction of pro-survival 
and pro-apoptotic components of the ISR might be anticipated to vary with the degree 
or type of stress and with whether the ultimate response is cell survival or apoptotic 
death.  In the case of this study, although the stress of a modest SAA deficiency was 
sustained, rats appeared to effectively adapt and showed no obvious adverse effects 
other than a slightly lower rate of growth. 
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Induction of the ISR in response to a marginal intake of essential amino acids could 
play a role in the beneficial effects of amino acid restriction on longevity in animal 
models 
A number of studies have shown an association of eIF2α phosphorylation with 
induction of a state of stress resistance in cells (Orentreich et al., 1993; Hosokawa et 
al., 1988).  This study now shows that modest SAA restriction can induce the ISR in 
liver of intact growing rats.  Others have shown that lowering the SAA level in the diet 
can extend lifespan in rats. Zimmerman et al. (2003) reported that lowering the content 
of SAA in the diet by removing cysteine and restricting the concentration of 
methionine extended all measured survival variables in various rat strains, and pair-
feeding of control rats with a SAA-supplemented diet demonstrated that the increase 
in survival was not simply due to caloric restriction.  Additionally, methionine 
restriction was shown to decrease mitochondrial oxygen radical production and 
oxidative damage to mitochondrial DNA and cellular proteins (Sanz et al., 2006).  The 
postulate that eIF2α phosphorylation in response to modest levels of cellular stress can 
play a key role in building resistance and tolerance toward subsequently imposed more 
severe stressful conditions has been supported by a variety of in vitro studies 
(Raffaghello et al., 2008; Lu et al., 2004b; Harding et al., 2003; Jousse et al., 2003).  
Additional studies, however, will be required to assess whether mild essential amino 
acid limitation can result in a more stress-resistant animal and whether enhanced 
phosphorylation of eIF2α and its downstream consequences contribute to the 
favorable effects of SAA restriction on longevity. 
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CHAPTER 5 
TOTAL 4E-BP1 LEVELS ARE ELEVATED IN LIVERS OF RATS FED DIETS 
LOW IN PROTEIN OR SULFUR AMINO ACIDS 
 
INTRODUCTION 
Adaptation to environmental stresses is important for survival.  In this context 
adaptation mechanisms for stressful conditions such as amino acid limitation are 
widely seen in nature. Because mammals lack a mechanism to store amino acids, a 
constant supply of them is essential (Wek et al., 2006; Tettweiler et al., 2005). Amino 
acid availability needs to be ensured so that protein synthesis can occur and support 
survival, growth and healing processes.  Optimization of amino acid uptake and 
utilization constitutes an important adaptation strategy during amino acid limitation. 
Such optimization can be achieved via reduction of protein synthesis, decreased 
growth and cell division, and increased synthesis of particular proteins including 
amino acid transporters and amino acyl-tRNA synthetases. 
Under normal circumstances, translation initiation requires the formation of 
two main complexes, the 43S pre-initiation complex and the eukaryotic translation 
initiation factor 4F (eIF4F) complex (Yamaguchi et al., 2008). The formation of the 
43S pre-initiation complex begins with the formation of a ternary complex composed 
of Met-tRNAiMet, eukaryotic initiation factor 2 (eIF2), and GTP (Holcik et al., 2005, 
Gabauer et al., 2004).  Once the ternary complex is formed it then associates with the 
40S pre-initiation complex and other initiation factors to generate the 43S pre-
initiation complex.  On the other hand, the eIF4F complex is comprised of three 
subunits:  eIF4E, which is the cap-binding protein; eIF4A, which is an RNA helicase; 
and eIF4G, which serves as a scaffolding protein (Gabauer et al., 2004).  The eIF4F 
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complex associates with the 5΄-cap structure of the mRNA through the binding of the 
eIF4E subunit to the m7GTP (m7GpppN) cap at the 5΄-end of the mature mRNA.  The 
eIF4G subunit recruits the 43S pre-initiation complex to the mRNA strand through the 
binding of the 43S pre-initiation complex to eIF3.  The 43S pre-initiation complex and 
the eIF4 proteins thus form a translation competent 48S complex, which begins to 
scan for the AUG (start codon) to begin translation.  Stable binding of the 43S pre-
initiation complex to the AUG codon triggers the joining of the large (60S) ribosomal 
subunit, associated with the hydrolysis of eIF2-bound GTP and release of eIF2-GDP, 
to form the 80S complex.  The 80S complex can catalyze the formation of the first 
peptide bond in the generation of the polypeptide chain (Gabauer et al., 2004).  To 
begin another round of initiation, eIF2-GDP is recycled to eIF2-GTP by a reaction 
catalyzed by eIF2B, the guanine nucleotide exchange factor for eukaryotic initiation 
factor 2 (Gabauer et al., 2004).   The 43S pre-initiation complex is needed for both 
cap-dependent and cap-independent initiation, whereas the eIF4F complex is needed 
only for cap-dependent initiation. 
In situations of nutrient deprivation or other stresses, translation initiation is 
regulated to allow for immediate and rapid response to changes in the environment.  
Two mechanisms have been found to prevent the assembly of the aforementioned 
complexes, one involving the regulation of the ability of eIF4E-binding protein (4E-
BP) to bind to eIF4E and block the formation of the eIF4F complex and another 
involving the regulation of the formation of the ternary complex which in turn affects 
the rate of formation of the 43S pre-initiation complex (Holcik et al., 2005).  
The 4E-BPs constitute a family of three small (10-12 kDa) acidic proteins that 
act as repressors of translation initiation (Gingras et al., 1999).  The three members of 
the 4E-BP family, 4E-BP1, 4E-BP2, and 4E-BP3, interact with eIF4E, the cap-binding 
component of the eIF4F complex, which recruits mRNA to the polysomes (Poulin et 
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al., 1998).  eIF4E is present in rate-limiting amounts so the binding of eIF4E by 4E-
BP inhibits complex assembly and thus represses cap-dependent translation (Mader et 
al., 1995).  The binding of eIF4E is reversible and is dependent on the phosphorylation 
state of 4E-BP.  Hypophosphorylated 4E-BP interacts with eIF4E whereas 
hyperphosphorylated 4E-BP does not (Gingras et al., 1999).  The three members of the 
4E-BP family are homologous to one another, with most striking homology in the 
middle region of the protein that contains the eIF4E binding motif and the residues 
that are phosphorylated.  The redundancy in genes encoding4E-BP emphasizes the 
importance of eIF4E binding (Poulin et al., 1998).  
The mammalian target of rapamycin (mTOR) pathway is responsible for 
regulating the phosphorylation state and eIF4E binding affinity of 4E-BP in response 
to insulin and other growth factors, amino acids, and cellular energy status.  mTOR 
signaling is positively regulated by growth factors such as insulin, ATP/AMP ratio, 
and amino acids, especially leucine (Schmelzle, 2000).  Under conditions of nutrient 
availability, active mTOR phosphorylates 4E-BP, rendering it inactive (Schmelzle, 
2000).  Under these conditions, eIF4E is able to bind to eIF4G, promoting the 
formation of the eIF4F complex and the initiation of cap-dependent mRNA 
translation.  However, low energy or low amino acid status in cells or a lack of insulin 
or IGF-1 can reduce the activation state of mTOR.  Inactive mTOR is unable to 
phosphorylate its downstream target 4E-BP, making 4E-BP available to bind to eIF4E 
and to displace eIF4G.  With the eIF4F complex unable to be assembled, cap-
dependent translation initiation is inhibited (Haghighat et al., 1995). 
The second known mechanism for regulation of translation initiation in 
response to nutrient deprivation or other stresses acts via the regulation of a group of 
eIF2α kinases.  One of these eIF2α kinases is General Control Nonderepressible 
kinase 2 (GCN2), which is activated in cells that are deprived of essential amino acids 
 74
(Harding et al., 2000). The histidyl-tRNA synthetase (HisRS)-like domain of GCN2 
senses the non-aminoacylated tRNAs that are increased during an amino acid 
deprivation state.  With the binding of tRNA, the HisRS domain undergoes a 
conformational change that propagates the juxtaposed protein kinase domain, eliciting 
kinase activation (Padyana, 2005).  Consequently, GCN2 kinase phosphorylates the 
Ser51 residue of the alpha subunit of eukaryotic initiation factor 2 (eIF2α).  The 
phosphorylation of eIF2α reduces the dissociation rate of eIF2 from eIF2B, thereby 
sequestering eIF2B.  As a result, GDP-GTP exchange is inhibited (Gabauer et al., 
2004).  The lack of eIF2-GTP reduces the formation of the ternary complex and hence 
the 43S pre-initiation complex, and global mRNA translation in suppressed (Gabauer 
et al., 2004; Harding et al., 2000).   
Somewhat paradoxically, the phosphorylation of eIF2α also increases the 
translation of a few specific existing mRNAs.  Upon eIF2α phosphorylation, upstream 
open reading frames (uORFs) allow for the upregulated translation of certain proteins, 
with activating transcription factor 4 (ATF4) being the best characterized.  ATF4 
induces the expression of other transcriptional regulators, solute carrier family acid 
transporters, genes involved in amino acid biosynthesis, and genes involved in cell 
cycle and DNA repair (Harding et al., 2000).  The downstream response of eIF2α 
phosphorylation has been termed the integrated stress response (ISR) and is associated 
with cell survival and stress resistance.  The ISR is so-named because other kinases in 
addition to GCN2 also phosphorylate eIF2α to activate the ISR.  These other kinases 
include the heme-regulated inhibitor kinase (HRI), which is stimulated by heme 
depletion; protein kinase activated by double-stranded RNA (PKR), which is 
stimulated by viral infection; and PKR-like endoplasmic reticulum kinase (PERK), 
which is activated under endoplasmic reticulum (ER) stress (Gabauer et al., 2004).  
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In a previous animal study (Sikalidis and Stipanuk, 2010), we noticed a 
marked increase in levels of total 4E-BP1 in rats fed a sulfur amino acid-deficient diet 
that was not accompanied with a change in the proportion of 4E-BP1 in the 
hyperphosphorylated state or in the phosphorylation of p70S6 kinase. As these results 
suggested that mTOR signaling was not suppressed in the livers of rats fed the sulfur 
amino acid deficient diet, we decided to investigate further how amino acid/protein 
deficiency under various dietary regimens affect 4E-BP1 levels, mTOR signaling, and 
eIF2α phosphorylation. 
In this study, we exposed rats to a variety of diets that were variably deficient 
in protein, energy, or both, and then examined changes in both 4E-BP total abundance 
and its phosphorylation state (target of mTOR), ribosomal protein S6 (rpS6 a target of 
p70S6 kinase which is a direct target of mTOR) phosphorylation state, and eIF2α 
phosphorylation state (target of GCN2). Thus we aimed to investigate the possibility 
of an increase in 4E-BP1 expression as a third mechanism in regulating translation 
initiation and whether this increased 4E-BP1 expression was associated with eIF2α 
phosphorylation and/or independent of mTOR activation state.  
We hypothesized that a deficiency of either protein or energy at the level of the 
liver would lead to a decrease in hyperphosphorylation of 4E-BP1, as predicted by our 
present understanding of signaling through the mTOR pathway.  In addition, we 
hypothesized that total 4E-BP1 would also be upregulated in response to a deficiency 
in protein or essential amino acids but not in response to energy or feed intake per se.  
Additionally, we conducted a time-course study with one of the deficient diets to 
determine how rapidly the changes in 4E-BP1 occur. 
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MATERIALS AND METHODS 
Diets.  All experimental diets were prepared by Dyets Inc. (Bethlehem, PA) in 
powdered form. The composition of the experimental diets is shown in Table 5.1.  
Diets varied in amount of soy protein or in the amount of L-methionine (M) or L-
cystine (C).  For diet preparation, the powdered diets were mixed with an equal 
volume (1 L/kg diet) of hot agar solution (3 g/L), and the mixture was cooled at room 
temperature, refrigerated and cut into cubes for feeding.  Three of these diets 
supported maximal or near-maximal rates of growth and were considered control 
group for the various deficient diets. 
 
Study 1 
Animals. Male Sprague-Dawley rats that weighed approximately 110 g were 
purchased from Harlan Sprague Dawley (Indianapolis, IN) and were housed in 
individual polycarbonate cages containing corncob bedding, in a holding room 
maintained at 20°C and 60–70% humidity with light from 21:00 to 09:00 h. Rats were 
allowed free access to diet and water at all times (except for the pair-fed animals).  
All rats were fed the 20% soy protein diet, which provided 4.9 Met 
equivalents/kg of diet, for 1 week for acclimation purposes prior to experimental 
group assignment. At the end of the adaptation week, rats were grouped by weight.  
Rats within each block were randomly distributed among the following dietary 
treatment groups:  20% soy protein diet, 10% soy protein diet, 10% soy protein 
supplemented with 0.34% methionine diet, protein free diet, 20% soy protein diet pair-
fed to intake of the protein-free group, 0.23% methionine/0.35% cysteine amino acid 
diet, 0.11% methionine/0.35% cysteine amino acid diet, 0.23% methionine amino acid 
diet, and 0.11% methionine amino acid diet. 
  
Table 5.1. Composition of experimental diets 
Ingredient Control  Control  Control   
 10% soy 
+ 
0.34% M 
10% soy 20% soy Protein free 0.23%M / 
0.35%C 
0.11%M / 
0.35%C 
0.11% M 0.23% M 
 g/kg 
Soy protein 
isolate 
(86% purity) 
100 100 200 0 0 0 0 0 
L-AA mix* 0 0 0 0 172 172 172 172 
L-Methionine  3.40 0 0 0 2.3 1.1 1.1 2.3 
L-Threonine 1.82 1.82 0 0 0 0 0 0 
L-Lysine 0.58 0.58 0 0 0 0 0 0 
L-Cystine  0 0 0 0 3.5 3.5 0 0 
Cornstarch 497.5 497.5 377.5 471.9 389.9 389.9 389.9 389.9 
Dextrinized 
cornstarch 
165 165 155 193.8 155 155 155 155 
Sucrose 94.2 97.6 100 125 102.4 103.6 107.1 105.9 
Cellulose 50 50 50 62.5 50 50 50 50 
Soybean oil 40 40 70 87.5 70 70 70 70 
TBHQ 0.008 0.008 0.014 0.018 0.01 0.01 0.01 0.01 
77 
  
 
 
 
 
 
 
Table 5.1 (Continued) 
Ingredient Control  Control  Control   
 10% soy 
+ 
0.34% M 
10% soy 20% soy Protein free 0.23%M / 
0.35%C 
0.11%M / 
0.35%C 
0.11% M 0.23% M 
Mineral mix 35 35 35 43.8 35 35 35 35 
Vitamin mix 10 10 10 12.5 10 10 10 10 
Choline 
bitartarate 
 
2.5 2.5 2.5 3.1 2.5 2.5 2.5 2.5 
Sodium 
bicarbonate 
 
0 0 0 0 7.4 7.4 7.4 7.4 
Methionine 
equivalents 
5.9 2.5 4.9 0 6.6 5.4 1.1 2.3 
* L-AA mix (g/kg): L-Arginine 6.3, L-Histidine 4.5, L-Tyrosine 9.2, L-Phenylalanine 8.7, L-Leucine 15.3, L-Isoleucine 8.4, L-Valine 9.9, Glycine 3.1, L-
Proline 20.4, L-Glutamic acid 36.2, L-Alanine 4.5, L-Aspartic acid 11.3, L-Serine 9.4, L-Lysine-HCl 16.1, L-Threonine 6.6, L-Tryptophan 2.1. 
- M= L-Methionine ; C= L-Cystine 
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Experimental diets were provided to rats for one week, with fresh diet being 
given daily at the beginning of each dark cycle. Feed intake and body weights were 
measured daily over the experimental period. On each day the pair-fed group was 
given control diet (20% soy diet) at the amount the protein free group had consumed 
the previous day. 
At the midpoint (between 12:50 and 14:20 h) of the dark cycle (feeding cycle) 
on day 7, rats were anesthetized and killed for the collection of samples.  Previous 
experiments (Sikalidis and Stipanuk, 2010) revealed no difference in the choice of the 
termination time-point (fed vs. overnight fast) on phosphorylation status of eIF2α, 4E-
BP1, or S6K. Liver and muscle (gastrocnemius) tissues were rapidly removed, rinsed 
with ice-cold saline, blotted, weighed and frozen in liquid nitrogen. Frozen tissues 
were stored at -80°C until analyses were performed. Rats were euthanized and 
samples were collected in the order of assigned weight blocks, but rats within each 
block were killed randomly. All animal procedures were approved by the Cornell 
University Institutional Animal Care and Use Committee. 
 
Study 2  
Animals. Male Sprague-Dawley rats that weighed approximately 115 g were 
housed with light from 6:00 to 18:00 h. Rats were allowed free access to food (with 
the exception of the pair-fed group) at all times.  All rats were fed an amino acid-based 
control diet that contained 0.23% methionine/ 0.35% cysteine for 1 week prior to 
experimental group assignment.  At the end of the acclimation week rats were blocked 
and rats within each block were assigned to 9 treatment groups (3 diets × 3 time-
points, 4 rats per group). Rats were fed the control 0.23% methionine/0.35% cysteine 
diet, the 0.11% methionine diet or were pair-fed with control diet at the intake of 
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0.11% methionine group. Rats were fed the assigned experimental diets, with fresh 
diet given at the beginning of the dark cycle each day.  Each day the pair-fed group 
was given control diet (0.23% methionine/0.35% cysteine) at the amount the 0.11% 
methionine group had consumed the previous day. Feed intake and body weight were 
measured daily. Rats were killed at the beginning of the light cycle on days 1, 3 and 5 
(4 rats from each of the 3 dietary treatments). For termination, rats were quickly 
decapitated so as to avoid anesthetics that might alter the plasma insulin and glucose 
measurements. The liver was rapidly removed, quickly rinsed with ice-cold saline, 
blotted, weighed and quickly frozen in liquid nitrogen.  Frozen tissues were stored at -
80°C until analysis.  
Blood parameters. Blood glucose was assessed immediately after decapitation 
with a commercial glucometer (Contour, Bayer GmbH). Plasma insulin and IGF-1 
measurements were done at the Hormone Assay & Analytical Services Core, 
Vanderbilt Diabetes Research and Training Center, supported by NIH grant DK20593. 
Plasma insulin was assayed via a radioimmunoassay (RIA), using a double antibody 
procedure by the Hormone Assay and Analytical Services Core, Vanderbilt Diabetes 
Research and Training Center. Plasma IGF-1 was measured by a multi-plexed assay 
using X-map technology via the Luminex100 system by the Hormone Assay and 
Analytical Services Core, Vanderbilt Diabetes Research and Training Center. 
Analysis of protein expression levels in liver homogenates.  Rat livers were 
homogenized to form a 20% (w/v) homogenate [1 part of liver (mg) plus 4 parts of 
buffer (μL)] in TNES lysis buffer with 1× mammalian protease inhibitor cocktail 
(Sigma-Aldrich) and 1× PhosStop phosphatase inhibitor cocktail (Roche Applied 
Science) as well as 50mM of NaF.  The same procedure was followed for the muscle 
samples.  Homogenates were centrifuged for 20 min at 4oC at 18,000×g to obtain the 
soluble protein fraction. The BCA assay was used to determine total protein 
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concentration of the soluble fraction.  Samples containing equal amounts of protein 
(50 μg) were loaded onto a 12% w/v acrylamide gel and run using a large-vertical 
electrophoresis apparatus at a constant I=25 mA per gel. The gel was electroblotted 
overnight onto a 0.45 µm Immobilin-P PVDF membrane (Millipore, Medford, MA).  
Membranes were immunoblotted using anti-4E-BP1, anti-eIF2α, and anti-eIF2αP, 
anti-S6 ribosomal total and S6 ribosomal-P, anti-PKD/PKCμ (Ser916), anti-PKD/PKCμ 
(Ser744/748), anti-PKC(pan) (βII Ser660), anti-PKCα/β II (Thr638/641), anti-PKCδ (Thr505), 
anti-PKCδ/μ (Ser643/676), anti-PKCμ (Thr538) and anti-PKCζ/λ (Thr410/403), anti-REDD1 
(Cell Signaling, Danvers, MA).  For study 1, visualization of bands was accomplished 
using horseradish peroxidase-coupled (HRP) secondary antibodies (1:25,000 dilution 
in 5% (w/v) dry fat free milk in 1×TBST) and chemiluminescent substrates (West 
Dura, Pierce) with exposure to autoradiography film.  Film images were digitized and 
analyzed using NIH Image 1.63 software.  Band intensities were normalized against 
corresponding bands for β-actin loading and transfer controls. For study 2, after 
incubation with respective primary antibodies, membranes were incubated in dark 
with IRDye®-labeled secondary antibody (1:15,000) in Odyssey blocking buffer plus 
0.1%Tween-20 and 0.01%SDS. Then, membranes were washed with PBS and 
scanned on an Odyssey scanner by Li-Cor Biosciences, Lincoln NE, on 680 nm (for β-
actin) and 800 nm (for the protein of interest) channels, using intensity values of 4.0 
and 8.5 respectively. Quantification of bands and normalization by β-actin was done 
using the Li-Cor Odyssey V3.0 software. 
Measurement of hepatic glutathione and cysteine levels.  Total intracellular 
cyst(e)ine levels were measured by a modified acid ninhydrin method of Gaitonde 
(1967), as described by Dominy et al. (2007).  Total glutathione levels were measured 
by the method of Cereser et al. (2001). 
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Statistical analysis.  For comparisons among dietary studies involving more 
than two groups (i.e., 20% soy, protein-free and pair-fed; 0.23%M/0.35%C, 0.11%M 
and pair-fed groups; and 0.23%M/0.35%C, 0.11%M/0.35%C, 0.23%M, and 0.11%M 
groups), the numerical data were analyzed by one-way ANOVA.  Differences were 
accepted as significantly different at P<0.05 by Dunnett’s mean comparison 
procedure, for which the 20% soy and the 0.23%M/0.35%C groups were used as 
control groups. For comparisons between two groups (i.e., 10% soy +0.34%M and 
10% soy groups), results were evaluated by Student’s t-test, and significance was 
accepted at P<0.05. 
 
RESULTS 
Study 1 
Body weight and feed intake 
Overall, at the end of the 7-day experimental period, rats switched from a 20% 
soy diet to a protein-free diet and rats switched from a complete amino acid diet 
(0.23%M/0.35%C) to either of three amino acid deficient diets (0.11%M, 0.23%M or 
0.11%M/0.35%C) exhibited lower feed intake (Table 5.2) as well as lower body 
weight (Table 5.3) compared to their corresponding controls. The group on the 
protein-free diet exhibited a weight loss at an average daily rate of -4.3±1.3g, whereas 
the group pair-fed to the protein-free group grew marginally at a rate of only 10% that 
of the 20% group (control).  The feed intake of the protein-free and pair-fed groups 
was ∼63% of the intake of the 20% soy group. Rats fed diets containing 0.11%M, 
0.23%M, and 0.11%M/0.35%C consumed 62%, 53% and 60%, respectively, as much 
diet as control (0.23%M/0.35%C) rats.  The rats on these deficient diets lost weight at 
an average daily rate of -4.3±1.8g, -2.9±2.2g and -1.1±1.4g, respectively, over 7 days 
as shown in Table 5.2. Rats fed a 10% soy protein diet did not differ significantly in 
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their feed intake, but the 10% soy protein group gained only 40% as much weight over 
7 days as did the control group that was fed the 10% soy + 0.34%M diet.  
 
Table 5.2.  Animal average daily weight change over the experimental periods 
Diet 10% 
soy 
+ 
0.34
%M 
10% 
soy 
 
0.23%
M/ 
0.35%C 
0.11%M 
/ 
0.35%C 
0.23%
M 
0.11%
M 
20% 
soy 
Pair-
fed 
Protein 
free 
Mean 
weight 
change 
(rat×day)-1 
(g) ± SD, 
N=6 
6.3 
±0.4 
2.5 
±2.0 
6.9 
±0.4 
-1.1 
±1.4 
-2.9 
±2.2 
-4.3 
±1.8 
6.6 
±0.5 
0.6 
±0.8 
-4.3  
±1.3 
 
Hepatic cysteine and GSH  
As shown in Figure 5.1, hepatic thiol levels, measured at the end of the 7-day 
dietary treatment period, were markedly lower for rats fed the 10% soy, protein-free, 
pair-fed (to protein-free) and the amino acid deficient diets (0.11%M, 0.23%M, and 
0.11%M/0.35%C) than in their respective controls (i.e., 10% soy+0.34%M, 20% soy 
and 0.23%M/0.35%C). Total cysteine in the 10% soy rats was 49% that in the 10% 
soy + 0.34% M control group.  Total cysteine in the protein-free and pair-fed rats was 
41% and 49%, respectively, that of control 20% soy-fed rats.  Further, hepatic cysteine 
levels of the rats on deficient amino acid-defined diets (0.11%M/0.35%C, 0.23%M
  
 
 
Table 5.3. Animal average daily feed intake over the experimental periods 
Diet 10% 
soy 
+ 
0.34%M 
10% 
soy 
 
0.23%M/  
0.35%C 
0.11%M/  
0.35%C 
0.23%M 0.11%M 20% soy Pair-fed Protein 
free 
Mean feed 
intake 
(rat×day)-1 (g) 
± SD, N=6 
19.8 
±0.4a* 
17.3 
±0.7a* 
19.3 
±0.5a 
11.6 
±0.6c 
10.2 
±1.2c 
11.9 
±0.7c 
19.2  
±0.5a 
12.0 
±0.3c 
12.0 
±0.3c 
Met-
equivalents 
consumed 
(rat×day)-1 (g) 
± SD 
0.117 
±0.002 
0.043 
±0.002 
0.127 
±0.003 
0.063 
±0.003 
0.023 
±0.003 
0.013 
±0.001 
0.094 
±0.002 
0.059 
±0.002 
0 
Met-
equivalents 
consumed as 
% of the 20% 
soy group 
124 46 135 67 24 14 100 63 0 
*Cumulative feed intake at the end of the 7-day experimental period was not different between the two groups (N=12).  
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and 0.11%M) were 71%, 52%, and 38% of control, respectively. The reductions of 
hepatic total cysteine levels reflect the sulfur amino acid deficiency induced by diet in 
the animals. 
Hepatic total glutathione levels tended to parallel cysteine levels, as shown in 
Figure 5.1.  Total hepatic glutathione for the 10% soy fed rats was only 17% of the 
level in 10% soy +0.34%M rats. Total hepatic glutathione was 48% and 36% of ad 
libitum control (20% soy) for the protein-free and pair-fed-to-protein-free groups, 
respectively. Additionally, levels of glutathione in the rats fed the 0.11%M/0.35%C, 
0.23%M and 0.11%M diets were 69%, 25% and 18% of control, respectively. 
 
mTOR and eIF2α kinase activation 
Total levels of 4E-BP1 protein were significantly increased in the livers of rats 
fed deficient diets compared to their respective controls, as shown in Figure 5.2. More 
specifically, rats on a 10% soy diet exhibited 2.4-times as much (P<0.001) 4E-BP1 as 
the methionine-supplemented control animals. Furthermore, hepatic levels of 4E-BP1 
in rats fed a 0.23%M or 0.11%M diet were nearly double (P<0.05) that of rats fed 
either the control 0.23%M/0.35%C diet or even the 0.11%M/0.35%C diet (that had the 
same average feed intake as the more deficient groups). Rats fed a protein-free diet 
demonstrated a nearly 60% increase (P<0.05) in hepatic 4E-BP1 levels compared to 
either control or their pair-fed counterparts.  These results thus show that 4E-BP1 
protein levels increased in rats fed diets deficient in protein or sulfur amino acids but 
not in rats with restricted intakes of diets adequate in protein or sulfur amino acids.   
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Figure 5.1.  Hepatic Cysteine and Glutathione. Total cysteine and glutathione levels in 
liver of rats fed the assigned diet for 7 days: 10% soy +0.34%M (control), 10% soy 
(SAA-deficient), N=12 ; 0.23%M/0.35%C (control), 0.11%M/0.35%C (SAA-
deficient), 0.23%M (SAA-deficient), 0.11%M (SAA-deficient), N=4 ; 20% soy 
(control), Pair-fed to protein-free (pair-fed control) and Protein-free, N=6. Values are 
means ± SEM. Different letter denotes statistically significant difference at P<0.05. 
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Figure 5.2.  Hepatic total 4EBP1. Representative western blots and fold relative to the 
mean for the control group values for total levels of 4E-BP1 in liver of rats fed the 
following diets for 7 days: 10% soy +0.34%M (control), 10% soy (SAA-deficient), 
N=12 ; 0.23%M/0.35%C (control), 0.11%M/0.35%C (SAA-deficient), 0.23%M 
(SAA-deficient), 0.11%M (SAA-deficient), N=4 ; 20% soy (control), Pair-fed to 
protein-free (pair-fed control) and Protein-free, N=6. Equal amounts of total protein 
were loaded per lane. All values are means ± SEM. Values denoted by different letters 
are significantly different at P<0.05. 
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Even though protein/amino acid deficiency had a profound and consistent 
impact on the levels of hepatic total 4E-BP1 in rats, the impact of these deficient diets 
on the phosphorylation state of 4E-BP1 was less significant.  More specifically, there 
was no difference in the phosphorylation state of hepatic 4E-BP1 between 10% 
soy+0.34%M and 10% soy fed rats. Even though the mean ratio of hyper/hypo-P 4E-
BP1 was lowered by close to 40% in liver of rats fed amino acid deficient diets (i.e., 
0.11%M/0.35%C, 0.23%M and 0.11%M) compared to control, the apparent trend for 
a decrease did not reach statistical significance. On the contrary, protein-free fed rats 
as well as their pair-fed group exhibited a significantly lower hyper/hypo-P 4E-BP1 
ratio, which was 20 to 30% of control (Figure 5.3), demonstrating that the mTOR 
pathway was suppressed.  We also assessed 4E-BP1 levels and phosphorylation status 
in the gastrocnemius muscle of rats fed several of the diets (i.e., the 10% soy+ 
0.34%M, 10% soy, 20% soy, and the protein free groups). We did not observe a 
difference in either the level of total 4E-BP1 or its phosphorylation status in skeletal 
muscle of the 10% soy+0.34%M and the 10% soy groups (data not shown). However, 
we did see a striking reduction in the phosphorylation of 4E-BP1 in muscle of the rats 
fed the protein free diet and in muscle of the pair-fed control rats compared to the 20% 
soy control group fed ad libitum, but the total levels of muscle 4E-BP1 did not differ 
among the three groups.  More specifically the hyper/hypo-P 4E-BP1 ratio was 8% 
(P<0.001) and 17% (P<0.001) of control for the protein free and the pair-fed group 
respectively (Figure 5.4).  In general, changes in the phosphorylation state of 4E-BP1 
in response to diet were similar for liver and muscle for these five treatment groups 
and generally reflected feed intake, whereas the increases in total 4E-BP1 were 
observed only in liver (not in muscle) and only in the rats more restricted in protein or 
amino acid intake (not in 10% soy or pair-fed groups). 
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Figure 5.3. Hepatic ratio of hyper-P/hypo-P 4E-BP1. Ratio for hyper-P/hypo-P 4E-
BP1 in liver of rats fed the following diets for 7 days: 10% soy +0.34%M (control), 
10% soy (SAA-deficient), N=12 ; 0.23%M/0.35%C (control), 0.11%M/0.35%C 
(SAA-deficient), 0.23%M (SAA-deficient), 0.11%M (SAA-deficient), N=4 ; 20% soy 
(control), Pair-fed to protein-free (pair-fed control) and Protein-free, N=6. Equal 
amounts of total protein were loaded per lane. All values are relative to the mean of 
the appropriate control group ± SEM. Values denoted by different letters are 
significantly different at P<0.05. 
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Figure 5.4.  Muscle ratio of hyper-P/hypo-P 4E-BP1. Ratio of hyper-P/hypo-P 4E-
BP1 in the gastrocnemius muscle of rats fed the following diets for 7 days: 10% soy 
+0.34%M (control), 10% soy (SAA-deficient), N=12 ; 0.23%M/0.35%C (control), 
0.11%M/0.35%C (SAA-deficient), 0.23%M (SAA-deficient), 0.11%M (SAA-
deficient), N=4 ; 20% soy (control), Pair-fed to protein-free (pair-fed control) and 
Protein-free, N=6. Equal amounts of total protein were loaded per lane. All values are 
relative to the mean of the appropriate control group ± SEM. Values denoted by 
different letters are significantly different at P<0.05. 
The phosphorylation state of the ribosomal protein S6 (ratio of rpS6-P to total 
rpS6) is frequently used as a reliable indicator of mTOR activation state; S6-kinase is 
a direct substrate of mTOR and rpS6 is the target of S6 kinase.  The ratio of rpS6-P to 
total rpS6 was significantly lower in liver of rats fed amino acid deficient diets (Figure 
5.5), as well as in rats fed a protein-free diet and their pair-fed group. There was 
however no difference in the phosphorylation status of rpS6 between the 10% 
soy+0.34%M and the 10% soy rats. As for 4E-BP1 phosphorylation status, the most 
dramatic reduction occurred for rats fed the protein-free diet or that were pair-fed to 
those rats.  
 
  91
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
10% soy 
+0.34% M
10% soy 0.23%M 
/0.35%C
0.11%M 
/0.35%C
0.23%M 0.11%M 20% soy Pair-fed Protein 
Free
rp
S6
-P
/to
ta
l f
ol
d
of
 ra
tio
n 
fo
r c
on
tro
l
a
a
a
b
b b
a
b
c
10%           10%
soy           soy 
+ 0.34%M   
0.23%M/      0.11%M/   0.23%M      0.11%M
0.35%C        0.35%C
P-rpS6  
Total-rpS6  
20%        Pair-fed       Protein
soy                              Free
 
Figure 5.5.  Hepatic ratio of ribosomal protein S6-P/total S6. Representative western 
blots and fold values for the ratio of phosphorylated rpS6 to total rpS6 in liver of rats 
fed the following diets for 7 days: 10% soy +0.34%M (control), 10% soy (SAA-
deficient), N=12 ; 0.23%M/0.35%C (control), 0.11%M/0.35%C (SAA-deficient), 
0.23%M (SAA-deficient), 0.11%M (SAA-deficient), N=4 ; 20% soy (control), Pair-
fed to protein-free (pair-fed control) and Protein-free, N=6. Equal amounts of total 
protein were loaded per lane. All values are relative to the mean of the appropriate 
control group ± SEM. Values denoted by different letters are significantly different at 
P<0.05. 
Phosphorylation of eIF2α was induced in liver of rats fed a 10% soy diet, as 
we previously reported (Sikalidis and Stipanuk, 2010). Unexpectedly, we did not 
observe an increase in eIF2α phosphorylation in liver of rats fed any of the other 
protein or sulfur amino acid deficient diets, except for those fed the 0.11%M amino 
acid diet. Surprisingly, rats fed the other amino acid deficient diets or the rats that 
consumed the protein-free diet had hepatic eIF2α-P to total eIF2α ratios that were 
similar to or less than those of their respective controls (Figure 5.6).  
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Figure 5.6.  Hepatic ratio of eIF2α-P/total eIF2α. Representative western blots and 
fold values for the ratio of Ser51 phosphorylated eIF2α to total eIF2α in liver of rats 
fed the following diets for 7 days: 10% soy +0.34%M (control), 10% soy (SAA-
deficient), N=12 ; 0.23%M/0.35%C (control), 0.11%M/0.35%C (SAA-deficient), 
0.23%M (SAA-deficient), 0.11%M (SAA-deficient), N=4 ; 20% soy (control), Pair-
fed to protein-free (pair-fed control) and Protein-free, N=6. Equal amounts of total 
protein were loaded per lane. All values are relative to the mean of the appropriate 
control group ± SEM. Values denoted by different letters are significantly different at 
P<0.05.  
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Study 2 
Body weight and feed intake 
In study 2, rats were fed either an adequate or a deficient amino acid based diet 
for up to 5 days.  Rats fed the control diet consumed an average of 17.7±0.5g/d (mean 
of the average feed intakes for each of days 1, 3 and 5) whereas those fed the 0.11%M 
diet consumed an average of 7.4±1.2g/d. The pair-fed group consumed an average of 
9.1±0.1g/d (pair-fed rats average intake was higher than that of the pair-fed rats due to 
them being given a high estimate of diet on day 1) (Table 5.4).  
After only 24 h of dietary treatment, body weights were still similar for the 
control and the pair-fed group but the 0.11%M group exhibited a small loss of weight 
(4% less than control).  After 3 days, the body weight for the pair-fed group was 10% 
lower than that of the control animals with ad libitum access to the complete amino 
acid diet, whereas the sulfur amino acid-deficient (0.11%M) group weighed 22% less 
than control, despite equivalent feed intake. Overall, rats on the control diet grew 
normally throughout the 5-day experimental period at an average rate of 6.7± 2.5g/d, 
the pair-fed rats mostly maintained their weight throughout the experimental period, 
and the 0.11%M group lost weight at a rate of -3.4±1.4 g/d between days 1 and 3 and -
2.2±1.3g/d between days 3 and 5 (Table 5.4).   
  
 
 
 
 
 
Table 5.4.  Body weights and feed intake from study 2 
 Time-point 1 Time-point 2 Time-point 3 
1 day on diets 3 days on diets 5 days on diets 
Complete Pair-fed 0.11%M Complete Pair-fed 0.11%M Complete Pair-fed 0.11%M 
Body weight  
(g) ± SEM 
154.5 
±2.7a 
157.8 
±4.7a 
148.3 
±3.7a 
176.3 
±2.9a 
158.8 
±3.3b 
138.0 
±1.6c 
192.3 
±1.8a 
156.0 
±2.5b 
133.5 
±2.3c 
Mean feed 
intake 
(rat×day)-1 
(g) ± SEM 
18.0 
±0.4a 
12.5 
±0.1b 
8.6 
±1.6c 
18.3 
±0.8a 
8.1 
±0.0b,* 
6.8 
±1.8b 
16.8 
±1.8a 
6.9 
±0.0b,* 
6.8 
±0.2b 
*All the diet given to rats was consumed, there was no measurable spillage effect, N=4 for time-points 1&3 and N=6 for time-point 2, significance 
accepted at P<0.05. 
• Feed intake values are mean of the average feed intakes for each of days 1, 3 and 5 ± SEM. 
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Hepatic cysteine and GSH  
As shown in Figure 5.7, hepatic cysteine levels were significantly lower, 
compared to controls fed ad libitum, in rats pair-fed to controls and in rats fed the 
0.11%M diet. Cysteine levels were 13% and 27% less than control, respectively, for 
pair-fed rats and 0.11%M rats on day 1. For day 3, the reductions were 14% (not 
significant) and 42%, respectively, whereas on day 5 the reductions in hepatic cysteine 
level compared to control were 19% (not significant) and 36%, respectively. Hepatic 
cysteine level in the 0.11%M group was significantly lower than that of the pair-fed 
control group at both day 3 and day 5, showing that the decrease in hepatic cysteine 
was much greater in animals fed the amino acid deficient diet than in those fed the 
adequate diet even when both groups consumed a deficient amount of energy (37%-
44% of the intake of control rats fed ad libitum) (Figure 5.7).  
Hepatic GSH was significantly reduced in both rats fed the 0.11%M diet and in 
the pair-fed control group.  In general, percentage reductions in hepatic GSH levels 
were greater than those for cysteine but followed a similar pattern.  Specifically, 
hepatic GSH was 35% and 45% of control in the pair-fed and 0.11%M groups, 
respectively, on day 1; 36% and 58%, respectively, on day 3; and 31% and 44%, 
respectively, on day 5 (Figure 5.7). Hepatic GSH levels were significantly lower in 
rats fed the amino acid deficient diet than in rats pair-fed the adequate diet, as was true 
for hepatic cysteine levels. 
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Figure 5.7.  Hepatic Cysteine and Glutathione. Total cysteine and glutathione levels in 
liver of rats fed a 0.11%M diet with no cyst(e)ine or a complete amino acid diet with 
ad libitum access or with feed restricted to match the intake of the 0.11%M group for 
1, 3 or 5 days. Values are means ± SEM, N=4. Values denoted by different letters are 
significantly different at P<0.05. 
 
Blood parameters (glucose, plasma insulin and IGF-1) 
Plasma glucose was not different among the treatment groups on day 1. On day 
3 plasma glucose was 25% and 20% lower than the control level in the pair-fed and 
0.11%M fed rats, respectively.  It was significantly lower only for the 0.11%M group 
on day 5 (Table 5.5).  
  
 
 
 
Table 5.5.  Blood parameters from study 2 
 Time-point 1 Time-point 2 Time-point 3 
1 day on diets 3 days on diets 5 days on diets 
Control Pair-fed 0.11%M Control Pair-fed 0.11%M Control Pair-fed 0.11%M 
Blood 
glucose 
(mg/dL) 
107.3 
±7.6a 
107.0 
±1.9a 
98.3 
±4.6a 
120.0 
±2.3a 
93.0 
±4.1b 
98.2 
±6.2b 
106.8 
±7.6a 
103.5 
±2.4a 
97.0 
±2.9b 
Plasma 
Insulin 
(ng/mL) 
0.62 
±0.03a 
0.49 
±0.05b 
0.44 
±0.07b 
0.84 
±0.08a 
0.36 
±0.02b 
0.42 
±0.06b 
1.38 
±0.24a 
0.59 
±0.04b 
0.51 
±0.03b 
Plasma 
IGF-1 
(ng/mL) 
-* -* -* 765.6 
±47.4a 
484.3 
±56.0b 
114.4 
±37.8c 
709.5 
±63.9a 
353.8 
±32.7b 
93.7 
±17.8c 
* No samples were analyzed at time-point 1. 
Values are mean measurements ± SEM, N=4 for time-points 1&3 and N=6 for time-point 2, significance accepted at P<0.05. 
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Plasma insulin was significantly lower in the pair-fed group (20% lower) and 
in the 0.11%M group (30% lower) compared to the ad libitum control group after 1 
day on the dietary treatments. The difference was even greater on days 3 and 5 when 
the plasma insulin levels of the pair-fed and 0.11%M rats were less than half of that in 
the controls (42% and 49%, respectively, for day 3; and 43% and 37%, respectively, 
for day 5) (Table 5.5). 
Plasma IGF-1 was assessed at the later two time-points to allow more time for 
a potential change in IGF-1 plasma levels. On day 3, plasma IGF-1 was significantly 
lower than control in both the pair-fed and the 0.11%M fed groups (63% and 15% of 
control, respectively). The pattern was similar on day 5, with IGF-1 levels at 50% and 
13% of control for the pair-fed and the 0.11%M fed groups, respectively (Table 5.5).  
 
Organ weights 
In absolute values, the weight of gastrocnemius muscle was approximately 10-
20% and 15-30% less than control in the pair-fed and the 0.11%M groups, 
respectively, but when corrected for difference in body weight, there was no 
difference among groups in relative muscle weight at the different time-points.  Liver 
weight was significantly lower in the pair-fed and 0.11%M groups compared to 
controls when expressed as a percentage of body weight: 10% lower for both the pair-
fed and 0.11%M groups on day 1; 30% lower for the pair-fed group and 10% lower 
for the 0.11%M group on day 3; and 15% and 11% lower, respectively, on day 5 
(Table 5.6). Overall, liver weight declined less in the rats fed the 0.11%M diet than in 
the pair-fed rats.  
 
 
  
 
 
 
 
 
Table 5.6.  Organ weights from study 2 
 Time-point 1 Time-point 2 Time-point 3 
1 day on diets 3 days on diets 5 days on diets 
Control Pair-fed 0.11% 
M 
Control Pair-fed 0.11%M Control Pair-fed 0.11%M 
Liver as % of body 
weight1 
4.23 
±0.05 
3.81 
±0.18 
3.81 
±0.21 
4.42 
±0.07 
3.20 
±0.08 
4.01 
±0.1 
4.43 
±0.23 
3.80 
±0.05 
4.01 
±0.09 
Gastrocnemius 
muscle as % of 
body weight1,2 
0.47 
±0.01 
0.46 
±0.01 
0.47 
±0.01 
0.45 
±0.01 
0.47 
±0.01 
0.49 
±0.02 
0.48 
±0.02 
0.46 
±0.01 
0.47 
±0.01 
1No statistical difference among treatments and time-points. 
2Gastrocnemius muscle was collected only from one of the rat’s back legs. 
N=4 for time-points 1&3 and N=6 for time-point 2, values are means ± SEM, significance accepted at P<0.05. 
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 Total 4E-BP levels 
Total levels of 4E-BP1 were not significantly elevated in liver of rats fed the 
0.11%M diet at 1, 3 or 5 days of treatment, although they were consistently slightly 
higher.  No increase in 4E-BP1 that approached that observed at 7 days in study 1 was 
observed.  The reason for this is unknown (Table 5.7).  
 
Table 5.7.  Mean fold change of ISR and mTOR components from study 2 
 Time-point 1 Time-point 2 Time-point 3 
1 day on diets 3 days on diets 5 days on diets 
Control Pair-
fed 
0.11%
M 
Control Pair-fed 0.11%
M 
Control Pair-fed 0.11%
M 
eIF2α-
P/total 
ratio 
1.00 
±0.07a 
1.27 
±0.10a 
0.99 
±0.08a 
1.00 
±0.03a 
1.09 
±0.10a 
0.81 
±0.08a 
1.00 
±0.14a 
1.09 
±0.07a 
0.92 
±0.10a 
4E-
BP1 
total 
1.00 
±0.16a 
1.01 
±0.24a 
1.21 
±0.29a 
1.00 
±0.14a 
0.90 
±0.19a 
1.14 
±0.18a 
1.00 
±0.14a 
0.85 
±0.11a 
1.14 
±0.12a 
4E-
BP1 
(γ/α+β) 
1.00 
±0.36a 
0.77 
±0.04a 
0.71 
±0.26a 
1.00 
±0.26a 
0.47 
±0.17a 
0.63 
±0.15a 
1.00 
±0.38a 
0.83 
±0.19a 
0.52 
±0.08a 
S6ribo
s-
P/total 
ratio 
1.00 
±0.15a 
0.85 
±0.07a 
0.44 
±0.03b 
1.00 
±0.17a 
0.77 
±0.14a,b 
0.53 
±0.08b 
1.00 
±0.13a 
0.62 
±0.14a,b 
0.48 
±0.13b 
Values are mean fold change compared to control ± SEM, N=4 for all time-points, 
significance accepted at P<0.05. 
 
eIF2α kinase and mTOR activation 
The phosphorylation status of eIF2α was not different among treatments at any 
time-point in study 2 thus making it unlikely that GCN2 was activated by amino acid 
limitation (Table 5.7). 
The ratio of rpS6-P to total rpS6 was significantly reduced in the liver of rats 
fed the 0.11%M diet compared to rats fed the control diet ad libitum at every time-
point. More specifically, the rpS6r-P/total rpS6 ratio in the 0.11%M treated rats was 
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about half of that in the controls. The pair-fed group exhibited a ratio of rpS6-P/total 
rpS6 of 85%, 77% and 62% of the ad libitum control group on days 1, 3 and 5, 
respectively, and was not significantly different from either the control or 0.11%M 
group (Table 5.7).    
The phosphorylation status of 4E-BP1 as assessed by the ratio of 4E-BP1 
(γ/α+β) was 77% and 70% of control for the pair-fed and 0.11%M groups, 
respectively, on day 1; 47% and 63% of control on day 3; and 83% and 53% of control 
on day 5. Although the differences did not quite reach significance, there was a pattern 
similar to the one observed for rpS6 phosphorylation.  
 
Other potential mediators of cellular responses 
Because we did not observe a significant change in the phosphorylation status 
of eIF2α that correlated with changes in 4E-BP1 levels in either study 1 or 2, we asked 
whether other signaling molecules could be activated during the nutritional stress. 
Protein kinase C (PKC) comprises a multigene family of serine/threonine kinases that 
function as metabolic switches in many signal transduction pathways and are 
implicated in a wide range of G protein-coupled receptor and other growth factor-
dependent cellular responses (Dempsey et al., 2000; Sabri and Steinberg, 2003). 
Therefore, we assessed the phosphorylation status of several isoforms of PKC, as it is 
involved in a variety of cellular responses and signaling cascades including gene 
expression and proliferation/growth.  More specifically we assessed the 
phosphorylation status of PKD/PKCμ (Ser916), PKD/PKCμ (Ser744/748), PKC (pan) (βII 
Ser660), PKCα/β II (Thr638/641), PKCδ (Thr505), PKCδ/μ (Ser643/676), PKCμ (Thr538) and 
PKCζ/λ (Thr410/403). We did not observe any changes in the phosphorylation status of 
these PKC isoforms in liver of rats the 0.11%M diet or in liver of rats pair-fed the 
control diet compared to the ad libitum controls (data not shown). Further, we assessed 
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levels of REDD1, a protein that functions as a negative regulator of mTOR, but found 
no significant differences in REDD1 content of liver of animals fed the various diets 
(data not shown).   
 
DISCUSSION 
Rats fed protein/amino acid deficient diets displayed reduced growth or weight loss 
and low cysteine and glutathione levels 
The diminished hepatic cysteine and glutathione levels of rats fed diets that 
were deficient in sulfur amino acids (i.e.: 10% soy, 0.11%M, 0.23%M, 
0.11%M/0.35%C) or devoid of protein and in the pair-fed control group with 
restricted intake of complete diet demonstrated that these rats were indeed deficient in 
sulfur amino acids. In fact, both cysteine and glutathione levels were reduced 
proportionally to the degree of sulfur amino acid deficiency. The respective percent 
reduction of hepatic cysteine and glutathione for the 0.11%M/0.35%C, 0,23%M, 
0.11%M, protein free, and pair-fed groups compared to controls were 28%, 47%, 
62%, 68% and 49% for cysteine and 30%, 75%, 82%, 64% and 52% for glutathione. 
The same pattern was seen in the time-course study in rats fed a 0.11%M diet and in 
the pair-fed group on the adequate amino acid diet and was already apparent at the 
earliest (day 1) time-point. These observations are consistent with the well-established 
effects of essential amino acid-deficient diets on growth of rats. The pattern for 
reduction in hepatic cysteine levels was similar to that for glutathione, consistent with 
the previously established relationship of tissue cysteine and glutathione levels and the 
marked effect of cysteine availability on tissue GSH levels (Dominy et al., 2007; 
Stipanuk et al., 1992).  This is consistent with previous reports that glutathione levels 
become depleted when sulfur amino acid intake is limited (Sikalidis and Stipanuk, 
2010; Stipanuk et al., 1992).  
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The pattern of body weight reduction of the rats on the sulfur amino acid 
deficient diets over the 7-day experimental period and over the 5-day time-course 
study also paralleled the degree of sulfur amino acid deficiency. For example, rats fed 
the 0.11%M/0.35%C diet lost 7% of their initial weight, 0.23%M rats lost 10%, and 
0.11%M rats 19% over 7 days, in contrast to a gain of 48 g (28.9% of initial body 
weight) over 7 days in rats fed the 0.23%M/0.35%C diet.  It is well-known that rats 
reduce feed intake when fed an amino acid-deficient or a protein-free diet (Gietzen et 
al., 2006, Hao et al., 2005), but growth of rats in this study was clearly affected both 
by the reduced food intake and the amino acid inadequacy of the diets.  For example, 
rats fed the protein free diet lost 17% of their initial weight whereas their pair-fed 
group gained approximately 1% of initial weight. Similarly, in study 2, weight loss 
was substantial in rats fed the 0.11%M diet whereas rats pair-fed an adequate diet 
were able to maintain their initial body weight.  Energy intake of the two groups was 
similar, but the intake of methionine equivalents was quite different, 7.5 mg.d-1.rat-1 for 
the 0.11%M group and 45 mg.d-1.rat-1 for the pair-fed group. Furthermore, rats fed a 
10% soy diet grew slower than those fed the 10% soy + 0.34%M diet even though 
again the feed intake was not different for these two groups.  
 
Protein/amino acid-deficiency but not energy restriction increases total 4E-BP1 in 
liver but not muscle of rats 
Total hepatic levels of 4E-BP1 were significantly induced in rats fed a protein-
free diet but not in pair-fed rats that had the same caloric intake but received a 20% 
soy protein diet. Also, in rats fed the 10% soy diet, total 4E-BP1 levels were 
significantly increased compared to rats fed the 10% soy+0.34%M diet while feed 
intake was similar for the two groups. Furthermore, we saw a significant increase in 
the levels of total 4E-BP1 in rats that consumed the 0.11%M or the 0.23%M diet 
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compared to those fed the 0.11%M/0.35%C diet despite similarly reduced feed intake 
in all three groups. Thus, we have several comparison sets of rats with similar food 
intakes but different amino acid or protein intakes.  In all cases, only rats with a lack 
of protein or essential amino acids exhibited an increased level of total 4E-BP1 protein 
levels. Our data suggest that diets limiting in essential amino acids (at least, sulfur 
amino acids) may negatively affect protein translation in the liver by elevating 
amounts of total 4E-BP1.  It would be of interest to determine if total 4E-BP1 is 
elevated in liver of children with kwashiorkor versus children with marasmus, given 
the association of diets with low levels of protein or proteins of low quality and the 
suppression of plasma levels of proteins synthesized in the liver (e.g., albumin) in 
children with kwashiorkor. 
Increased total 4E-BP1 levels in response to essential amino acid limitation 
have been reported in in vitro studies (Palii et al., 2008; Willet et al., 2009). When 
HepG2/C3A cells were cultured in media lacking one essential amino acid at a time, 
Palii et al. (2008) reported that total 4E-BP1 levels increased in response to nearly all 
of the single essential amino acid depletions whereas the ratio of phosphorylated/total 
4E-BP1 remained unchanged (Palii et al., 2008). Work in C2C12 myoblasts by Willet 
et al. (2009) showed that mTOR inhibition with RAD001 led to suppression of protein 
synthesis and increased 4E-BP1 mRNA and protein levels, but had no effect on the 
phosphorylation of 4E-BP1 (Willet et al., 2009). Experiments with tumor cells 
(Rousseau et al, 1996) and with Drosophila (Miron et al., 2001) have demonstrated 
that the eIF4E-binding proteins act as negative regulators of cell growth. Other in vitro 
research (Azar et al., 2010) demonstrated that total 4E-BP1 increases significantly 
when cells suppress translation as they are reaching confluence.  The same group 
(Azar et al., 2010) further showed, in various cell types, that cell cycle and protein 
synthesis are faster in cells where 4E-BP1 is either downregulated via siRNA 
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transfection, hence suggesting a link between amount of total 4E-BP1 and potency of 
translation suppression. 
In our studies, in the gastrocnemius muscle, we saw little change in total 4E-
BP1 levels in response to protein or amino acid-deficient diets, although we did 
observed decreases in the phosphorylation of 4E-BP1.  A report of higher levels of 
total 4E-BP1 in skeletal muscle of aged rats suggests that regulation of total 4E-BP1 
may occur in skeletal muscle under some conditions.  Paturi et al. (2010) observed that 
4E-BP1 total protein level was elevated by 55% in aged rats compared to young rats, 
whereas the 4E-BP1 phosphorylation status was not significantly different.  
 
Rats on protein/amino acid-deficient diets exhibited suppressed mTOR signaling 
The mTOR system responds to both energy (increased insulin, reduced 
AMPK) and increased availability of amino acids. In condition of low amino acid 
availability and/or decreased food intake, mTOR signaling would be expected to be 
suppressed based on the reports of a number of groups (Kimball et al., 2004; Proud et 
al., 2004; Kimball et al., 2002, Hong-Brown et al., 2005; Richardson et al., 2004; 
Fingar et al., 2004a and 2004b; Varry et al., 1999).  We evaluated mTOR activation 
indirectly via the phosphorylation status of its direct phosphorylation target 4E-BP1 
and the phosphorylation status of ribosomal protein S6 (rpS6, which is phosphorylated 
by p70S6 kinase, a direct target of mTOR).  Our studies indicated that reduction of the 
phosphorylation of 4E-BP1 did not occur in the liver of rats fed the 10% soy protein 
diet, although there was substantially more total 4E-BP1, and hence more active 
hypophosphorylated 4E-BP1, in liver of these rats. This suggests that regulation of 
total 4E-BP1 protein levels may respond to amino acid limitation in the absence of 
changes in food intake and, hence, insulin levels and availability of exogenous fuels.  
However, we did observe significantly lower hyperphosphorylation of 4E-BP1 in liver 
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of rats fed either the protein-free diet or pair-fed a 20% soy protein diet at the reduced 
intake of the protein-free group.  Both groups had similar ratios of 
hypophosphorylated to hyperphosphorylated 4E-BP1, although only the protein-free 
group exhibited a greater level of total 4E-BP1.  In addition, a similar trend was 
observed in rats fed amino acid-based diets.  Rats fed a marginally sulfur amino acid 
deficient diet (0.11%M/0.35%Cys) had reduced food intake and reduced mTOR 
signaling (particularly as evidenced by rpS6 phosphorylation) but no change in the 
hepatic total 4E-BP1 level, whereas rats fed more severely deficient diets (0.23%M or 
0.11%M), which had similarly reduced food intake, exhibited an increase in total 4E-
BP1 as well as suppressed hyperphosphorylation of 4E-BP1.  These results suggest 
that the phosphorylation state of hepatic 4E-BP1, regulated by mTOR signaling, might 
be mainly due to the level of insulin or insulin-like growth factor signaling or fuel 
availability rather than to a decrease in amino acid availability, whereas total 4E-BP1 
levels might be responding mainly to amino acid levels.  When both protein and total 
energy intakes are deficient, both the increase in total 4E-BP1 and the decrease in 
hyperphosphorylation of 4E-BP1 would result in more active hypophosphorylated 4E-
BP1and contribute to suppression of translation initiation.   
Because the results of the first study suggested that insulin or insulin-like 
growth factor signaling were more important than amino acid availability in regulating 
mTOR signaling, as evidenced by phosphorylation of 4E-BP1 and rpS6, we assessed 
plasma insulin and IGF-1 concentrations in the subsequent study with rats fed the 
0.11%M and 0.23%M/0.35%C amino acid diets.  Compared to the control group fed 
the complete diet ad libitum, plasma insulin levels were lower and similar in rats fed 
the 0.11%M diet and in rats pair-fed the complete 0.23%M/0.35%C diet.  Thus, 
plasma insulin levels correspond closely with reduced mTOR signaling in liver of 
these rats.  Plasma IGF-1 levels were also significantly lower in both the 0.11%M and 
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pair-fed rats, compared to the control rats fed ad libitum, but, in marked contrast to 
insulin levels, the plasma IGF-1 levels in rats fed the 0.11%M diet were only 25% of 
those in the pair-fed control group.  Thus, the dietary sulfur amino acid deficiency had 
a large effect on the plasma IGF-1 level, raising the question of whether IGF-1 
signaling could affect 4E-BP1 protein levels.   
IGF-1 has been shown to induce mTOR signaling in a variety of studies (Glass 
DJ, 2010; Inoki et al., 2002; Rommel et al., 2001; Baumann et al., 2009).  Feng and 
Levine (2010) reported that the IGF-1/Akt/mTOR axis signals for cell growth in 
response to high levels of amino acids.  It has been suggested that under stress 
conditions (including nutrient deprivation), when cell division procedure is more 
prone to errors, p53 shuts down the IGF-1/Akt pathway and subsequently the mTOR 
pathway by inducing the expression of an array of genes (e.g., IGF-BP3, PTEN, 
TSC2, AMPKβ1, sestrins 1 and 2, and REDD1) that are known to negatively regulate 
mTOR in order to minimize the error frequency of cell division (Feng and Lavine, 
2010; Feng et al.,, 2007, 2005; Lavine et al., 2006, Ellisen et al., 2002; Stambolic et 
al., 2001). Although our data do not suggest a close relationship between plasma IGF-
1 levels and mTOR activity, IGF-1 levels do generally parallel the degree of growth 
suppression, with both being more reduced in rats deficient in both amino acids and 
total energy than in rats deficient in energy alone.  The role of p53 in mediating the 
IGF-1/Akt pathway suggests that p53 should be considered as a possible regulator of 
total 4E-BP1 protein levels, particularly if a connection with IGF-1 signaling can be 
demonstrated in future studies.  
 
  108
The GCN2/eIF2α integrated stress response pathway was not highly induced in 
livers of rats fed protein/amino acid-deficient diets 
As GCN2 is activated during amino acid deprivation to phosphorylate eIF2α in 
turn to suppress global translation and induce the expression of specific proteins 
(Deval et al., 2009; Clemens et al., 2001), we initially hypothesized that 4E-BP1 
would be one of the proteins whose expression is upregulated with phosphorylation of 
eIF2α. Some evidence for the interrelation of mTOR with GCN2 was provided in a 
study by Anthony et al. (2004), in which GCN2‐/‐ mice that were fed a leucine‐free 
diet for 6 days exhibited the expected block in hepatic eIF2α phosphorylation and, 
somewhat surprisingly, also failed to display the decrease in phosphorylation of S6K1 
and 4E‐BP1 observed in wild‐type mice, suggesting that GCN2 activity is an 
important contributor to the nutritional regulation of the mTOR pathway (Anthony et 
al., 2004). Also in vitro studies by Lu et al. (2004) have indicated that 4E-BP mRNA 
levels are increased when eIF2α is phosphorylated (Lu et al., 2004). In our studies 
however, we only observed increased eIF2α phosphorylation levels paralleling the 
increase of total 4E-BP1 only in the case of rats fed a 10% soy diet and in those fed 
the 0.11%M diet. Interestingly, we did not see induction of eIF2α phosphorylation in 
the case of rats fed the protein-free or the other amino acid-deficient diets.  
Furthermore, we did not see upregulation of downstream targets of eIF2α 
phosphorylation in liver of rats fed the protein-free or other amino acid-deficient diets 
(e.g., ATF4, ATF3, ASNS and SLC7A11) confirming the lack of induction of GCN2 
(data not shown).  Our studies, therefore, suggest that increases in hepatic total 4E-
BP1 are independent of eIF2α phosphorylation status although they seem to be 
dependent upon a deficiency or imbalance of essential amino acids in the diet.  
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Regulation of total eIF4E-binding protein levels represents a third mechanism for 
control of protein translation  
 Our results demonstrate that protein or amino acid-deficient diets result in an 
increase in the level of hepatic total 4E-BP1 but no further change in the 
phosphorylation state of 4E-BP1 beyond that accounted for by the associated 
suppression of feed intake.  This results in an increase in the absolute amount of 
hypophosphorylated 4E-BP1 available to bind eIF4E and block cap-dependent 
translation initiation.  We further observed that protein or amino acid deficient diets 
resulted in an increase of total 4E-BP1 whether or not eIF2α phosphorylation, 
presumably via activation of GCN2, occurred and whether or not downstream targets 
of the integrated stress response pathway were affected.  Hence in addition to eIF2α 
phosphorylation and mTOR signaling via the lowered phosphorylation of 4E-BP1 in 
response to amino acid limitation, we propose that increased expression of total 4E-BP 
protein is a third mechanism for protein translation attenuation in response to amino 
acid limitation.   
Subsequent studies are needed to address how the amino acid deficiency is 
sensed and what signaling pathway is involved in increased expression of 4E-BP1 as 
well as possible tissue specificity for this mechanism.  Given the association of 4E-
BP1 levels with plasma IGF-1 levels that we observed, the insulin-like growth factor 
regulatory network should be further considered as one possibility for regulation of 
4E-BP expression and regulation of protein translation.  
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SUMMARY 
The long-term overall objective of this work was to increase understanding of 
the protein and essential amino acid contribution to the regulation of protein 
translation and the induction of the integrated stress response by investigating cellular 
and animal responses to indispensable amino acid deficiency.  More specifically, we 
initially aimed to further assess the role of eIF2α phosphorylation and downstream 
transcriptional regulation on the ability of mammalian cells to adapt to a lack of 
indispensable amino acids.  We first compared the response of a hepatoma cell line 
(HepG2/C3A) to leucine versus cysteine deprivation to obtain a list of genes that were 
differentially expressed in response to a deficiency of both amino acids.  By focusing 
on genes differentially expressed under both conditions, we aimed to identify genes 
that were being regulated via the eIF2α phosphorylation pathway and not by the 
mTOR pathway.  The comparison of cells exposed to deficiencies of two different 
amino acids was done to facilitate selection of genes whose expression was more 
likely to be altered specifically in response to GCN2-induced eIF2α phosphorylation.  
Our gene expression studies in HepG2/C3A cells identified a number of genes 
involved in cell growth and division that were consistently down-regulated under 
conditions of either cysteine or leucine deprivation, as well as a number of genes 
involved in amino acid uptake, aminoacyl-tRNA synthesis, and the ISR that were 
consistently up-regulated.  These suggest that the cell attempts to adapt to an amino 
acid-limited environment by facilitating more efficient utilization of the limited 
resource (i.e., amino acids) and up-regulating stress-response genes, while at the same 
time, suppressing overall protein synthesis, cell proliferation, and growth.  All of these 
responses can be seen as consistent with cell or organismal survival under conditions 
of nutrient limitation.   
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More specifically, we observed eIF2α phosphorylation and up-regulation of 
protein levels for ATF4, ATF3, and ASNS in cells cultured in cyst(e)ine- or leucine-
deficient medium and induction of CHOP in cells cultured in leucine-deficient, but not 
in cyst(e)ine-deficient medium (Lee et al., 2008; Sikalidis et al., 2010).  Microarray 
analysis of gene expression in cells cultured under the same conditions showed 
upregulation of mRNA levels for ASNS, ATF3, ATF4, C/EBP-β, CHOP, SLC7A1, 
SLC7A11, and TRIB3. The mRNA levels for a variety of aminoacyl-tRNA 
synthetases (e.g., CARS, SARS, WARS) and CTH (cystathionine γ-lyase) [along with 
those for VLDR (very low density lipoprotein receptor), CLCN3 (chloride channel 3), 
and TXNIP (thioredoxin interacting protein)] were also consistently up-regulated in 
response to amino acid deprivation in a GCN2-dependent fashion (Lee et al., 2008; 
Deval et al., 2009; Sikalidis et al., 2010).  The results of this study add to our 
understanding of how gene expression changes in response to amino acid deprivation 
in a human-derived cell line.   
In continuation, we wanted to see if the results obtained from our in vitro 
studies would hold in an animal model.  More specifically, we wanted to assess 
whether the eIF2α phosphorylation pathway might play a role in regulating nutrient 
utilization or stress responses in animals fed diets limiting in an indispensable amino 
acid.  Because the models used to study eIF2α-kinase–mediated responses to amino 
acid deficiency have commonly used media or diets devoid of one or more essential 
amino acids, we asked whether eIF2α-kinase–mediated responses would be induced in 
animals fed a more typical diet that was marginal in essential amino acid composition 
but not as imbalanced as one in which one essential amino acid is totally absent.  Our 
rat study with the SAA-deficient diet revealed a robust and sustained activation of the 
eIF2α phosphorylation/ATF4−mediated ISR in liver of rats fed a SAA-deficient diet, 
and our observations suggest that components of the ISR, such as induction of amino 
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acid transporters and aminoacyl-tRNA synthetases, may be responsible for an apparent 
adaptation that occurred over the first four days animals were fed the SAA-deficient 
diet, allowing an increase in the rate of growth over the remaining three days of the 
experimental period (Sikalidis and Stipanuk, 2010). Components of the ISR that are 
associated with apoptosis or translational recovery were not induced, suggesting that 
the ISR was adaptive and promoted survival and growth under conditions of modest 
indispensable amino acid limitation. Furthermore, our results confirm other reports 
(Palii et al., 2009; Lu et al., 2004b) that upregulation of 4E-BP1 expression is a 
downstream component of the ISR in liver and suggest that eIF2α kinase-dependent, 
mTOR-independent changes in 4E-BP availability may affect eIF4F complex 
formation in response to amino acid limitation.  
Additionally to the two known mechanisms of 4E-BP hypophosphorylation 
and eIF2α phosphorylation in inhibiting translation initiation, recent evidence suggests 
the possibility of a third mechanism, the induction of 4E-BP expression.  The 
phosphorylation of eIF2α increases the translation of a few specific existing mRNAs, 
including ATF4, which induces the expression of genes known to be associated with 
cell survival and stress resistance.  Since 4E-BP is a repressor of translation initiation 
that aids in survival during low energy and low amino acid status, it is possible that 
4E-BP is one of the proteins whose expression is induced during nutrient deficiency.  
To investigate the possibility of an increase in 4E-BP1 expression as a third 
mechanism in regulating translation initiation, 4E-BP1 protein levels were assessed in 
the livers and muscles of rats treated with a variety of diets aiming to create varying 
conditions (low energy, low protein, no protein).   
In these studies, as well as in the one with SAA-deficient rats, we consistently 
observed an increase in total amount of 4E-BP1 in the protein free regiment but not in 
the energy restricted state. Furthermore the hyper/hypo-P 4E-BP1 ratio was somewhat 
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reduced mostly for the protein free and energy restricted group which along with the 
consistent markedly reduction of the Phospho/total S6ribosomal ratio suggests that the 
mTOR signaling was functioning as expected. As no significant changes in the 
phosphorylation of eIF2α were observed in this set of studies, it appears that 
deficiency of proteins or essential amino acids but not energy leads to increased levels 
of 4E-BP1 in the livers of rats but this response does not seem to be GCN2 dependent 
(eIF2α phosphorylation).  
Further, we conducted a time-course animal study with the goal to capture the 
time at which the response to amino acid limitation is initiated.  Although we were 
successful in inducing a sulfur amino acid deficiency we were unable to definitively 
identify a time-point at which a response initiates.  We did observe however, that since 
the first day on amino acid deficient diet rats exhibited lower insulin and IGF-1 levels 
as well as reduced phosphorylation of S6ribosomal protein. These observations 
suggest that mTOR signaling was suppressed. We saw an increase (although not 
significant) in the levels of total 4E-BP1 but we did not see any change in the 
phosphorylation status of eIF2α.  
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RESEARCH QUESTIONS & FUTURE DIRECTIONS 
One issue we came across in this work was the lack of agreement of cell 
studies for eIF2α-P/ATF4 gene targets.  This situation could be attributed to the 
different kind of cells used in various studies (MEF wild-type, MEFs ATF4-/-, MEF 
GCN2-/-, HepG2/C3A) and different treatment/experimental design (use of 
tunicamycin, drug-induced activation of an artificial eIF2α kinase, withdrawal of 
different amino acids).  It appears that the choice of cell-line and the experimental 
procedures influence the outcomes at a point where consensus is limited. 
Another issue was the inability to repeat strong induction of eIF2α/ISR in rats 
with diets different from the 10% soy diet we first used.  Although the experimental 
procedures were not very different (same strain of rats, similar age and weights, same 
housing conditions and diet preparation method) it seemed that the robust response of 
eIF2α/ISR is more a result of a subtle imbalance in the amino acid ratio/contribution in 
the diet, which is fairly challenging to repeat. 
 
Determining whether phosphorylation of eIF2α by GCN2 is essential for induction 
of 4E-BP1 expression 
Several in vitro studies have shown induction of gene expression for 4E-BP1 
by amino acid deprivation.  Actual protein levels of 4E-BP1 however, have not been 
extensively studied in vitro when amino acids are withdrawn.  Our in vivo studies 
show that amino acid deficient diets can increase levels of 4E-BP1 in rats.  To confirm 
the reported in vitro results (message level) and our in vivo observations, mRNA and 
protein levels of 4E-BP1 under an amino acid deprivation regiment in vitro (using a 
variety of cell-lines) could be measured. 
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Determining whether ATF4 induction is essential for induction of 4E-BP1 
expression                 
If the upregulation of 4E-BP1 is dependent on GCN2 activation and 
subsequent eIF2α phosphorylation, it would be predicted that it is also dependent on 
ATF4 expression.   Increased ATF4 expression may suffice to achieve the responses 
observed with amino acid deprivation or, alternatively, ATF4 may be necessary but 
not sufficient to deliver the response due to a requirement for additional GCN2/eIF2α-
mediated events.  Amino acid deprivation can be induced in ATF4-/- and wild type 
cells and the phosphorylation of eIF2α as well as total 4E-BP1 can be measured. Also 
wild type cells can be knocked-down with siRNA to see if an intermediate response in 
the total 4E-BP1 levels would be produced. 
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APPENDIX 1 
Materials and Methods in detail 
RNA extraction and microarray analysis 
Dishes of HepG2/C3A cells cultured as described above were washed twice 
with ice-cold PBS, and cells were then directly lysed into denaturation solution. Total 
RNA was extracted from cells with an RNeasy Micro kit (Qiagen Inc., Valencia, CA). 
Microarray analysis was done on three individual cultures of cells for each treatment 
group.  
These total RNA samples were labeled according to the standard one-cycle 
amplification and labeling protocol developed by Affymetrix (Santa Clara, CA). 
Labeled cRNAs were hybridized on Affymetrix GeneChip Human U133 plus 2.0 
Array containing over 47,000 transcripts. Hybridized GeneChips were then stained, 
washed, and scanned by GeneChip Scanner 3000. The raw array data were processed 
by Affymetrix GCOS software to obtain detection calls and signal values. The signals 
were scaled to a target value of 500 with GCOS software. The scaled signal values 
were log2-transformed and centered by subtracting median signal from each gene 
across all arrays in the experiment.  A t-test was applied on the normalized signal of 
each probe-set to look for differential genes between the two experimental conditions. 
A significance level cutoff was empirically established at P < 0.0001, based on the 
number of genes passing the cutoff, the magnitude of fold changes, and the 
relationship between fold changes and P values, to select differential gene sets. Our 
complete microarray data have been deposited in the NCBI Gene Expression Omnibus 
(GEO, accession no. GSE13142).    
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Microarray results were confirmed by quantitative RT-PCR for several of the 
eIF2α phosphorylation/ATF4−induced genes as well as for NQO1, a gene that 
responds to oxidative stress but whose expression was not affected by amino acid 
deprivation, and VSNL1, a gene whose expression was down-regulated by amino acid 
deprivation.  Isolated RNA was treated with DNase I, and first-strand cDNA was 
subsequently produced with the Invitrogen Superscript III kit and random primers. 
qRT-PCR was done with an Applied Biosystems 7500 Real Time PCR System, 
TaqMan Universal PCR Master Mix, and TaqMan gene expression assays for the 
specific genes (Applied Biosciences, Foster City, CA); 18S rRNA was used as the 
endogenous control. 
 
Nuclear extraction procedure 
To obtain nuclear extracts for measurement of CHOP expression levels, liver 
tissue was homogenized in cold 10 mM HEPES buffer, pH 7.9, with 10 mM KCl, 0.1 
mM EDTA, 0.1 mM EGTA, and 1 mM DTT (Sha et al, 2009).  Cells were allowed to 
swell on ice for 15 min and were then lysed with the addition of 10% NP-40 (0.6% 
final volume) and vigorous vortexing. The lysate was transferred to a pre-chilled tube 
and centrifuged at 4oC for 5 min at 12,000 × g.  Supernatant (cytosolic fraction) was 
removed and the pellet was re-suspended in ice-cold 20 mM HEPES buffer, pH 7.9, 
with 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, and 1 mM DTT and vortexed 
vigorously. The extract was then centrifuged at 4oC for 5 min at 12,000 × g to obtain 
the supernatant (nuclear fraction). 
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Measurement of hepatic glutathione and cysteine levels.   
Total intracellular cyst(e)ine levels were measured by a modification of the 
method of Gaitonde (Gaitonde, 1967). Liver tissues were homogenized in 5% (w/v) 
sulfosalicylic acid (SSA) to form a 20% (w/v) homogenate. The homogenate was 
centrifuged at 4oC at 18,000 × g for 20 min to collect the supernatant. The pH of the 
SSA supernatant was adjusted to 8.3 using 10 N NaOH, and then 500 mM 
dithiothreitol (DTT) was added to yield a final concentration of 5 mM. Samples were 
reduced with DTT for 15 min at room temperature. Following reduction, a 100 μL 
aliquot of sample was acidified with 0.l mL glacial acetic acid and then reacted with 
0.1 mL acid ninhydrin reagent (250 mg ninhydrin dissolved in a mixture of 6 mL 
glacial acetic acid and 4 mL of 12 N HCl) for 10 min at 100°C. After being heated, the 
sample mixture was cooled on ice for 3 min and then diluted to 1.0 mL with 95% 
ethanol. Sample absorbance was measured at 560 nm.  Cysteine levels were quantified 
using cysteine hydrochloride standards (0–500 μM) dissolved in 5% SSA and 
processed in the same manner as the samples. Testing of this procedure by our 
laboratory has shown it to be a highly selective and sensitive means of detecting 
cysteine levels between 5 and 500 μM in cell extracts (Dominy et al., 2007).  
Total glutathione levels were measured using an HPLC method as described by 
Cereser et al, 2001.  Briefly, liver tissue was homogenized in 2.5% perchloric acid to 
form a 20% (w/v) homogenate. The homogenate was centrifuged at 4oC at 18,000 × g 
for 20 min to collect the supernatant. Then 90 μL of boric acid buffer (pH 9.0) was 
added to 10 μL of sample supernatant. Immediately 100 μL of o-phthaldialdehyde 
(OPA) solution was added, and the mixture was incubated at room temperature for 5 
min. After the incubation step, 800 μL of 500 mM KPO4 buffer (pH 7.0) was added, 
and this final mixture was analyzed by HPLC using an injection volume of 20 μL.  
HPLC was performed using a Nova-Pak C18 Column, 3.9×150 mm (Waters Corp., 
  119
Milford, MA) and a gradient mobile phase generated using 50 mM KPO4 buffer, pH 
7.0 (eluent A) and 50 mM KPO4 buffer, pH 7.0, with 3% (v/v) tetrahydrofuran and 
40% (v/v) acetonitrile (eluent B).  The flow rate was 1 mL/min.  The mobile phase 
was started at 95% A, linearly changed to 70% A over 10 min, then linearly changed 
to 0% A over 5 min, and held at 0% A for 3 min.  To regenerate the column prior to 
injection of the subsequent sample, the mobile phase was moved back to 95% A over 
3 min and equilibrated for 8 min.  Detection was conducted on a Waters 2475 
fluorometer at a λ=340 nm wavelength with an emission of 420 nm.    
 
Identification of CARS as a possible ATF4 direct target  
Using the Genomatix MatInspectror on-line software (Genomatix GmbH, 
Munich, Germany) to perform a promoter sequence analysis for transcription factor 
binding sites (in silico), we identified an AARE (genomic sequence: GTTGCATCA) 
at position 516-524 upstream of the transcription start site at position 571 in the 
human CARS gene (Gene ID: 833, Homo sapiens chromosome 11, cysteinyl-tRNA 
synthetase, sequence GXP_169570).  Using the same approach, we were able to 
identify an AARE (genomic sequence: GTTGCATCA) at position 517-525 upstream 
of the transcription start site at position 575 in the rat CARS gene (Gene ID: 293638, 
Rattus norvegicus chromosome 1, cysteinyl-tRNA synthetase, sequence 
GXP_1735315).  Thus, CARS (Cysteinyl-tRNA synthetase) is also likely a direct 
target of ATF4. 
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APPENDIX 2 
 
Table A1.  Antibodies and dilutions used for immunoblotting described in chapters 3 
& 4 
Antibody Supplier 1o dilution 
P-eIF2α (Ser51) (119A11)* Cell Signaling Technology 1:1000 in 5% BSA 
eIF2α total* Cell Signaling Technology 1:1000 in 5% BSA 
ATF4 Gift, M.S. Kilberg 1:1000 in 5% BSA 
ATF3 (C-19) Santa Cruz Biotechnology 1:200 in 5% FFM 
ASNS (C-14) Santa Cruz Biotechnology 1:200 in 5% FFM 
SLC7A11 (xCT) Abcam Inc. 1:1000 in 5% FFM 
CARS Abcam Inc. 1:500 in 5% FFM 
CTH Abnova 1:500 in 5% FFM 
CHOP (GADD153) Santa Cruz Biotechnology 1:500 in 5% FFM 
TRIB3 Santa Cruz Biotechnology 1:400 in 5% FFM 
GADD34 (H-193) Santa Cruz Biotechnology 1:400 in 5% FFM 
Redd1 Cell Signaling Technology 1:1000 in 5% BSA 
4E-BP1 total* Cell Signaling Technology 1:1000 in 5% BSA 
Phospho-p70 S6 Kinase Cell Signaling Technology 1:1000 in 5% BSA 
p70 S6 Kinase (total) Cell Signaling Technology 1:1000 in 5% BSA 
p-S6ribosomal protein*  Cell Signaling Technology 1:1000 in 5% BSA 
S6ribosomal protein (total)* Cell Signaling Technology 1:1000 in 5% BSA 
GCLC Neomarkers 1:2000 in 5% BSA 
β-actin (control) Cell Signaling Technology 1:1000 in 5% BSA 
*If the Li-Cor system was used, antibodies were diluted in a solution 1:1 (PBS:Rockland blocking 
buffer) + 0.1% Tween-20). 
BSA: Bovine Serum Albumin; FFM: Fat Free Milk.  BSA and FFM solutions are w/v prepared in 1× 
TBST (Tris Buffer Saline Tween-20).  
Abcam Inc., Cambridge, MA ; Abnova, Walnut, CA ; Cell Signaling Technology, Danvers, MA ; 
Neomarkers, Freemont, CA ; Santa Cruz Biotechnology, Santa Cruz, CA.
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APPENDIX 3 
Table A2. Adopted from Lee et al., 2008; Table 2, Differential expression of genes in 
response to cysteine deprivation1 
 
  
Fold Difference 
 
Probe id Gene Symbol Long –Cys/ 
Short +Cys 
Long – Cys/ 
Long + Cys 
Short – 
Cys/ 
Long + Cys 
Gene Title 
      
218098_at ARFGEF2 1.61 1.97 1.75 ADP-ribosylation 
factor guanine 
nucleotide-exchange 
factor 2 (brefeldin A-
inhibited) 
205047_s_at ASNS 2.43 1.56 1.35 asparagine synthetase 
202672_s_at ATF3 3.24 10.28 7.34 activating 
transcription factor 3 
212971_at CARS 1.98 2.69 2.28 cysteinyl-tRNA 
synthetase 
227558_at CBX4 1.94 2.49 2.05 chromobox homolog 
4 (Pc class homolog, 
Drosophila) 
212501_at CEBPB 2.98 4.60 4.46 CCAAT/enhancer 
binding protein 
(C/EBP), β 
204203_at CEBPG 1.90 2.56 2.48 CCAAT/enhancer 
binding protein 
(C/EBP), γ 
201925_s_at DAF 2.75 4.20 3.61 decay accelerating 
factor for 
complement (CD55, 
Cromer blood group 
system) 
201919_at FLJ10618 1.90 2.65 2.57 hypothetical protein 
FLJ10618 
204131_s_at FOXO3A 1.80 2.84 3.11 forkhead box O3A 
203725_at GADD45A 1.78 5.59 3.79 growth arrest and 
DNA-damage-
inducible, α 
203925_at GCLM 1.88 3.25 1.97 glutamate-cysteine 
ligase, modifier 
subunit 
210587_at INHBE 4.47 6.76 10.59 inhibin, βE 
203320_at LNK 2.65 3.41 4.40 lymphocyte adaptor 
protein 
208786_s_at MAP1LC3B 2.08 3.68 1.70 microtubule-
associated protein 1 
light chain 3β 
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Table A2. (Continued) 
  
Fold Difference 
 
Probe id Gene Symbol Long –Cys/ 
Short +Cys 
Long – Cys/ 
Long + Cys 
Short – 
Cys/ 
Long + Cys 
Gene Title 
      
236285_at MGC16635 2.18 11.32 5.35 hypothetical protein 
BC009980 
204538_x_at NPIP /// 
LOC339047 
/// 
LOC440341 
2.39 2.76 2.09 nuclear pore complex 
interacting protein /// 
hypothetical protein 
LOC339047 /// 
similar to 
hypothetical protein 
LOC339047 
207528_s_at SLC7A11 2.92 5.61 4.93 solute carrier family 
7 (cationic amino 
acid transporter, y+ 
system), member 11 
209921_at  4.56 13.77 14.86 
217678_at  4.98 9.88 11.41  
203438_at STC2 3.00 5.99 8.30 stanniocalcin 2 
218145_at TRIB3 2.79 4.03 5.38 tribbles homolog 3 
(Drosophila) 
226181_at TUBE1 3.40 4.52 5.88 tubulin, ε1 
201266_at TXNRD1 1.69 3.62 2.04 thioredoxin reductase 
1 
209822_s_at VLDLR 3.09 3.52 3.06 very low-density 
lipoprotein receptor 
218919_at ZFAND1 2.11 2.42 2.46 zinc finger, AN1-
type domain 1 
227755_at  2.31 5.86 6.03 CDNA clone 
IMAGE:4077090, 
partial cds 
1For inclusion in this table, a gene had to be differentially expressed with a significance level of                 
P < 0.0001 for all 3 treatment comparisons. 
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APPENDIX 4 
Table A3. Genes by category/function differentially upregulated/downregulated in 
amino acid-deficient HepG2/3A cells1 
Upregulated #genes Downregulated #genes 
Genes with known functional 
AAREs 
5 Cell cycle/Cell Division 26 
Amino acid metabolism 5 Calcium signaling 2 
Endosomal/lysosomal system 4 Cytoskeleton 1 
GAPs and GEFs 2 Fatty acid and sterol 
metabolism 
11 
Growth regulation 5 Nucleotide 
synthesis/metabolism 
8 
Cytoskeleton 2 Other 16 
Transcriptional regulators 3 Unknown function(s) 3 
Other 7   
Unknown function(s) 18   
1To be included in this table, differential gene expression had to meet a statistical cutoff of P<0.0001. 
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APPENDIX 5 
Supplemental materials on Chapter 4 
Table S1.  Genes whose expression was upregulated in HepG2/C3A cells cultured in 
–Leu medium1 
Probe ID Gene Symbol Gene Title 
Fold 
Difference 
P 
204072_s_at 13CDNA73 hypothetical protein CG003 1.85 1.14E-05 
209993_at ABCB1 ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
2.05 1.86E-05 
213532_at ADAM17 a disintegrin and metalloproteinase domain 17 
(tumor necrosis factor, alpha, converting 
enzyme) 
1.30 2.18E-07 
204333_s_at AGA aspartylglucosaminidase 1.41 6.40E-05 
210517_s_at AKAP12 A kinase (PRKA) anchor protein (gravin) 12 3.04 1.51E-05 
225524_at ANTXR2 anthrax toxin receptor 2 2.57 4.25E-06 
209369_at ANXA3 annexin A3 1.57 9.19E-05 
218098_at ARFGEF2 ADP-ribosylation factor guanine nucleotide-
exchange factor 2 (brefeldin A-inhibited) 
1.85 3.58E-05 
209435_s_at ARHGEF2 rho/rac guanine nucleotide exchange factor 
(GEF) 2 
4.40 9.89E-06 
225283_at ARRDC4 arrestin domain containing 4 5.28 2.99E-06 
205047_s_at ASNS asparagine synthetase 3.48 2.30E-07 
207076_s_at ASS argininosuccinate synthetase 1.67 9.54E-07 
202672_s_at ATF3 activating transcription factor 3 4.00 8.21E-06 
203080_s_at BAZ2B bromodomain adjacent to zinc finger domain, 
2B 
1.73 2.95E-05 
226517_at BCAT1 
 
branched chain aminotransferase 1, cytosolic 
 
1.98 5.52E-06 
225285_at 1.87 9.42E-05 
232698_at BPIL1 bactericidal/permeability-increasing protein-
like 1 
1.61 7.15E-05 
200920_s_at BTG1 B-cell translocation gene 1, anti-proliferative 1.47 9.56E-06 
203612_at BYSL bystin-like 1.35 8.56E-05 
226892_at C10orf12 chromosome 10 open reading frame 12 1.77 3.16E-05 
226398_s_at C10orf4 chromosome 10 open reading frame 4 2.15 1.01E-06 
218983_at C1RL complement component 1, r subcomponent-
like 
1.80 9.01E-05 
218094_s_at C20orf35 chromosome 20 open reading frame 35 1.42 4.22E-05 
224932_at C22orf16 chromosome 22 open reading frame 16 3.81 7.23E-08 
235051_at C3orf6 chromosome 3 open reading frame 6 1.42 4.18E-05 
205500_at C5 complement component 5 1.96 1.72E-05 
220088_at C5R1 complement component 5 receptor 1 (C5a 
ligand) 
2.13 7.35E-05 
226135_at C6orf107 chromosome 6 open reading frame 107 1.57 9.14E-05 
226301_at C6orf192 chromosome 6 open reading frame 192 1.43 8.77E-05 
220755_s_at C6orf48 chromosome 6 open reading frame 48 1.79 5.82E-05 
227443_at C9orf150 chromosome 9 open reading frame 150 2.31 1.47E-05 
221865_at C9orf91 chromosome 9 open reading frame 91 2.81 6.07E-05 
213161_at C9orf97 chromosome 9 open reading frame 97 /// 
chromosome 9 open reading frame 97 
1.89 6.66E-05 
217873_at CAB39 calcium binding protein 39 1.43 5.89E-05 
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Table S1 (Continued) 
Probe ID Gene Symbol Gene Title Fold Difference 
P 
212711_at CAMSAP1 calmodulin regulated spectrin-associated 
protein 1 
1.61 9.32E-05 
221040_at CAPN10 calpain 10 1.31 6.01E-05 
212971_at CARS cysteinyl-tRNA synthetase 2.30 8.72E-07 
227558_at CBX4 chromobox homolog 4 (Pc class homolog, 
Drosophila) 
2.82 2.93E-06 
225010_at CCDC6 coiled-coil domain containing 6 1.42 9.44E-05 
221511_x_at CCPG1 cell cycle progression 1 3.02 3.15E-05 
218157_x_at CDC42SE1 
 
CDC42 small effector 1 
 
2.37 4.13E-06 
229120_s_at 2.36 6.67E-05 
212501_at CEBPB CCAAT/enhancer binding protein (C/EBP), 
beta 
3.34 1.22E-05 
225527_at CEBPG CCAAT/enhancer binding protein (C/EBP), 
gamma 
2.39 3.51E-05 
204203_at   2.21 4.13E-05 
213618_at CENTD1 centaurin, delta 1 1.65 3.81E-05 
204258_at CHD1 chromodomain helicase DNA binding protein 
1 
1.64 9.02E-05 
226803_at CHMP4C chromatin modifying protein 4C 2.10 9.61E-06 
200811_at CIRBP cold inducible RNA binding protein 1.73 2.16E-05 
224998_at CKLFSF4 chemokine-like factor super family 4 1.61 3.50E-05 
201734_at CLCN3 chloride channel 3 2.44 1.17E-05 
201735_s_at 2.42 2.70E-05 
204576_s_at CLUAP1 clusterin associated protein 1 1.60 1.24E-06 
201161_s_at CSDA cold shock domain protein A 1.68 3.50E-05 
208867_s_at CSNK1A1 casein kinase 1, alpha 1 1.60 8.45E-05 
204971_at CSTA cystatin A (stefin A) 2.66 8.00E-05 
206085_s_at CTH cystathionase (cystathionine gamma-lyase) 3.06 1.19E-05 
227520_at CXorf15 chromosome X open reading frame 15 1.63 3.52E-05 
206754_s_at CYP2B7P1 cytochrome P450, family 2, subfamily B, 
polypeptide 7 pseudogene 1 
2.34 6.45E-06 
201925_s_at DAF decay accelerating factor for complement 
(CD55, Cromer blood group system) 
5.53 5.07E-05 
1555950_a_at 4.27 3.77E-06 
224911_s_at DCBLD2 discoidin, CUB and LCCL domain containing 
2 
1.82 5.45E-05 
209383_at DDIT3 DNA-damage-inducible transcript 3 6.68 3.76E-05 
222239_s_at DDX26 DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 26 
1.43 1.51E-05 
221780_s_at DDX27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 
27 
1.68 4.30E-05 
201479_at DKC1 dyskeratosis congenita 1, dyskerin 1.31 5.89E-06 
224822_at DLC1 deleted in liver cancer 1 2.03 6.45E-06 
201681_s_at DLG5 discs, large homolog 5 (Drosophila) 1.59 4.45E-05 
205963_s_at DNAJA3 DnaJ (Hsp40) homolog, subfamily A, member 
3 
1.67 7.57E-05 
1554078_s_at   1.55 1.84E-05 
204135_at DOC1 downregulated in ovarian cancer 1 1.69 7.07E-06 
212254_s_at DST dystonin 1.77 9.24E-05 
201041_s_at DUSP1 dual specificity phosphatase 1 1.87 7.42E-05 
226952_at EAF1 ELL associated factor 1 1.73 3.07E-05 
227404_s_at EGR1 early growth response 1 4.54 5.22E-06 
201694_s_at 3.49 1.21E-05 
200597_at EIF3S10 eukaryotic translation initiation factor 3, 
subunit 10 theta, 150/170kDa 
1.77 5.89E-05 
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Table S1 (Continued) 
Probe ID Gene Symbol Gene Title Fold Difference 
P 
200005_at EIF3S7 eukaryotic translation initiation factor 3, 
subunit 7 zeta, 66/67kDa /// eukaryotic 
translation initiation factor 3, subunit 7 zeta, 
66/67kDa 
1.41 2.15E-05 
221539_at EIF4EBP1 eukaryotic translation initiation factor 4E 
binding protein 1 
1.87 7.53E-06 
235296_at EIF5A2 eukaryotic translation initiation factor 5A2 2.34 2.08E-05 
220161_s_at EPB41L4B erythrocyte membrane protein band 4.1 like 
4B 
1.84 3.45E-05 
223427_s_at 1.74 8.64E-05 
200843_s_at EPRS glutamyl-prolyl-tRNA synthetase 1.84 2.73E-05 
235745_at ERN1 endoplasmic reticulum to nucleus signalling 1 2.31 3.24E-05 
227696_at EXOSC6 exosome component 6 1.95 1.74E-05 
225591_at FBXO25 F-box protein 25 1.57 6.55E-05 
224318_s_at FLJ10081 hypothetical protein FLJ10081 1.38 9.15E-05 
201919_at FLJ10618 Hypothetical protein FLJ10618 2.17 3.79E-06 
225327_at FLJ10980 hypothetical protein FLJ10980 1.91 9.31E-05 
228262_at FLJ14503 hypothetical protein FLJ14503 1.75 4.26E-05 
218984_at FLJ20485 hypothetical protein FLJ20485 1.28 1.56E-05 
1557828_a_at FLJ21657 hypothetical protein FLJ21657 1.78 6.40E-05 
222872_x_at FLJ22833 hypothetical protein FLJ22833 2.22 3.86E-05 
226184_at FMNL2 formin-like 2 1.74 4.02E-05 
228463_at FOXA3 forkhead box A3 1.55 8.50E-05 
224891_at FOXO3A forkhead box O3A 1.77 1.31E-05 
223287_s_at FOXP1 forkhead box P1 2.21 2.22E-05 
218373_at FTS fused toes homolog (mouse) 1.51 1.52E-05 
208693_s_at GARS glycyl-tRNA synthetase 2.21 8.04E-05 
212378_at GART phosphoribosylglycinamide formyltransferase, 
phosphoribosylglycinamide synthetase, 
phosphoribosylaminoimidazole synthetase 
1.33 5.40E-05 
210002_at GATA6 GATA binding protein 6 1.21 5.97E-05 
221577_x_at GDF15 growth differentiation factor 15 2.88 6.37E-06 
202722_s_at GFPT1 glutamine-fructose-6-phosphate transaminase 
1 
2.21 3.24E-05 
209248_at GHITM growth hormone inducible transmembrane 
protein 
1.86 8.50E-05 
203159_at GLS glutaminase 1.97 1.79E-05 
213021_at GOSR1 golgi SNAP receptor complex member 1 1.58 2.93E-05 
208813_at GOT1 glutamic-oxaloacetic transaminase 1, soluble 
(aspartate aminotransferase 1) 
1.64 6.69E-06 
224634_at GPATC4 G patch domain containing 4 1.30 6.23E-05 
222953_at GPR83 G protein-coupled receptor 83 6.41 2.80E-07 
209409_at GRB10 growth factor receptor-bound protein 10 2.84 4.66E-05 
235381_at HBXAP hepatitis B virus x associated protein 1.50 2.80E-05 
200690_at HSPA9B heat shock 70kDa protein 9B (mortalin-2) 2.29 1.70E-05 
228002_at IDI2 isopentenyl-diphosphate delta isomerase 2 1.65 5.76E-05 
202147_s_at IFRD1 interferon-related developmental regulator 1 2.71 7.06E-05 
210587_at INHBE inhibin, beta E 4.61 2.37E-05 
202794_at INPP1 inositol polyphosphate-1-phosphatase 1.65 1.76E-07 
226216_at INSR Insulin receptor 1.48 7.99E-05 
209098_s_at JAG1 jagged 1 (Alagille syndrome) 2.10 9.40E-05 
201648_at JAK1 Janus kinase 1 (a protein tyrosine kinase) 1.54 7.04E-05 
226352_at JMY Junction-mediating and regulatory protein 2.71 1.50E-05 
217938_s_at KCMF1 potassium channel modulatory factor 1 1.32 2.76E-05 
  127
Table S1 (Continued) 
Probe ID Gene Symbol Gene Title Fold Difference 
P 
221125_s_at KCNMB3 potassium large conductance calcium-
activated channel, subfamily M beta member 
3 
5.21 5.45E-06 
212395_s_at KIAA0090 KIAA0090 1.57 8.17E-05 
216913_s_at KIAA0690 KIAA0690 2.24 9.26E-06 
212942_s_at KIAA1199 KIAA1199 2.44 1.13E-05 
224826_at KIAA1434 hypothetical protein KIAA1434 1.60 5.74E-05 
233893_s_at KIAA1530 KIAA1530 protein 1.68 1.18E-05 
225770_at KIAA1972 KIAA1972 protein 1.13 5.23E-05 
212162_at KIDINS220 kinase D-interacting substance of 220 kDa 1.27 9.69E-05 
202393_s_at KLF10 Kruppel-like factor 10 3.08 4.82E-05 
205569_at LAMP3 lysosomal-associated membrane protein 3 5.87 7.83E-06 
236565_s_at LARP6 La ribonucleoprotein domain family, member 
6 
3.37 5.10E-06 
202386_s_at LKAP limkain b1 1.94 3.20E-05 
209205_s_at LMO4 LIM domain only 4 2.06 9.63E-05 
221501_x_at LOC339047 hypothetical protein LOC339047 2.25 7.87E-05 
235147_at LOC440928 hypothetical gene supported by AK096649 1.62 4.20E-05 
220437_at LOC55908 hepatocellular carcinoma-associated gene 
TD26 
5.20 3.46E-07 
226650_at LOC90637 hypothetical protein LOC90637 1.68 5.15E-06 
227145_at LOXL4 lysyl oxidase-like 4 3.36 3.95E-05 
211615_s_at LRPPRC leucine-rich PPR-motif containing /// leucine-
rich PPR-motif containing 
1.36 1.39E-06 
226206_at MAFK v-maf musculoaponeurotic fibrosarcoma 
oncogene homolog K (avian) 
1.81 9.33E-05 
226084_at MAP1B microtubule-associated protein 1B 2.93 5.07E-06 
208786_s_at MAP1LC3B microtubule-associated protein 1 light chain 3 
beta 
2.93 7.36E-06 
201475_x_at MARS methionine-tRNA synthetase 2.26 7.23E-05 
235141_at MARVELD2 MARVEL domain containing 2 1.70 2.83E-05 
236814_at MDM4 Mdm4, transformed 3T3 cell double minute 4, 
p53 binding protein (mouse) 
2.10 1.68E-05 
213696_s_at MED8 mediator of RNA polymerase II transcription, 
subunit 8 homolog (yeast) 
1.34 3.58E-05 
212535_at MEF2A MADS box transcription enhancer factor 2, 
polypeptide A (myocyte enhancer factor 2A) 
1.71 2.12E-05 
236285_at MGC16635 hypothetical protein BC009980 7.04 6.98E-06 
223297_at MGC4268 hypothetical protein MGC4268 1.54 1.31E-05 
219270_at MGC4504 hypothetical protein MGC4504 3.44 9.31E-05 
219959_at MOCOS molybdenum cofactor sulfurase 2.30 5.93E-05 
219451_at MSRB2 methionine sulfoxide reductase B2 1.75 9.43E-05 
225520_at MTHFD1L methylenetetrahydrofolate dehydrogenase 
(NADP+ dependent) 1-like 
2.04 9.76E-06 
233665_x_at MTO1 mitochondrial translation optimization 1 
homolog (S. cerevisiae) 
1.37 6.07E-05 
203037_s_at MTSS1 metastasis suppressor 1 1.97 2.04E-05 
228846_at MXD1 MAX dimerization protein 1 3.27 6.90E-05 
226275_at 2.14 1.45E-05 
202431_s_at MYC v-myc myelocytomatosis viral oncogene 
homolog (avian) 
2.17 5.68E-05 
201976_s_at MYO10 myosin X 2.92 1.29E-05 
211916_s_at MYO1A myosin IA /// myosin IA 1.56 1.56E-05 
218330_s_at NAV2 neuron navigator 2 2.12 4.67E-06 
201384_s_at NBR1 neighbor of BRCA1 gene 1 1.36 4.71E-05 
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207700_s_at NCOA3 nuclear receptor coactivator 3 1.35 3.00E-05 
213331_s_at NEK1 NIMA (never in mitosis gene a)-related kinase 
1 
1.46 5.62E-05 
200759_x_at NFE2L1 nuclear factor (erythroid-derived 2)-like 1 1.99 4.54E-05 
203574_at NFIL3 nuclear factor, interleukin 3 regulated 1.76 9.17E-07 
223439_at NKAP NF-kappaB activating protein 2.51 1.15E-05 
204538_x_at NPIP /// 
LOC339047 /// 
LOC440341 
nuclear pore complex interacting protein /// 
hypothetical protein LOC339047 /// similar to 
hypothetical protein LOC339047 
2.40 4.38E-05 
207563_s_at OGT O-linked N-acetylglucosamine (GlcNAc) 
transferase (UDP-N-
acetylglucosamine:polypeptide-N-
acetylglucosaminyl transferase) 
1.66 3.97E-05 
1554503_a_at OSCAR osteoclast-associated receptor 2.77 1.49E-05 
210401_at P2RX1 purinergic receptor P2X, ligand-gated ion 
channel, 1 
3.45 1.26E-07 
209230_s_at P8 p8 protein (candidate of metastasis 1) 2.20 1.25E-06 
200816_s_at PAFAH1B1 platelet-activating factor acetylhydrolase, 
isoform Ib, alpha subunit 45kDa 
1.66 8.96E-05 
204005_s_at PAWR PRKC, apoptosis, WT1, regulator 1.46 3.25E-05 
224986_s_at PDPK1 3-phosphoinositide dependent protein kinase-
1 
1.72 4.74E-05 
218336_at PFDN2 prefoldin 2 1.47 2.14E-05 
209803_s_at PHLDA2 pleckstrin homology-like domain, family A, 
member 2 
2.99 7.89E-06 
209318_x_at PLAGL1 pleiomorphic adenoma gene-like 1 1.18 8.11E-05 
218258_at POLR1D polymerase (RNA) I polypeptide D, 16kDa 1.13 5.66E-05 
202066_at PPFIA1 protein tyrosine phosphatase, receptor type, f 
polypeptide (PTPRF), interacting protein 
(liprin), alpha 1 
1.54 5.44E-05 
201500_s_at PPP1R11 protein phosphatase 1, regulatory (inhibitor) 
subunit 11 
1.67 7.36E-06 
37028_at PPP1R15A protein phosphatase 1, regulatory (inhibitor) 
subunit 15A 
2.87 1.14E-05 
202014_at 2.22 1.45E-05 
203338_at PPP2R5E protein phosphatase 2, regulatory subunit B 
(B56), epsilon isoform 
1.54 5.52E-05 
1555781_at PQLC2 PQ loop repeat containing 2 1.69 3.15E-05 
212217_at PREPL prolyl endopeptidase-like 1.94 4.26E-05 
225278_at PRKAB2 protein kinase, AMP-activated, beta 2 non-
catalytic subunit 
1.70 1.23E-05 
1558027_s_at 1.62 1.81E-05 
215707_s_at PRNP prion protein (p27-30) (Creutzfeld-Jakob 
disease, Gerstmann-Strausler-Scheinker 
syndrome, fatal familial insomnia) 
2.04 5.79E-05 
202529_at PRPSAP1 phosphoribosyl pyrophosphate synthetase-
associated protein 1 
1.46 9.15E-05 
202525_at PRSS8 protease, serine, 8 (prostasin) 2.83 5.77E-06 
212222_at PSME4 proteasome (prosome, macropain) activator 
subunit 4 
1.24 2.86E-05 
224937_at PTGFRN prostaglandin F2 receptor negative regulator 1.30 5.70E-05 
203997_at PTPN3 protein tyrosine phosphatase, non-receptor 
type 3 
1.89 1.41E-06 
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201166_s_at PUM1 pumilio homolog 1 (Drosophila) 1.42 1.04E-05 
216221_s_at PUM2 pumilio homolog 2 (Drosophila) 1.39 5.99E-05 
213530_at RAB3GAP RAB3 GTPase-activating protein 1.78 6.18E-05 
224880_at RALA v-ral simian leukemia viral oncogene homolog 
A (ras related) 
1.81 1.35E-05 
201712_s_at RANBP2 RAN binding protein 2 1.30 3.77E-05 
210676_x_at RANBP2L1 RAN binding protein 2-like 1 1.49 7.01E-05 
220746_s_at RAP80 receptor associated protein 80 1.42 1.07E-05 
223467_at RASD1 RAS, dexamethasone-induced 1 3.59 8.35E-05 
203250_at RBM16 RNA binding motif protein 16 1.54 7.02E-05 
218134_s_at RBM22 RNA binding motif protein 22 1.17 8.57E-06 
214113_s_at RBM8A RNA binding motif protein 8A 1.37 6.92E-05 
213878_at RECQL RecQ protein-like (DNA helicase Q1-like) 2.03 9.25E-05 
212116_at RFP ret finger protein 1.25 2.45E-05 
209568_s_at RGL1 ral guanine nucleotide dissociation stimulator-
like 1 
2.52 3.13E-05 
219610_at RGNEF rho-guanine nucleotide exchange factor 1.40 1.93E-05 
212120_at RHOQ ras homolog gene family, member Q 1.96 2.01E-05 
223168_at RHOU ras homolog gene family, member U 1.43 9.01E-05 
202130_at RIOK3 RIO kinase 3 (yeast) /// RIO kinase 3 (yeast) 2.05 3.74E-05 
212155_at RNF187 ring finger protein 187 1.93 5.49E-05 
210716_s_at RSN restin (Reed-Steinberg cell-expressed 
intermediate filament-associated protein) 
2.03 1.41E-05 
231894_at SARS seryl-tRNA synthetase 3.49 3.02E-05 
200802_at 2.12 1.10E-06 
213435_at SATB2 SATB family member 2 1.87 2.90E-05 
224983_at SCARB2 scavenger receptor class B, member 2 1.54 3.79E-05 
224250_s_at SECISBP2 SECIS binding protein 2 1.55 5.97E-05 
218265_at 1.44 1.62E-05 
202318_s_at SENP6 SUMO1/sentrin specific protease 6 1.63 5.69E-05 
212190_at SERPINE2 serine (or cysteine) proteinase inhibitor, clade 
E (nexin, plasminogen activator inhibitor type 
1), member 2 
2.49 6.82E-06 
202656_s_at SERTAD2 SERTA domain containing 2 1.58 3.75E-05 
36545_s_at SFI1 Sfi1 homolog, spindle assembly associated 
(yeast) 
3.14 2.68E-05 
214402_s_at 1.89 7.82E-05 
212322_at SGPL1 sphingosine-1-phosphate lyase 1 1.40 5.79E-05 
210101_x_at SH3GLB1 SH3-domain GRB2-like endophilin B1 1.59 3.75E-05 
209091_s_at 1.57 1.96E-05 
209090_s_at 1.30 8.96E-05 
214437_s_at SHMT2 serine hydroxymethyltransferase 2 
(mitochondrial) 
1.39 3.52E-05 
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207097_s_at SLC17A2 solute carrier family 17 (sodium phosphate), 
member 2 
2.96 1.97E-05 
213549_at SLC18A2 solute carrier family 18 (vesicular 
monoamine), member 2 
1.47 2.42E-05 
209610_s_at SLC1A4 solute carrier family 1 (glutamate/neutral 
amino acid transporter), member 4 
1.77 2.69E-05 
201920_at SLC20A1 solute carrier family 20 (phosphate 
transporter), member 1 
1.26 3.62E-05 
228497_at SLC22A15 solute carrier family 22 (organic cation 
transporter), member 15 
4.31 1.42E-05 
217122_s_at SLC35E2 solute carrier family 35, member E2 1.81 6.87E-05 
224579_at SLC38A1 Solute carrier family 38, member 1 1.82 1.29E-05 
200924_s_at SLC3A2 solute carrier family 3 (activators of dibasic 
and neutral amino acid transport), member 2 
2.18 9.81E-05 
212295_s_at SLC7A1 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 1 
2.58 1.11E-05 
209921_at SLC7A11 solute carrier family 7, (cationic amino acid 
transporter, y+ system) member 11 
4.18 6.76E-07 
217678_at 3.21 2.25E-06 
225516_at SLC7A2 solute carrier family 7 (cationic amino acid 
transporter, y+ system), member 2 
2.83 7.95E-06 
203373_at SOCS2 suppressor of cytokine signaling 2 2.44 6.61E-05 
228662_at SOCS7 suppressor of cytokine signaling 7 1.64 1.41E-05 
206239_s_at SPINK1 serine protease inhibitor, Kazal type 1 3.92 7.57E-05 
1554807_a_at SPIRE1 spire homolog 1 (Drosophila) 2.15 2.56E-05 
226342_at SPTBN1 spectrin, beta, non-erythrocytic 1 4.63 8.23E-06 
200672_x_at 2.49 7.07E-05 
212071_s_at 2.13 4.10E-05 
203439_s_at STC2 stanniocalcin 2 1.81 4.73E-05 
228967_at SUI1 putative translation initiation factor 1.61 6.29E-05 
213090_s_at TAF4 TAF4 RNA polymerase II, TATA box 
binding protein (TBP)-associated factor, 
135kDa 
1.36 3.87E-05 
225308_s_at TANC TPR domain, ankyrin-repeat and coiled-coil-
containing 
1.74 8.95E-05 
201263_at TARS threonyl-tRNA synthetase 1.87 6.08E-05 
226409_at TBC1D20 TBC1 domain family, member 20 1.34 8.04E-05 
221471_at TDE1 tumor differentially expressed 1 1.31 3.43E-05 
208944_at TGFBR2 transforming growth factor, beta receptor II 
(70/80kDa) 
1.28 3.53E-05 
226628_at THOC2 THO complex 2 1.46 5.54E-05 
225698_at TIGA1 TIGA1 2.68 3.14E-07 
228256_s_at 1.93 1.38E-05 
202085_at TJP2 tight junction protein 2 (zona occludens 2) 1.26 9.91E-05 
228284_at TLE1 /// 
LOC389863 
transducin-like enhancer of split 1 (E(sp1) 
homolog, Drosophila) /// hypothetical gene 
supported by BC000228; NM_005077 
1.87 7.50E-05 
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236430_at TMED6 transmembrane emp24 protein transport 
domain containing 6 
2.25 4.38E-05 
209226_s_at TNPO1 transportin 1 1.40 5.11E-05 
202241_at TRIB1 tribbles homolog 1 (Drosophila) 2.08 1.43E-05 
1555788_a_at TRIB3 tribbles homolog 3 (Drosophila) 3.96 5.90E-06 
218145_at 3.19 2.83E-05 
210266_s_at TRIM33 tripartite motif-containing 33 1.89 8.34E-05 
218972_at TTC17 tetratricopeptide repeat domain 17 2.40 6.09E-05 
201010_s_at TXNIP thioredoxin interacting protein 3.17 2.10E-05 
208174_x_at U2AF1L2 U2(RNU2) small nuclear RNA auxiliary 
factor 1-like 2 
1.41 5.88E-05 
211285_s_at UBE3A ubiquitin protein ligase E3A (human 
papilloma virus E6-associated protein, 
Angelman syndrome) 
1.22 2.44E-05 
201535_at UBL3 ubiquitin-like 3 1.81 3.45E-05 
222991_s_at UBQLN1 ubiquilin 1 1.33 4.64E-06 
232299_at UNQ830 ASCL830 2.00 9.80E-05 
220419_s_at USP25 ubiquitin specific protease 25 1.85 1.06E-05 
221654_s_at USP3 ubiquitin specific protease 3 1.48 2.72E-05 
212066_s_at USP34 ubiquitin specific protease 34 1.38 2.05E-05 
221513_s_at UTP14C /// 
UTP14A 
UTP14, U3 small nucleolar ribonucleoprotein, 
homolog C (yeast) /// UTP14, U3 small 
nucleolar ribonucleoprotein, homolog A 
(yeast) 
1.51 4.72E-05 
209822_s_at VLDLR very low density lipoprotein receptor 3.04 4.05E-05 
217742_s_at WAC WW domain containing adaptor with coiled-
coil 
1.65 2.71E-05 
200629_at WARS tryptophanyl-tRNA synthetase 4.46 1.87E-05 
200628_s_at 2.56 4.32E-05 
224813_at WASL Wiskott-Aldrich syndrome-like 1.93 8.33E-05 
218107_at WDR26 WD repeat domain 26 1.49 2.73E-06 
219001_s_at WDR32 WD repeat domain 32 1.42 2.20E-06 
221735_at WDR48 WD repeat domain 48 1.38 4.80E-05 
221712_s_at WDR74 WD repeat domain 74 /// WD repeat domain 
74 
1.58 7.22E-05 
212048_s_at YARS tyrosyl-tRNA synthetase 1.99 5.34E-05 
222408_s_at YPEL5 yippee-like 5 (Drosophila) 2.12 2.79E-05 
217783_s_at 1.69 7.09E-05 
210275_s_at ZA20D2 zinc finger, A20 domain containing 2 1.68 5.98E-05 
205788_s_at ZC3H11A zinc finger CCCH-type containing 11A 1.46 5.61E-05 
223506_at ZC3H8 zinc finger CCCH-type containing 8 3.20 1.11E-05 
217367_s_at ZHX3 zinc fingers and homeoboxes 3 1.28 5.43E-05 
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223642_at ZIC2 Zic family member 2 (odd-paired homolog, 
Drosophila) 
2.03 7.54E-05 
225221_at ZKSCAN1 zinc finger with KRAB and SCAN domains 1 1.46 5.04E-05 
202136_at ZMYND11 zinc finger, MYND domain containing 11 1.43 7.58E-06 
215022_x_at ZNF11B zinc finger protein 11B 1.77 3.49E-05 
202049_s_at ZNF262 zinc finger protein 262 1.24 3.18E-05 
225539_at ZNF295 zinc finger protein 295 1.38 3.38E-05 
204175_at ZNF593 zinc finger protein 593 1.15 3.38E-05 
227822_at ZNF605 zinc finger protein 605 1.94 2.73E-05 
211257_x_at ZNF638 zinc finger protein 638 1.33 2.40E-05 
227755_at  CDNA clone IMAGE:4077090, partial cds 5.24 3.16E-06 
225522_at  similar to BMP2 inducible kinase 3.12 1.23E-05 
226886_at  clone 114 tumor rejection antigen mRNA, 
complete cds 
1.97 3.38E-05 
1555832_s_at  Homo sapiens, clone IMAGE:4096273, 
mRNA 
1.81 5.95E-05 
235360_at  unknown mRNA 1.81 9.65E-05 
239065_at   1.76 1.27E-05 
224606_at  Homo sapiens, clone IMAGE:4096273, 
mRNA 
1.74 7.85E-07 
229428_at  CDNA FLJ40725 fis, clone TKIDN1000001, 
highly similar to translocase of inner 
mitochondrial membrane 23 
1.73 3.95E-05 
217625_x_at  hypothetical gene supported by AK024177 1.73 8.97E-05 
225935_at  FP6778 1.66 3.84E-05 
234985_at   1.63 4.02E-05 
212462_at   1.62 8.34E-05 
226669_at   1.54 4.09E-05 
227356_at  CDNA: FLJ22198 fis, clone HRC01218 1.51 6.95E-05 
226949_at   1.48 6.85E-06 
228661_s_at  CDNA FLJ11489 fis, clone HEMBA1001915 1.39 9.69E-05 
229803_s_at  AF034176 Human mRNA (Tripodis and 
Ragoussis) Homo sapiens cDNA clone ntcon5 
contig 
1.39 7.09E-06 
243553_x_at   1.16 2.38E-05 
1To be included in this table, differential gene expression had to meet a statistical cutoff of P<0.0001. 
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1554878_a_at ABCD3 ATP-binding cassette, sub-family D 
(ALD), member 3 
0.42 8.83E-
05 
218405_at ABT1 activator of basal transcription 1 0.67 7.64E-
05 
234312_s_at ACAS2 acetyl-Coenzyme A synthetase 2 (ADP 
forming) 
0.42 1.69E-
05 
209608_s_at ACAT2 acetyl-Coenzyme A acetyltransferase 2 
(acetoacetyl Coenzyme A thiolase) 
0.27 3.17E-
06 
208950_s_at ALDH7A1 aldehyde dehydrogenase 7 family, 
member A1 
0.51 8.69E-
05 
208951_at 0.47 2.04E-
05 
220148_at ALDH8A1 aldehyde dehydrogenase 8 family, 
member A1 
0.37 2.65E-
05 
214687_x_at ALDOA aldolase A, fructose-bisphosphate 0.66 6.82E-
05 
238996_x_at 0.50 2.75E-
06 
226414_s_at ANAPC11 APC11 anaphase promoting complex 
subunit 11 homolog (yeast) 
0.65 2.84E-
05 
208722_s_at ANAPC5 anaphase promoting complex subunit 5 0.72 6.04E-
05 
222608_s_at ANLN anillin, actin binding protein (scraps 
homolog, Drosophila) 
0.32 5.27E-
05 
201590_x_at ANXA2 annexin A2 0.64 1.01E-
05 
213503_x_at 0.62 3.68E-
05 
201302_at ANXA4 annexin A4 0.57 1.85E-
05 
201301_s_at 0.54 7.14E-
07 
208074_s_at AP2S1 adaptor-related protein complex 2, sigma 
1 subunit 
0.70 8.13E-
05 
206632_s_at APOBEC3B apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide-like 3B 
0.28 1.11E-
06 
229526_at AQP11 aquaporin 11 0.54 3.40E-
05 
225171_at ARHGAP18 Rho GTPase activating protein 18 0.36 1.84E-
05 
211935_at ARL6IP ADP-ribosylation factor-like 6 interacting 
protein 
0.53 1.57E-
05 
219094_at ARMC8 armadillo repeat containing 8 0.75 9.35E-
05 
210971_s_at ARNTL aryl hydrocarbon receptor nuclear 
translocator-like 
0.56 8.84E-
06 
222912_at ARRB1 arrestin, beta 1 0.64 7.68E-
05 
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205673_s_at ASB9 ankyrin repeat and SOCS box-containing 9 0.33 9.02E-05 
209517_s_at ASH2L ash2 (absent, small, or homeotic)-like 
(Drosophila) 
0.77 8.46E-05 
244519_at ASXL1 additional sex combs like 1 (Drosophila) 0.53 2.55E-05 
202961_s_at ATP5J2 ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit f, isoform 
2 
0.59 4.48E-05 
233110_s_at BCL2L12 BCL2-like 12 (proline rich) 0.60 3.61E-05 
210334_x_at BIRC5 baculoviral IAP repeat-containing 5 
(survivin) 
0.27 5.40E-05 
227291_s_at BOLA3 bolA-like 3 (E. coli) 0.72 9.96E-05 
235609_at BRIP1 BRCA1 interacting protein C-terminal 
helicase 1 
0.38 2.66E-05 
202427_s_at BRP44 brain protein 44 0.62 5.18E-05 
209642_at BUB1 BUB1 budding uninhibited by 
benzimidazoles 1 homolog (yeast) 
0.33 7.79E-05 
201457_x_at BUB3 BUB3 budding uninhibited by 
benzimidazoles 3 homolog (yeast) 
0.72 4.97E-05 
219067_s_at C10orf86 chromosome 10 open reading frame 86 0.56 1.24E-05 
202562_s_at C14orf1 chromosome 14 open reading frame 1 0.41 1.32E-05 
217188_s_at 0.40 4.13E-05 
214264_s_at C14orf143 chromosome 14 open reading frame 143 0.52 7.15E-05 
238691_at C14orf62 chromosome 14 open reading frame 62 0.73 6.13E-05 
218493_at C16orf33 chromosome 16 open reading frame 33 0.40 7.57E-06 
221739_at C19orf10 chromosome 19 open reading frame 10 0.76 4.12E-05 
212003_at C1orf144 chromosome 1 open reading frame 144 0.53 1.20E-05 
225687_at C20orf129 chromosome 20 open reading frame 129 0.37 5.83E-05 
219512_at C20orf172 chromosome 20 open reading frame 172 0.38 5.55E-06 
224972_at C20orf52 chromosome 20 open reading frame 52 0.59 3.70E-05 
226936_at C6orf173 chromosome 6 open reading frame 173 0.34 1.83E-05 
228053_s_at C9orf105 chromosome 9 open reading frame 105 0.71 7.35E-05 
210691_s_at CACYBP calcyclin binding protein 0.65 8.12E-05 
201381_x_at 0.65 6.01E-05 
209563_x_at CALM1 calmodulin 1 (phosphorylase kinase, delta) 0.64 3.12E-05 
200935_at CALR calreticulin 0.42 5.90E-05 
225693_s_at CAMTA1 calmodulin binding transcription activator 1 0.69 6.75E-06 
201432_at CAT catalase 0.64 3.81E-05 
213226_at CCNA2 cyclin A2 0.34 2.20E-05 
203418_at 0.27 1.51E-05 
228729_at CCNB1 cyclin B1 0.35 9.74E-06 
214710_s_at 0.35 2.70E-05 
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266_s_at CD24 CD24 antigen (small cell lung carcinoma 
cluster 4 antigen) 
0.58 7.94E-05 
201028_s_at CD99 CD99 antigen 0.66 1.46E-05 
203214_x_at CDC2 cell division cycle 2, G1 to S and G2 to M 0.30 3.59E-05 
210559_s_at 0.29 2.17E-05 
203968_s_at CDC6 CDC6 cell division cycle 6 homolog (S. 
cerevisiae) 
0.30 2.39E-06 
203967_at 0.27 1.88E-05 
204252_at CDK2 cyclin-dependent kinase 2 0.45 4.15E-06 
211804_s_at 0.34 9.04E-05 
204159_at CDKN2C cyclin-dependent kinase inhibitor 2C (p18, 
inhibits CDK4) 
0.27 5.00E-05 
209714_s_at CDKN3 cyclin-dependent kinase inhibitor 3 (CDK2-
associated dual specificity phosphatase) 
0.34 6.12E-05 
204962_s_at CENPA centromere protein A, 17kDa 0.38 8.50E-05 
209194_at CETN2 centrin, EF-hand protein, 2 0.38 2.64E-06 
205394_at CHEK1 CHK1 checkpoint homolog (S. pombe) 0.42 1.20E-05 
205393_s_at 0.38 1.44E-05 
210416_s_at CHEK2 CHK2 checkpoint homolog (S. pombe) 0.38 6.75E-05 
201953_at CIB1 calcium and integrin binding 1 (calmyrin) 0.58 1.59E-05 
204170_s_at CKS2 CDC28 protein kinase regulatory subunit 2 0.46 3.95E-06 
1554804_a_at CLDN19 claudin 19 0.51 4.65E-05 
222409_at CORO1C coronin, actin binding protein, 1C 0.75 9.26E-05 
203880_at COX17 COX17 homolog, cytochrome c oxidase 
assembly protein (yeast) 
0.52 3.53E-06 
218057_x_at COX4NB COX4 neighbor 0.70 1.14E-05 
201441_at COX6B1 cytochrome c oxidase subunit Vib 
polypeptide 1 (ubiquitous) 
0.62 5.63E-05 
206651_s_at CPB2 carboxypeptidase B2 (plasma, 
carboxypeptidase U) 
0.30 4.79E-06 
205081_at CRIP1 cysteine-rich protein 1 (intestinal) 0.28 1.44E-05 
201112_s_at CSE1L CSE1 chromosome segregation 1-like (yeast) 0.50 5.96E-06 
210766_s_at 0.47 1.74E-06 
228906_at CXXC6 CXXC finger 6 0.51 4.95E-05 
207843_x_at CYB5 cytochrome b-5 0.67 5.85E-06 
209366_x_at 0.64 1.93E-05 
1554574_a_at CYB5R3 cytochrome b5 reductase 3 0.49 5.67E-05 
216607_s_at CYP51A1 cytochrome P450, family 51, subfamily A, 
polypeptide 1 
0.26 4.31E-05 
202428_x_at DBI diazepam binding inhibitor (GABA receptor 
modulator, acyl-Coenzyme A binding 
protein) 
0.42 1.63E-05 
209389_x_at 0.25 3.27E-06 
222889_at DCLRE1B DNA cross-link repair 1B (PSO2 homolog, 
S. cerevisiae) 
0.54 3.10E-05 
226980_at DEPDC1B DEP domain containing 1B 0.36 3.56E-05 
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209549_s_at DGUOK deoxyguanosine kinase 0.74 4.27E-05 
202534_x_at DHFR dihydrofolate reductase 0.43 5.72E-05 
48808_at 0.36 1.95E-05 
218285_s_at DHRS6 dehydrogenase/reductase (SDR family) 
member 6 
0.53 9.70E-05 
203764_at DLG7 discs, large homolog 7 (Drosophila) 0.37 9.47E-05 
215253_s_at DSCR1 Down syndrome critical region gene 1 0.81 7.79E-05 
222680_s_at DTL denticleless homolog (Drosophila) 0.42 2.14E-06 
1553984_s_at DTYMK deoxythymidylate kinase (thymidylate 
kinase) 
0.43 3.54E-05 
203270_at 0.39 3.54E-05 
208956_x_at DUT dUTP pyrophosphatase 0.50 7.95E-05 
209932_s_at 0.40 1.78E-06 
228033_at E2F7 E2F transcription factor 7 0.45 5.24E-05 
219990_at E2F8 E2F transcription factor 8 0.36 1.86E-05 
220942_x_at E2IG5 growth and transformation-dependent protein 0.62 3.92E-05 
223193_x_at 0.60 6.19E-05 
202735_at EBP emopamil binding protein (sterol isomerase) 0.32 2.82E-06 
213787_s_at 0.29 1.24E-05 
223087_at ECHDC1 enoyl Coenzyme A hydratase domain 
containing 1 
0.67 4.94E-06 
201135_at ECHS1 enoyl Coenzyme A hydratase, short chain, 1, 
mitochondrial 
0.75 8.93E-05 
201341_at ENC1 ectodermal-neural cortex (with BTB-like 
domain) 
0.49 1.94E-05 
202596_at ENSA endosulfine alpha 0.59 4.85E-05 
209527_at EXOSC2 exosome component 2 0.67 3.95E-05 
208964_s_at FADS1 
 
fatty acid desaturase 1 0.33 3.85E-05 
208962_s_at 0.29 7.16E-05 
202218_s_at FADS2 fatty acid desaturase 2 0.57 1.69E-05 
225684_at FAM33A family with sequence similarity 33, member 
A 
0.56 3.38E-05 
203564_at FANCG Fanconi anemia, complementation group G 0.45 2.19E-05 
203255_at FBXO11 F-box protein 11 0.60 1.42E-06 
239358_at FDFT1 farnesyl-diphosphate farnesyltransferase 1 0.56 1.51E-05 
208647_at 0.37 9.33E-08 
210950_s_at 0.30 2.55E-05 
201275_at FDPS farnesyl diphosphate synthase (farnesyl 
pyrophosphate synthetase, 
dimethylallyltranstransferase, 
geranyltranstransferase) 
0.37 3.38E-06 
204768_s_at FEN1 flap structure-specific endonuclease 1 0.34 3.41E-06 
204767_s_at 0.28 1.66E-05 
45633_at FLJ13912 hypothetical protein FLJ13912 0.58 8.54E-05 
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219544_at FLJ22624 FLJ22624 protein 0.43 2.77E-05 
205674_x_at FXYD2 FXYD domain containing ion transport 
regulator 2 
0.60 6.08E-05 
203178_at GATM glycine amidinotransferase (L-
arginine:glycine amidinotransferase) 
0.40 1.51E-05 
36475_at GCAT glycine C-acetyltransferase (2-amino-3-
ketobutyrate coenzyme A ligase) 
0.58 9.06E-06 
204867_at GCHFR GTP cyclohydrolase I feedback regulator 0.31 2.44E-05 
230788_at GCNT2 glucosaminyl (N-acetyl) transferase 2, I-
branching enzyme 
0.52 3.79E-06 
214430_at GLA galactosidase, alpha 0.43 5.98E-05 
200681_at GLO1 glyoxalase I 0.54 2.74E-06 
200946_x_at GLUD1 glutamate dehydrogenase 1 0.79 2.01E-05 
235678_at GM2A GM2 ganglioside activator 0.49 9.12E-05 
215891_s_at 0.44 3.24E-05 
212737_at 0.36 5.83E-05 
205240_at GPSM2 G-protein signalling modulator 2 (AGS3-
like, C. elegans) 
0.65 2.01E-05 
208336_s_at GPSN2 glycoprotein, synaptic 2 0.48 5.89E-06 
214091_s_at GPX3 glutathione peroxidase 3 (plasma) 0.61 4.80E-05 
202554_s_at GSTM3 glutathione S-transferase M3 (brain) 0.57 9.47E-05 
1557915_s_at GSTO1 glutathione S-transferase omega 1 0.73 7.79E-05 
223128_at H17 hypothetical protein H17 0.78 3.33E-05 
202487_s_at H2AFV H2A histone family, member V 0.58 4.73E-05 
201036_s_at HADHSC L-3-hydroxyacyl-Coenzyme A 
dehydrogenase, short chain 
0.43 6.49E-05 
203138_at HAT1 histone acetyltransferase 1 0.45 2.49E-05 
218662_s_at HCAP-G chromosome condensation protein G 0.38 4.61E-05 
223556_at HELLS helicase, lymphoid-specific 0.35 5.45E-05 
202540_s_at HMGCR 3-hydroxy-3-methylglutaryl-Coenzyme A 
reductase 
0.36 1.40E-05 
202539_s_at 0.31 1.04E-05 
205822_s_at HMGCS1 3-hydroxy-3-methylglutaryl-Coenzyme A 
synthase 1 (soluble) 
0.27 5.41E-05 
209709_s_at HMMR hyaluronan-mediated motility receptor 
(RHAMM) 
0.39 4.75E-05 
222396_at HN1 hematological and neurological expressed 1 0.68 4.40E-05 
216855_s_at HNRPU heterogeneous nuclear ribonucleoprotein U 
(scaffold attachment factor A) 
0.68 4.87E-05 
206445_s_at HRMT1L2 HMT1 hnRNP methyltransferase-like 2 (S. 
cerevisiae) 
0.80 7.75E-05 
209513_s_at HSDL2 hydroxysteroid dehydrogenase like 2 0.71 1.76E-07 
218026_at HSPC009 HSPC009 protein 0.57 2.00E-06 
217774_s_at HSPC152 hypothetical protein HSPC152 0.68 7.46E-05 
206855_s_at HYAL2 hyaluronoglucosaminidase 2 0.70 6.87E-06 
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204615_x_at IDI1 isopentenyl-diphosphate delta isomerase 1 0.24 9.61E-06 
208881_x_at 0.23 8.21E-07 
203854_at IF I factor (complement) 0.52 2.48E-05 
201163_s_at IGFBP7 insulin-like growth factor binding protein 7 0.71 6.76E-05 
201234_at ILK integrin-linked kinase 0.67 8.68E-05 
242787_at INCENP Inner centromere protein antigens 
135/155kDa 
0.56 2.13E-05 
206245_s_at IVNS1ABP influenza virus NS1A binding protein 0.64 2.43E-05 
202503_s_at KIAA0101 KIAA0101 0.39 4.50E-05 
243136_at KIAA0182 KIAA0182 protein 0.62 5.22E-05 
221952_x_at KIAA1393 KIAA1393 0.48 9.55E-05 
218755_at KIF20A kinesin family member 20A 0.29 8.38E-05 
204162_at KNTC2 kinetochore associated 2 0.52 2.99E-05 
211762_s_at KPNA2 karyopherin alpha 2 (RAG cohort 1, importin 
alpha 1) /// karyopherin alpha 2 (RAG cohort 
1, importin alpha 1) 
0.63 6.01E-05 
201650_at KRT19 keratin 19 0.48 1.10E-05 
219541_at LIME1 Lck interacting transmembrane adaptor 1 0.45 5.16E-05 
200805_at LMAN2 lectin, mannose-binding 2 0.73 4.12E-05 
218574_s_at LMCD1 LIM and cysteine-rich domains 1 0.74 2.49E-05 
225614_at LOC113174 hypothetical protein BC012010 0.56 7.90E-05 
225404_at LOC113444 hypothetical protein BC011880 0.76 1.96E-05 
222622_at LOC283871 hypothetical protein LOC283871 0.32 5.42E-05 
225967_s_at LOC284184 hypothetical LOC284184 0.65 1.30E-05 
230937_at LOC285835 hypothetical protein LOC285835 0.81 5.52E-06 
224637_at LOC400948 similar to RIKEN cDNA 2310016E02 0.62 7.41E-06 
237017_s_at LOC440286 LOC440286 0.49 2.59E-05 
208107_s_at LOC81691 exonuclease NEF-sp /// exonuclease NEF-sp 0.55 3.20E-05 
202209_at LSM3 LSM3 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 
0.45 7.15E-05 
202736_s_at LSM4 LSM4 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 
0.50 3.23E-05 
202245_at LSS lanosterol synthase (2,3-oxidosqualene-
lanosterol cyclase) 
0.25 1.18E-05 
212282_at MAC30 hypothetical protein MAC30 0.40 9.05E-05 
212279_at 0.31 7.42E-07 
208309_s_at MALT1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
0.69 8.11E-05 
207256_at MBL2 mannose-binding lectin (protein C) 2, soluble 
(opsonic defect) 
0.46 4.39E-07 
226238_at MCEE methylmalonyl CoA epimerase 0.60 1.35E-05 
201555_at MCM3 MCM3 minichromosome maintenance 
deficient 3 (S. cerevisiae) 
0.39 2.61E-05 
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222036_s_at MCM4 MCM4 minichromosome maintenance deficient 
4 (S. cerevisiae) 
0.44 9.38E-07 
201930_at MCM6 MCM6 minichromosome maintenance deficient 
6 (MIS5 homolog, S. pombe) (S. cerevisiae) 
0.33 2.69E-05 
224320_s_at MCM8 MCM8 minichromosome maintenance deficient 
8 (S. cerevisiae) 
0.55 9.60E-05 
204825_at MELK maternal embryonic leucine zipper kinase 0.33 6.66E-05 
225568_at MGC14141 hypothetical protein MGC14141 0.29 3.70E-05 
226456_at MGC24665 hypothetical protein MGC24665 0.27 2.40E-05 
227063_at MGC40107 hypothetical protein MGC40107 0.47 5.33E-06 
228221_at MGC45474 hypothetical protein MGC45474 0.72 2.21E-05 
225799_at MGC4677 
/// 
LOC541471 
hypothetical protein MGC4677 /// hypothetical 
LOC541471 protein 
0.49 7.80E-05 
231736_x_at MGST1 microsomal glutathione S-transferase 1 0.78 5.62E-05 
217909_s_at MLX MAX-like protein X 0.78 8.14E-05 
226790_at MOPT protein containing single MORN motif in testis 0.57 7.09E-05 
205235_s_at MPHOSPH1 M-phase phosphoprotein 1 0.40 1.13E-05 
225298_at MR-1 myofibrillogenesis regulator 1 0.54 3.23E-05 
204386_s_at MRP63 mitochondrial ribosomal protein 63 0.63 6.28E-05 
217907_at MRPL18 mitochondrial ribosomal protein L18 0.70 9.17E-06 
213897_s_at MRPL23 mitochondrial ribosomal protein L23 0.61 5.50E-05 
224330_s_at MRPL27 mitochondrial ribosomal protein L27 /// 
mitochondrial ribosomal protein L27 
0.74 9.95E-05 
222993_at MRPL37 mitochondrial ribosomal protein L37 0.71 7.32E-05 
227186_s_at MRPL41 mitochondrial ribosomal protein L41 0.66 6.31E-06 
210008_s_at MRPS12 mitochondrial ribosomal protein S12 0.50 2.35E-05 
202911_at MSH6 mutS homolog 6 (E. coli) 0.58 2.37E-06 
211450_s_at 0.548 5.26E-06 
213629_x_at MT1F metallothionein 1F (functional) 0.44 3.01E-05 
217165_x_at 0.44 5.21E-05 
204745_x_at MT1G metallothionein 1G 0.40 6.57E-05 
206461_x_at MT1H metallothionein 1H 0.53 5.56E-05 
204326_x_at MT1X metallothionein 1X 0.38 7.93E-06 
222400_s_at MTCBP-1 membrane-type 1 matrix metalloproteinase 
cytoplasmic tail binding protein-1 
0.54 7.17E-05 
217761_at 0.45 1.00E-06 
214268_s_at MTMR4 myotubularin related protein 4 0.70 2.01E-05 
36907_at MVK mevalonate kinase (mevalonic aciduria) 0.48 5.38E-05 
201969_at NASP nuclear autoantigenic sperm protein (histone-
binding) 
0.48 3.76E-05 
202839_s_at NDUFB7 NADH dehydrogenase (ubiquinone) 1 beta 
subcomplex, 7, 18kDa 
0.53 7.45E-05 
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201757_at NDUFS5 NADH dehydrogenase (ubiquinone) Fe-S 
protein 5, 15kDa (NADH-coenzyme Q 
reductase) 
0.57 7.91E-05 
201840_at NEDD8 neural precursor cell expressed, 
developmentally down-regulated 8 
0.54 5.01E-05 
219502_at NEIL3 nei endonuclease VIII-like 3 (E. coli) 0.47 2.75E-05 
201076_at NHP2L1 NHP2 non-histone chromosome protein 2-like 1 
(S. cerevisiae) 
0.79 7.02E-05 
218133_s_at NIF3L1 NIF3 NGG1 interacting factor 3-like 1 (S. 
pombe) 
0.65 5.02E-05 
209104_s_at NOLA2 nucleolar protein family A, member 2 (H/ACA 
small nucleolar RNPs) 
0.70 1.10E-06 
200701_at NPC2 Niemann-Pick disease, type C2 0.67 2.32E-05 
219347_at NUDT15 nudix (nucleoside diphosphate linked moiety 
X)-type motif 15 
0.49 1.31E-05 
219978_s_at NUSAP1 nucleolar and spindle associated protein 1 0.37 2.61E-05 
218039_at 0.35 4.92E-05 
202397_at NUTF2 nuclear transport factor 2 0.55 1.90E-05 
213599_at OIP5 Opa interacting protein 5 0.31 2.09E-05 
218162_at OLFML3 olfactomedin-like 3 0.43 7.20E-05 
205085_at ORC1L origin recognition complex, subunit 1-like 
(yeast) 
0.43 6.82E-05 
201014_s_at PAICS phosphoribosylaminoimidazole carboxylase, 
phosphoribosylaminoimidazole 
succinocarboxamide synthetase 
0.71 9.98E-05 
219148_at PBK PDZ binding kinase 0.26 5.09E-05 
227759_at PCSK9 proprotein convertase subtilisin/kexin type 9 0.18 2.66E-05 
208638_at PDIA6 protein disulfide isomerase family A, member 6 0.62 4.66E-05 
216640_s_at 0.60 3.67E-05 
226452_at PDK1 pyruvate dehydrogenase kinase, isoenzyme 1 0.63 4.36E-05 
221521_s_at Pfs2 DNA replication complex GINS protein PSF2 0.23 5.21E-06 
200737_at PGK1 phosphoglycerate kinase 1 0.65 3.54E-05 
201968_s_at PGM1 phosphoglucomutase 1 0.66 8.98E-05 
213227_at PGRMC2 progesterone receptor membrane component 2 0.70 2.46E-05 
202620_s_at PLOD2 procollagen-lysine, 2-oxoglutarate 5-
dioxygenase 2 
0.51 8.34E-05 
202619_s_at 0.43 9.50E-05 
205909_at POLE2 polymerase (DNA directed), epsilon 2 (p59 
subunit) 
0.34 1.27E-05 
211730_s_at POLR2L polymerase (RNA) II (DNA directed) 
polypeptide L, 7.6kDa /// polymerase (RNA) II 
(DNA directed) polypeptide L, 7.6kDa 
0.44 3.78E-06 
204839_at POP5 processing of precursor 5, ribonuclease P/MRP 
subunit (S. cerevisiae) 
0.64 3.21E-05 
209482_at POP7 processing of precursor 7, ribonuclease P 
subunit (S. cerevisiae) 
0.55 4.25E-05 
200968_s_at PPIB peptidylprolyl isomerase B (cyclophilin B) 0.54 9.24E-05 
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235113_at PPIL5 peptidylprolyl isomerase (cyclophilin)-like 5 0.37 3.99E-05 
235061_at PPM1K protein phosphatase 1K (PP2C domain 
containing) 
0.54 3.68E-06 
204284_at PPP1R3C protein phosphatase 1, regulatory (inhibitor) 
subunit 3C 
0.65 5.16E-05 
200975_at PPT1 palmitoyl-protein thioesterase 1 (ceroid-
lipofuscinosis, neuronal 1, infantile) 
0.70 8.93E-05 
200844_s_at PRDX6 peroxiredoxin 6 0.82 7.34E-05 
205053_at PRIM1 primase, polypeptide 1, 49kDa 0.56 2.25E-05 
205628_at PRIM2A primase, polypeptide 2A, 58kDa 0.58 1.30E-05 
204304_s_at PROM1 prominin 1 0.68 2.73E-05 
226611_s_at PRR6 proline rich 6 0.57 2.10E-06 
200786_at PSMB7 proteasome (prosome, macropain) subunit, beta 
type, 7 
0.82 1.85E-05 
212296_at PSMD14 proteasome (prosome, macropain) 26S subunit, 
non-ATPase, 14 
0.80 1.15E-05 
200772_x_at PTMA prothymosin, alpha (gene sequence 28) 0.59 1.23E-05 
219654_at PTPLA protein tyrosine phosphatase-like (proline 
instead of catalytic arginine), member a 
0.69 8.82E-05 
203554_x_at PTTG1 pituitary tumor-transforming 1 0.40 6.57E-05 
223032_x_at PX19 px19-like protein 0.66 3.12E-06 
242414_at QPRT quinolinate phosphoribosyltransferase 
(nicotinate-nucleotide pyrophosphorylase 
(carboxylating)) 
0.72 2.16E-05 
209849_s_at RAD51C RAD51 homolog C (S. cerevisiae) 0.56 2.12E-05 
206066_s_at 0.43 1.49E-05 
217775_s_at RDH11 retinol dehydrogenase 11 (all-trans and 9-cis) 0.61 8.28E-07 
203696_s_at RFC2 replication factor C (activator 1) 2, 40kDa 0.45 7.32E-05 
204127_at RFC3 
 
replication factor C (activator 1) 3, 38kDa 0.33 8.61E-05 
204128_s_at 0.26 2.47E-05 
204023_at RFC4 replication factor C (activator 1) 4, 37kDa 0.37 2.62E-05 
1552502_s_at RHBDL2 rhomboid, veinlet-like 2 (Drosophila) 0.49 7.57E-05 
212651_at RHOBTB1 Rho-related BTB domain containing 1 0.67 5.59E-05 
203022_at RNASEH2A ribonuclease H2, large subunit 0.39 3.82E-06 
203436_at RPP30 ribonuclease P/MRP 30kDa subunit 0.60 3.98E-06 
201476_s_at RRM1 
 
ribonucleotide reductase M1 polypeptide 0.49 1.46E-05 
201477_s_at 0.39 5.46E-06 
209773_s_at RRM2 ribonucleotide reductase M2 polypeptide 0.28 1.03E-05 
203186_s_at S100A4 S100 calcium binding protein A4 (calcium 
protein, calvasculin, metastasin, murine 
placental homolog) 
0.28 4.93E-06 
209146_at SC4MOL sterol-C4-methyl oxidase-like 0.28 1.86E-06 
231059_x_at SCAND1 SCAN domain containing 1 0.85 2.53E-05 
200832_s_at SCD 
 
stearoyl-CoA desaturase (delta-9-desaturase) 0.47 9.65E-05 
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211162_x_at   0.15 8.88E-05 
211708_s_at 0.14 1.47E-05 
222747_s_at SCML1 sex comb on midleg-like 1 (Drosophila) 0.56 8.63E-06 
201194_at SEPW1 selenoprotein W, 1 0.59 5.35E-05 
33323_r_at SFN Stratifin 0.58 2.87E-05 
209980_s_at SHMT1 serine hydroxymethyltransferase 1 (soluble) 0.38 7.44E-06 
219733_s_at SLC27A5 solute carrier family 27 (fatty acid transporter), 
member 5 
0.46 8.09E-06 
202497_x_at SLC2A3 
 
solute carrier family 2 (facilitated glucose 
transporter), member 3 
0.29 1.93E-05 
202498_s_at 0.28 7.08E-06 
202499_s_at 0.20 2.49E-05 
222088_s_at SLC2A3 /// 
SLC2A14 
solute carrier family 2 (facilitated glucose 
transporter), member 3 /// solute carrier family 2 
(facilitated glucose transporter), member 14 
0.28 8.11E-05 
1555500_s_at SLC2A4RG SLC2A4 regulator 0.66 9.22E-05 
217289_s_at SLC37A4 solute carrier family 37 (glycerol-6-phosphate 
transporter), member 4 
0.66 1.30E-05 
219795_at SLC6A14 solute carrier family 6 (amino acid transporter), 
member 14 
0.60 2.45E-06 
204240_s_at SMC2L1 SMC2 structural maintenance of chromosomes 
2-like 1 (yeast) 
0.51 8.39E-05 
201664_at SMC4L1 
 
SMC4 structural maintenance of chromosomes 
4-like 1 (yeast) 
0.54 4.33E-05 
201663_s_at 0.48 2.11E-05 
206055_s_at SNRPA1 small nuclear ribonucleoprotein polypeptide A' 0.67 8.63E-06 
209891_at SPBC25 spindle pole body component 25 homolog (S. 
cerevisiae) 
0.23 2.04E-06 
201240_s_at SPCS2 signal peptidase complex subunit 2 homolog (S. 
cerevisiae) 
0.63 5.12E-06 
209218_at SQLE squalene epoxidase 0.37 5.50E-05 
213562_s_at 0.31 7.66E-05 
213577_at 0.23 3.03E-07 
218283_at SS18L2 synovial sarcoma translocation gene on 
chromosome 18-like 2 
0.56 6.44E-06 
212625_at STX10 syntaxin 10 0.70 9.98E-05 
200740_s_at SUMO3 SMT3 suppressor of mif two 3 homolog 3 
(yeast) 
0.66 3.98E-05 
222977_at SURF4 surfeit 4 0.67 2.86E-05 
222979_s_at 0.62 3.59E-05 
209358_at TAF11 TAF11 RNA polymerase II, TATA box binding 
protein (TBP)-associated factor, 28kDa 
0.61 9.35E-05 
1555724_s_at TAGLN Transgelin 0.52 2.30E-05 
220789_s_at TBRG4 transforming growth factor beta regulator 4 0.70 1.22E-05 
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200085_s_at TCEB2 transcription elongation factor B (SIII), 
polypeptide 2 (18kDa, elongin B) /// 
transcription elongation factor B (SIII), 
polypeptide 2 (18kDa, elongin B) 
0.80 1.41E-05 
226320_at THOC4 THO complex 4 0.53 4.34E-05 
202338_at TK1 
 
 
thymidine kinase 1, soluble 0.24 1.44E-05 
1554408_a_at 0.21 8.91E-06 
224413_s_at TM2D2 TM2 domain containing 2 /// TM2 domain 
containing 2 
0.60 3.63E-05 
1554485_s_at TMEM37 transmembrane protein 37 0.36 3.59E-05 
1554483_at 0.34 3.27E-05 
218073_s_at TMEM48 transmembrane protein 48 0.54 3.61E-05 
225182_at TMEM50B transmembrane protein 50B 0.54 7.91E-05 
223396_at TMEM60 transmembrane protein 60 0.76 1.98E-05 
228369_at TNRC5 trinucleotide repeat containing 5 0.73 5.38E-05 
201292_at TOP2A topoisomerase (DNA) II alpha 170kDa 0.52 4.00E-05 
213011_s_at TPI1 triosephosphate isomerase 1 0.70 4.06E-05 
222976_s_at TPM3 tropomyosin 3 0.67 8.97E-05 
203824_at TSPAN8 tetraspanin 8 0.34 6.01E-05 
204822_at TTK TTK protein kinase 0.48 9.49E-05 
212320_at TUBB tubulin, beta polypeptide 0.46 2.81E-05 
203272_s_at TUSC2 tumor suppressor candidate 2 0.60 9.07E-06 
224511_s_at TXNL5 thioredoxin-like 5 /// thioredoxin-like 5 0.48 4.75E-05 
202589_at TYMS 
 
thymidylate synthetase 
 
0.53 3.23E-06 
1554696_s_at 0.43 5.13E-07 
205890_s_at UBD ubiquitin D 0.45 2.78E-05 
223229_at UBE2T ubiquitin-conjugating enzyme E2T (putative) 0.27 1.73E-05 
218190_s_at UCRC ubiquinol-cytochrome c reductase complex (7.2 
kD) 
0.51 7.33E-05 
209103_s_at UFD1L ubiquitin fusion degradation 1-like 0.63 9.69E-05 
225655_at UHRF1 ubiquitin-like, containing PHD and RING finger 
domains, 1 
0.34 2.21E-05 
202330_s_at UNG uracil-DNA glycosylase 0.42 5.19E-05 
1569532_a_at UNQ2541 MSFL2541 0.19 1.97E-07 
202090_s_at UQCR ubiquinol-cytochrome c reductase, 6.4kDa 
subunit 
0.67 7.06E-05 
203797_at VSNL1 visinin-like 1 0.33 2.66E-05 
203721_s_at WDR50 WD repeat domain 50 0.75 8.31E-05 
223868_s_at WWOX WW domain containing oxidoreductase 0.78 8.67E-05 
218349_s_at ZWILCH Zwilch, kinetochore associated, homolog 
(Drosophila) 
0.45 3.28E-05 
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204026_s_at ZWINT ZW10 interactor 0.34 1.30E-05 
229189_s_at  CDNA FLJ90295 fis, clone NT2RP2000240 0.74 4.77E-05 
224752_at  Homo sapiens, Similar to hypothetical protein 
MGC10526, clone IMAGE:4133906, mRNA 
0.69 2.04E-05 
225716_at  Full-length cDNA clone CS0DK008YI09 of 
HeLa cells Cot 25-normalized of Homo sapiens 
(human) 
0.68 4.02E-05 
238056_at  CDNA FLJ13332 fis, clone OVARC1001813 0.63 9.23E-05 
227349_at  CDNA FLJ11381 fis, clone HEMBA1000501 0.55 6.19E-05 
227491_at  CDNA: FLJ22539 fis, clone HRC13227 0.47 1.84E-05 
226006_at   0.46 5.59E-05 
227921_at   0.31 9.53E-06 
1To be included in this table, differential gene expression had to meet a statistical cutoff of P<0.0001. 
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–Cys medium1 
Probe ID Gene Symbol Gene Title Fold Difference 
P 
205434_s_at AAK1 AP2 associated kinase 1 1.95 1.64E-06 
213353_at ABCA5 
ATP-binding cassette, sub-family A 
(ABC1), member 5 
3.33 9.65E-06 
209993_at ABCB1 
ATP-binding cassette, sub-family B 
(MDR/TAP), member 1 
2.34 3.83E-05 
222592_s_at ACSL5 
acyl-CoA synthetase long-chain 
family member 5 
2.21 1.06E-06 
200996_at ACTR3 
ARP3 actin-related protein 3 homolog 
(yeast) 
1.58 1.30E-05 
203935_at ACVR1 activin A receptor, type I 2.24 2.73E-05 
209122_at ADFP adipose differentiation-related protein 2.35 1.53E-06 
202912_at ADM adrenomedullin 1.98 4.02E-06 
210517_s_at 
AKAP12 
A kinase (PRKA) anchor protein 
(gravin) 12 
6.06 1.77E-06 
227529_s_at 
A kinase (PRKA) anchor protein 
(gravin) 12 
6.20 2.72E-05 
227530_at 
A kinase (PRKA) anchor protein 
(gravin) 12 
7.50 2.13E-05 
206561_s_at AKR1B10 
aldo-keto reductase family 1, member 
B10 (aldose reductase) 
1.59 4.20E-05 
1562102_at AKR1C1 
Aldo-keto reductase family 1, 
member C2 (dihydrodiol 
dehydrogenase 2; bile acid binding 
protein; 3-alpha hydroxysteroid 
dehydrogenase, type III) 
3.70 1.18E-05 
217626_at 
AKR1C1 /// 
AKR1C2 
aldo-keto reductase family 1, member 
C1 (dihydrodiol dehydrogenase 1; 20-
alpha (3-alpha)-hydroxysteroid 
dehydrogenase) /// aldo-keto 
reductase family 1, member C2 
(dihydrodiol dehydrogenase 2; bile 
acid binding protein; 3-alpha 
hydroxysteroid dehydrogenase, type 
III) 
5.59 6.83E-05 
1555854_at AKR1C2 
Aldo-keto reductase family 1, 
member C2 (dihydrodiol 
dehydrogenase 2; bile acid binding 
protein; 3-alpha hydroxysteroid 
dehydrogenase, type III) 
6.34 5.41E-05 
201197_at AMD1 adenosylmethionine decarboxylase 1 1.32 9.66E-05 
207992_s_at AMPD3 
adenosine monophosphate deaminase 
(isoform E) 
3.43 1.59E-05 
221522_at ANKRD27 
ankyrin repeat domain 27 (VPS9 
domain) 
1.73 9.36E-05 
205082_s_at AOX1 
 
aldehyde oxidase 1 3.14 2.50E-05 
205083_at aldehyde oxidase 1 3.08 7.64E-06 
39248_at AQP3 aquaporin 3 10.01 4.64E-06 
206784_at AQP8 aquaporin 8 2.10 3.11E-05 
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205239_at AREG 
amphiregulin (schwannoma-derived 
growth factor) 
14.00 6.41E-06 
218098_at 
ARFGEF2 
ADP-ribosylation factor guanine 
nucleotide-exchange factor 2 
(brefeldin A-inhibited) 
1.97 8.84E-05 
222518_at 
ADP-ribosylation factor guanine 
nucleotide-exchange factor 2 
(brefeldin A-inhibited) 
2.09 3.48E-05 
203946_s_at ARG2 arginase, type II 2.25 3.25E-05 
209435_s_at ARHGEF2 
rho/rac guanine nucleotide exchange 
factor (GEF) 2 
5.53 4.38E-05 
201880_at ARIH1 
Ariadne homolog, ubiquitin-
conjugating enzyme E2 binding 
protein, 1 (Drosophila) 
1.56 1.35E-05 
217852_s_at 
ARL10C 
ADP-ribosylation factor-like 10C 1.90 1.67E-05 
222442_s_at ADP-ribosylation factor-like 10C 2.04 9.87E-05 
205020_s_at ARL4 ADP-ribosylation factor-like 4 1.99 3.81E-05 
225283_at ARRDC4 arrestin domain containing 4 3.84 4.86E-05 
233857_s_at ASB2 
ankyrin repeat and SOCS box-
containing 2 
1.83 3.35E-05 
205047_s_at ASNS asparagine synthetase 1.56 4.23E-06 
210896_s_at ASPH aspartate beta-hydroxylase 2.78 2.90E-05 
1554980_a_at 
ATF3 
activating transcription factor 3 4.30 6.17E-05 
202672_s_at activating transcription factor 3 10.28 1.72E-07 
212536_at ATP11B ATPase, Class VI, type 11B 1.44 2.41E-05 
202874_s_at ATP6V1C1 
ATPase, H+ transporting, lysosomal 
42kDa, V1 subunit C, isoform 1 
1.87 8.28E-06 
242230_at ATXN1 ataxin 1 3.88 3.77E-05 
221485_at B4GALT5 
UDP-Gal:betaGlcNAc beta 1,4- 
galactosyltransferase, polypeptide 5 
1.40 2.21E-05 
224957_at BC022357 cDNA sequence BC022357 1.52 6.23E-05 
204032_at BCAR3 
breast cancer anti-estrogen resistance 
3 
2.29 7.63E-05 
203053_at BCAS2 
breast carcinoma amplified sequence 
2 
1.83 5.05E-05 
209311_at BCL2L2 BCL2-like 2 1.77 3.00E-05 
202710_at BET1 BET1 homolog (S. cerevisiae) 1.70 7.69E-06 
208685_x_at BRD2 bromodomain containing 2 1.84 1.69E-05 
214820_at BRWD1 
bromodomain and WD repeat domain 
containing 1 
1.54 4.34E-05 
225976_at BTF3L4 basic transcription factor 3-like 4 1.64 9.21E-05 
225334_at C10orf32 
chromosome 10 open reading frame 
32 
1.88 5.48E-06 
226398_s_at C10orf4 chromosome 10 open reading frame 4 2.41 9.27E-05 
223059_s_at C10orf45 
chromosome 10 open reading frame 
45 
2.20 4.41E-05 
229801_at C10orf47 
chromosome 10 open reading frame 
47 
2.73 7.19E-05 
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221260_s_at C12orf22 
chromosome 12 open reading frame 
22 /// chromosome 12 open reading 
frame 22 
2.75 5.39E-05 
202623_at C14orf11 
chromosome 14 open reading frame 
11 
1.76 3.08E-06 
225679_at C14orf35 
chromosome 14 open reading frame 
35 
1.66 6.76E-05 
224798_s_at C15orf17 
chromosome 15 open reading frame 
17 
2.09 4.06E-05 
204700_x_at C1orf107 
chromosome 1 open reading frame 
107 
1.81 8.31E-05 
1553333_at C1orf161 
chromosome 1 open reading frame 
161 
2.56 2.50E-06 
215767_at C2orf10 chromosome 2 open reading frame 10 1.69 7.90E-06 
221245_s_at C2orf31 
chromosome 2 open reading frame 31 
/// chromosome 2 open reading frame 
31 
1.43 2.62E-05 
220088_at C5R1 
complement component 5 receptor 1 
(C5a ligand) 
9.36 2.03E-06 
226135_at C6orf107 
chromosome 6 open reading frame 
107 
2.46 7.14E-05 
224808_s_at C7orf20 chromosome 7 open reading frame 20 1.60 5.31E-05 
227443_at C9orf150 
chromosome 9 open reading frame 
150 
4.96 5.42E-05 
212765_at CAMSAP1L1 
calmodulin regulated spectrin-
associated protein 1-like 1 
2.46 6.25E-05 
218929_at CARF 
collaborates/cooperates with ARF 
(alternate reading frame) protein 
2.12 8.24E-06 
212971_at CARS cysteinyl-tRNA synthetase 2.69 9.89E-07 
227558_at CBX4 
chromobox homolog 4 (Pc class 
homolog, Drosophila) 
2.49 1.17E-05 
202047_s_at CBX6 chromobox homolog 6 2.21 9.10E-05 
205627_at CDA cytidine deaminase 2.93 7.09E-05 
202284_s_at CDKN1A 
cyclin-dependent kinase inhibitor 1A 
(p21, Cip1) 
3.17 2.62E-05 
236313_at CDKN2B 
cyclin-dependent kinase inhibitor 2B 
(p15, inhibits CDK4) 
2.15 4.41E-06 
203098_at CDYL chromodomain protein, Y-like 2.03 5.46E-05 
203099_s_at CDYL chromodomain protein, Y-like 1.75 8.63E-05 
212501_at CEBPB 
CCAAT/enhancer binding protein 
(C/EBP), beta 
4.60 7.19E-07 
204203_at 
CEBPG 
CCAAT/enhancer binding protein 
(C/EBP), gamma 
2.56 2.40E-05 
225527_at 
CCAAT/enhancer binding protein 
(C/EBP), gamma 
3.31 8.54E-06 
204066_s_at CENTG2 centaurin, gamma 2 2.06 4.03E-05 
206861_s_at CGGBP1 CGG triplet repeat binding protein 1 1.74 6.77E-06 
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205308_at CGI-62 CGI-62 protein 1.82 6.51E-05 
201734_at 
CLCN3 
Chloride channel 3 2.09 3.25E-05 
201735_s_at chloride channel 3 2.04 4.82E-05 
205830_at CLGN calmegin 2.89 1.09E-05 
214683_s_at CLK1 CDC-like kinase 1 2.01 7.92E-05 
203630_s_at COG5 
component of oligomeric golgi 
complex 5 
1.96 3.02E-05 
224828_at 
CPEB4 
cytoplasmic polyadenylation element 
binding protein 4 
2.37 4.02E-05 
224831_at 
cytoplasmic polyadenylation element 
binding protein 4 
2.56 9.57E-05 
223115_at CRSP6 
cofactor required for Sp1 
transcriptional activation, subunit 6, 
77kDa 
1.34 8.44E-05 
206085_s_at 
CTH 
cystathionase (cystathionine gamma-
lyase) 
2.90 2.74E-05 
217127_at 
cystathionase (cystathionine gamma-
lyase) 
2.86 1.11E-05 
202087_s_at CTSL cathepsin L 1.72 9.85E-05 
1557954_at CXorf15 
Chromosome X open reading frame 
15 
1.98 8.81E-05 
201289_at CYR61 cysteine-rich, angiogenic inducer, 61 4.63 7.57E-06 
216060_s_at DAAM1 
dishevelled associated activator of 
morphogenesis 1 
2.16 3.21E-05 
201925_s_at 
DAF 
decay accelerating factor for 
complement (CD55, Cromer blood 
group system) 
4.20 8.05E-07 
201926_s_at 
decay accelerating factor for 
complement (CD55, Cromer blood 
group system) 
3.05 1.54E-05 
224911_s_at DCBLD2 
discoidin, CUB and LCCL domain 
containing 2 
1.96 1.74E-05 
224796_at DDEF1 
development and differentiation 
enhancing factor 1 
1.91 1.24E-05 
202887_s_at DDIT4 DNA-damage-inducible transcript 4 2.01 2.55E-05 
218819_at DDX26 
DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 26 
2.40 7.30E-05 
222543_at DERL1 Der1-like domain family, member 1 1.74 4.13E-06 
223140_s_at DHX36 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 36 
1.81 3.01E-05 
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212854_x_at 
DJ328E19.C1.1 
/// FLJ20719 /// 
LOC200030 /// 
MGC8902 /// 
AE01 /// AG1 
/// LOC440675 
hypothetical protein DJ328E19.C1.1 
/// hypothetical protein FLJ20719 /// 
AG1 protein 
1.94 4.20E-05 
201104_x_at 
hypothetical protein DJ328E19.C1.1 
/// hypothetical protein FLJ20719 /// 
hypothetical protein LOC200030 /// 
hypothetical protein MGC8902 /// 
AE01 mRNA /// AG1 protein /// 
hypothetical LOC440675 
1.96 8.61E-05 
214693_x_at 
hypothetical protein DJ328E19.C1.1 
/// hypothetical protein FLJ20719 /// 
hypothetical protein LOC200030 /// 
hypothetical protein MGC8902 /// 
similar to KIAA1693 protein /// AE01 
mRNA /// AG1 protein /// 
hypothetical LOC440675 
1.97 5.67E-05 
210762_s_at 
DLC1 
deleted in liver cancer 1 2.62 7.42E-06 
224822_at deleted in liver cancer 1 2.64 5.38E-05 
203811_s_at DNAJB4 
DnaJ (Hsp40) homolog, subfamily B, 
member 4 
1.76 2.75E-05 
209015_s_at DNAJB6 
DnaJ (Hsp40) homolog, subfamily B, 
member 6 
1.58 4.74E-05 
202843_at DNAJB9 
DnaJ (Hsp40) homolog, subfamily B, 
member 9 
2.04 9.87E-05 
225174_at DNAJC10 
DnaJ (Hsp40) homolog, subfamily C, 
member 10 
1.60 7.40E-05 
1554966_a_at 
DOC1 
downregulated in ovarian cancer 1 3.67 3.08E-05 
204135_at downregulated in ovarian cancer 1 3.13 7.20E-06 
215626_at DOCK9 Dedicator of cytokinesis 9 1.31 2.95E-07 
208486_at DRD5 dopamine receptor D5 5.03 4.43E-05 
212254_s_at DST dystonin 2.20 4.72E-05 
205761_s_at DUS4L 
dihydrouridine synthase 4-like (S. 
cerevisiae) 
1.57 2.94E-05 
201041_s_at DUSP1 dual specificity phosphatase 1 7.17 2.09E-05 
201536_at DUSP3 
dual specificity phosphatase 3 
(vaccinia virus phosphatase VH1-
related) 
2.55 3.48E-06 
209457_at DUSP5 dual specificity phosphatase 5 2.94 4.19E-06 
238458_at EFHA2 EF-hand domain family, member A2 1.39 5.90E-05 
212830_at EGFL5 EGF-like-domain, multiple 5 2.28 1.77E-05 
225827_at EIF2C2 
eukaryotic translation initiation factor 
2C, 2 
2.30 4.60E-05 
227930_at EIF2C4 
Eukaryotic translation initiation factor 
2C, 4 
1.79 1.26E-05 
235296_at EIF5A2 
eukaryotic translation initiation factor 
5A2 
3.46 9.82E-07 
212420_at ELF1 
E74-like factor 1 (ets domain 
transcription factor) 
1.87 7.13E-05 
222433_at ENAH enabled homolog (Drosophila) 1.81 5.76E-05 
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205767_at EREG epiregulin 6.77 2.51E-05 
206429_at 
F2RL1 
coagulation factor II (thrombin) 
receptor-like 1 
5.20 2.31E-05 
213506_at 
coagulation factor II (thrombin) 
receptor-like 1 
4.51 1.63E-05 
227880_s_at FAM11A 
family with sequence similarity 11, 
member A 
1.49 4.16E-05 
235030_at FAM55C 
family with sequence similarity 55, 
member C 
1.34 4.80E-05 
226541_at FBXO30 F-box protein 30 2.71 7.01E-05 
47773_at FBXO42 F-box protein 42 2.28 9.32E-06 
201919_at FLJ10618 Hypothetical protein FLJ10618 2.65 2.79E-05 
225573_at FLJ12592 putative acyl-CoA dehydrogenase 1.45 6.67E-05 
219397_at FLJ13448 hypothetical protein FLJ13448 1.62 2.36E-05 
1554102_a_at FLJ14624 hypothetical protein FLJ14624 0.74 5.18E-05 
225412_at FLJ14681 Hypothetical protein FLJ14681 1.59 8.40E-06 
230009_at FLJ21103 Hypothetical protein FLJ21103 1.52 5.99E-05 
218867_s_at 
FLJ21415 
hypothetical protein FLJ21415 1.88 1.75E-05 
222767_s_at hypothetical protein FLJ21415 2.21 2.63E-05 
226038_at FLJ23749 hypothetical protein FLJ23749 1.40 9.99E-05 
225848_at FLJ31413 hypothetical protein FLJ31413 2.11 4.96E-05 
225466_at FLJ36874 hypothetical protein FLJ36874 1.57 5.13E-05 
227856_at FLJ39370 hypothetical protein FLJ39370 4.19 4.42E-05 
208614_s_at FLNB 
filamin B, beta (actin binding protein 
278) 
1.76 3.97E-05 
209189_at FOS 
v-fos FBJ murine osteosarcoma viral 
oncogene homolog 
2.25 5.79E-05 
204420_at FOSL1 FOS-like antigen 1 4.89 5.02E-05 
204131_s_at 
FOXO3A 
forkhead box O3A 2.84 2.40E-05 
224889_at forkhead box O3A 2.04 8.04E-05 
223287_s_at 
FOXP1 
forkhead box P1 3.45 4.45E-05 
224837_at forkhead box P1 2.49 6.40E-05 
224838_at forkhead box P1 2.55 8.36E-05 
227475_at FOXQ1 forkhead box Q1 2.88 1.00E-05 
207345_at 
FST 
follistatin 2.16 1.32E-05 
226847_at follistatin 2.51 3.76E-05 
203725_at GADD45A 
growth arrest and DNA-damage-
inducible, alpha 
5.59 9.86E-07 
218871_x_at 
GALNACT-2 
chondroitin sulfate GalNAcT-2 4.51 6.90E-05 
222235_s_at chondroitin sulfate GalNAcT-2 5.77 8.99E-07 
212378_at GART 
phosphoribosylglycinamide 
formyltransferase, 
phosphoribosylglycinamide 
synthetase, 
phosphoribosylaminoimidazole 
synthetase 
1.62 6.34E-05 
202922_at GCLC 
glutamate-cysteine ligase, catalytic 
subunit 
2.57 2.12E-05 
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202923_s_at  
glutamate-cysteine ligase, catalytic 
subunit 
2.47 3.31E-05 
203925_at GCLM 
glutamate-cysteine ligase, modifier 
subunit 
3.25 4.44E-06 
219508_at GCNT3 
glucosaminyl (N-acetyl) transferase 3, 
mucin type 
3.53 1.70E-06 
203986_at GENX-3414 genethonin 1 2.58 7.57E-05 
202722_s_at GFPT1 
glutamine-fructose-6-phosphate 
transaminase 1 
1.97 8.70E-05 
1554510_s_at GHITM 
growth hormone inducible 
transmembrane protein 
1.83 2.22E-05 
203159_at GLS glutaminase 1.53 2.16E-05 
222808_at GLT28D1 
glycosyltransferase 28 domain 
containing 1 
1.82 6.98E-05 
206917_at 
GNA13 
guanine nucleotide binding protein (G 
protein), alpha 13 
4.04 1.95E-05 
224761_at 
guanine nucleotide binding protein (G 
protein), alpha 13 
2.94 2.22E-05 
227539_at 
Guanine nucleotide binding protein 
(G protein), alpha 13 
3.49 4.34E-06 
207812_s_at GORASP2 
golgi reassembly stacking protein 2, 
55kDa 
1.27 1.96E-05 
208813_at GOT1 
glutamic-oxaloacetic transaminase 1, 
soluble (aspartate aminotransferase 1) 
1.83 2.92E-06 
225420_at GPAM 
glycerol-3-phosphate acyltransferase, 
mitochondrial 
1.54 4.40E-05 
222953_at GPR83 G protein-coupled receptor 83 9.89 4.11E-07 
209409_at GRB10 
growth factor receptor-bound protein 
10 
3.07 7.38E-05 
225276_at GSPT1 G1 to S phase transition 1 1.79 1.73E-05 
205930_at GTF2E1 
general transcription factor IIE, 
polypeptide 1, alpha 56kDa 
1.47 6.78E-06 
202453_s_at GTF2H1 
general transcription factor IIH, 
polypeptide 1, 62kDa 
1.99 5.45E-05 
221050_s_at 
GTPBP2 
GTP binding protein 2 7.04 3.67E-05 
223789_s_at GTP binding protein 2 5.85 4.68E-07 
206643_at HAL histidine ammonia-lyase 2.09 1.14E-05 
220491_at HAMP hepcidin antimicrobial peptide 2.29 4.38E-06 
217168_s_at HERPUD1 
homocysteine-inducible, endoplasmic 
reticulum stress-inducible, ubiquitin-
like domain member 1 
2.44 3.80E-05 
215071_s_at HIST1H2AC histone 1, H2ac 5.43 1.27E-06 
218091_at HRB HIV-1 Rev binding protein 1.63 8.80E-05 
203202_at HRB2 HIV-1 rev binding protein 2 1.60 8.27E-05 
218936_s_at HSPC128 HSPC128 protein 2.18 1.15E-05 
202146_at 
IFRD1 
interferon-related developmental 
regulator 1 
5.28 1.46E-05 
202147_s_at 
interferon-related developmental 
regulator 1 
5.45 3.40E-06 
201393_s_at IGF2R insulin-like growth factor 2 receptor 1.92 4.39E-05 
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217489_s_at IL6R interleukin 6 receptor 2.28 5.80E-07 
241808_at IL7 Interleukin 7 2.18 1.51E-05 
202859_x_at IL8 interleukin 8 2.90 7.81E-05 
210587_at INHBE inhibin, beta E 6.76 9.62E-06 
224569_s_at IRF2BP2 
interferon regulatory factor 2 binding 
protein 2 
1.34 4.95E-05 
205032_at ITGA2 
integrin, alpha 2 (CD49B, alpha 2 
subunit of VLA-2 receptor) 
4.68 4.37E-05 
211945_s_at ITGB1 
integrin, beta 1 (fibronectin receptor, 
beta polypeptide, antigen CD29 
includes MDF2, MSK12) 
1.22 4.32E-06 
209098_s_at 
JAG1 
jagged 1 (Alagille syndrome) 5.87 5.20E-05 
209099_x_at jagged 1 (Alagille syndrome) 3.38 4.58E-05 
216268_s_at jagged 1 (Alagille syndrome) 3.72 2.24E-05 
202040_s_at JARID1A 
Jumonji, AT rich interactive domain 
1A (RBBP2-like) 
1.64 2.16E-05 
201464_x_at 
JUN 
v-jun sarcoma virus 17 oncogene 
homolog (avian) 
4.31 1.32E-06 
201466_s_at 
v-jun sarcoma virus 17 oncogene 
homolog (avian) 
4.83 8.13E-06 
212447_at KBTBD2 
kelch repeat and BTB (POZ) domain 
containing 2 
1.56 7.15E-05 
217938_s_at KCMF1 
potassium channel modulatory factor 
1 
1.73 2.56E-05 
201751_at KIAA0063 KIAA0063 gene product 2.20 2.97E-05 
212056_at KIAA0182 KIAA0182 protein 1.79 3.45E-05 
212474_at KIAA0241 KIAA0241 protein 1.61 5.47E-05 
200897_s_at 
KIAA0992 
palladin 4.25 9.51E-05 
200907_s_at palladin 4.68 2.90E-05 
221802_s_at KIAA1598 KIAA1598 1.51 6.32E-05 
203390_s_at KIF3C kinesin family member 3C 2.37 4.05E-06 
224662_at KIF5B kinesin family member 5B 1.71 4.46E-05 
202393_s_at KLF10 Kruppel-like factor 10 3.51 8.68E-06 
208960_s_at 
KLF6 
Kruppel-like factor 6 3.80 6.68E-05 
208961_s_at Kruppel-like factor 6 4.19 2.95E-05 
213233_s_at KLHL9 kelch-like 9 (Drosophila) 1.45 3.27E-05 
213656_s_at KNS2 kinesin 2 60/70kDa 2.44 1.36E-05 
204385_at 
KYNU 
kynureninase (L-kynurenine 
hydrolase) 
3.33 8.88E-07 
210663_s_at 
kynureninase (L-kynurenine 
hydrolase) 
4.06 1.11E-05 
217388_s_at 
kynureninase (L-kynurenine 
hydrolase) 
3.36 2.93E-06 
205569_at LAMP3 
lysosomal-associated membrane 
protein 3 
2.97 6.37E-05 
212137_at LARP1 
La ribonucleoprotein domain family, 
member 1 
1.21 1.30E-05 
226750_at LARP2 
La ribonucleoprotein domain family, 
member 2 
1.77 9.30E-05 
     
  153
     
Table S3 (Continued) 
Probe ID Gene Symbol Gene Title Fold Difference 
P 
208952_s_at LARP5 
La ribonucleoprotein domain family, 
member 5 
1.18 8.53E-05 
236565_s_at LARP6 
La ribonucleoprotein domain family, 
member 6 
3.59 1.85E-05 
223162_s_at LCHN LCHN protein 1.26 8.92E-05 
202068_s_at LDLR 
low density lipoprotein receptor 
(familial hypercholesterolemia) 
1.73 3.85E-05 
1552546_a_at LETM2 
leucine zipper-EF-hand containing 
transmembrane protein 2 
2.50 5.36E-06 
209205_s_at LMO4 LIM domain only 4 3.50 8.66E-06 
203320_at LNK lymphocyte adaptor protein 3.41 3.26E-05 
227586_at LOC124491 LOC124491 1.50 7.12E-05 
235191_at LOC148189 hypothetical protein LOC148189 2.95 8.57E-06 
221501_x_at LOC339047 hypothetical protein LOC339047 2.98 2.22E-05 
237737_at 
LOC375010 /// 
LOC401131 
hypothetical LOC375010 /// 
hypothetical LOC401131 
2.53 2.58E-05 
239751_at LOC392791 hypothetical LOC392791 3.74 8.64E-05 
214035_x_at LOC399491 LOC399491 protein 2.79 6.05E-05 
206741_at LOC51066 fls485 1.63 7.23E-05 
220437_at LOC55908 
hepatocellular carcinoma-associated 
gene TD26 
2.40 4.69E-05 
206584_at LY96 lymphocyte antigen 96 6.22 3.19E-06 
36711_at MAFF 
v-maf musculoaponeurotic 
fibrosarcoma oncogene homolog F 
(avian) 
4.19 1.39E-05 
226084_at MAP1B microtubule-associated protein 1B 3.53 1.45E-05 
208785_s_at 
MAP1LC3B 
microtubule-associated protein 1 light 
chain 3 beta 
3.49 7.03E-06 
208786_s_at 
microtubule-associated protein 1 light 
chain 3 beta 
3.68 3.72E-06 
203353_s_at MBD1 methyl-CpG binding domain protein 1 1.62 4.13E-06 
1554544_a_at 
MBP 
myelin basic protein 2.33 4.74E-05 
210136_at myelin basic protein 2.56 6.83E-05 
200797_s_at MCL1 
myeloid cell leukemia sequence 1 
(BCL2-related) 
3.12 6.09E-07 
212535_at MEF2A 
MADS box transcription enhancer 
factor 2, polypeptide A (myocyte 
enhancer factor 2A) 
1.96 7.25E-05 
225955_at METRNL 
meteorin, glial cell differentiation 
regulator-like 
3.40 9.65E-05 
227395_at MGC10233 Leucine rich repeat containing 35 1.73 1.83E-05 
1560019_at MGC11082 Hypothetical protein MGC11082 2.95 4.91E-06 
224480_s_at MGC11324 
hypothetical protein MGC11324 /// 
hypothetical protein MGC11324 
4.25 9.40E-08 
214696_at MGC14376 hypothetical protein MGC14376 3.54 2.85E-07 
236285_at MGC16635 Hypothetical protein BC009980 11.32 1.34E-06 
1552277_a_at MGC17337 
similar to RIKEN cDNA 5730528L13 
gene 
2.06 3.36E-06 
     
  154
Table S3 (Continued) 
Probe ID Gene Symbol Gene Title Fold Difference 
P 
243999_at MGC19764 hypothetical protein MGC19764 2.10 5.57E-06 
223297_at MGC4268 hypothetical protein MGC4268 1.91 2.77E-05 
55081_at MICAL-L1 MICAL-like 1 2.23 3.00E-05 
227527_at MLL2 
myeloid/lymphoid or mixed-lineage 
leukemia 2 
1.30 8.62E-05 
1557455_s_at 
MOSPD1 
motile sperm domain containing 1 3.93 1.84E-07 
218853_s_at motile sperm domain containing 1 3.80 3.01E-06 
212859_x_at MT1E metallothionein 1E (functional) 1.47 8.87E-05 
212250_at MTDH metadherin 
1.39 8.17E-05 
226275_at 
MXD1 
MAX dimerization protein 1 4.40 3.82E-06 
228846_at MAX dimerization protein 1 4.19 4.81E-07 
204527_at MYO5A 
myosin VA (heavy polypeptide 12, 
myoxin) 
1.49 7.24E-06 
229432_at NAGS N-acetylglutamate synthase 3.42 5.97E-05 
209949_at NCF2 
neutrophil cytosolic factor 2 (65kDa, 
chronic granulomatous disease, 
autosomal 2) 
12.40 5.02E-07 
226490_at NHSL1 NHS-like 1 1.88 9.50E-05 
223439_at NKAP NF-kappaB activating protein 1.53 6.13E-05 
202679_at NPC1 Niemann-Pick disease, type C1 1.51 1.94E-05 
204538_x_at 
NPIP /// 
LOC339047 /// 
LOC440341 
nuclear pore complex interacting 
protein /// hypothetical protein 
LOC339047 /// similar to hypothetical 
protein LOC339047 
2.76 5.28E-05 
214870_x_at 
nuclear pore complex interacting 
protein /// hypothetical protein 
LOC339047 /// similar to hypothetical 
protein LOC339047 
2.86 2.31E-05 
225768_at NR1D2 
nuclear receptor subfamily 1, group 
D, member 2 
1.56 6.87E-05 
201865_x_at 
NR3C1 
nuclear receptor subfamily 3, group 
C, member 1 (glucocorticoid receptor) 
2.62 2.38E-05 
216321_s_at 
nuclear receptor subfamily 3, group 
C, member 1 (glucocorticoid receptor) 
3.04 4.91E-05 
202073_at OPTN optineurin 1.51 4.57E-05 
230830_at OSTbeta organic solute transporter beta 1.45 9.98E-05 
218196_at OSTM1 
osteopetrosis associated 
transmembrane protein 1 
2.02 8.38E-05 
222839_s_at PAPOLG poly(A) polymerase gamma 1.78 2.91E-05 
204004_at 
PAWR 
PRKC, apoptosis, WT1, regulator 2.10 3.39E-05 
204005_s_at PRKC, apoptosis, WT1, regulator 2.12 5.19E-05 
218718_at PDGFC platelet derived growth factor C 1.52 6.51E-05 
205094_at PEX12 peroxisomal biogenesis factor 12 1.94 1.98E-06 
209346_s_at PI4KII phosphatidylinositol 4-kinase type II 1.88 7.38E-05 
215236_s_at PICALM 
phosphatidylinositol binding clathrin 
assembly protein 
1.83 3.55E-05 
214152_at PIGB phosphatidylinositol glycan, class B 2.34 3.54E-05 
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204285_s_at 
PMAIP1 
phorbol-12-myristate-13-acetate-
induced protein 1 
4.41 3.47E-06 
204286_s_at 
phorbol-12-myristate-13-acetate-
induced protein 1 
3.28 4.72E-05 
218224_at PNMA1 paraneoplastic antigen MA1 2.87 2.79E-06 
222572_at PPM2C 
protein phosphatase 2C, magnesium-
dependent, catalytic subunit 
3.30 7.59E-06 
202014_at 
PPP1R15A 
protein phosphatase 1, regulatory 
(inhibitor) subunit 15A 
8.56 2.89E-05 
37028_at 
protein phosphatase 1, regulatory 
(inhibitor) subunit 15A 
6.17 1.79E-05 
201375_s_at PPP2CB 
protein phosphatase 2 (formerly 2A), 
catalytic subunit, beta isoform 
1.65 9.48E-05 
202313_at PPP2R2A 
protein phosphatase 2 (formerly 2A), 
regulatory subunit B (PR 52), alpha 
isoform 
1.49 4.35E-05 
229322_at PPP2R5E 
protein phosphatase 2, regulatory 
subunit B (B56), epsilon isoform 
1.99 4.46E-05 
202429_s_at PPP3CA 
protein phosphatase 3 (formerly 2B), 
catalytic subunit, alpha isoform 
(calcineurin A alpha) 
1.63 2.89E-05 
218329_at PRDM4 PR domain containing 4 1.30 7.91E-05 
215707_s_at PRNP 
prion protein (p27-30) (Creutzfeld-
Jakob disease, Gerstmann-Strausler-
Scheinker syndrome, fatal familial 
insomnia) 
2.10 7.84E-05 
225183_at PRO0149 PRO0149 protein 1.89 2.73E-06 
204447_at ProSAPiP1 ProSAPiP1 protein 3.18 4.76E-05 
203997_at PTPN3 
protein tyrosine phosphatase, non-
receptor type 3 
2.21 7.73E-05 
222980_at 
RAB10 
RAB10, member RAS oncogene 
family 
1.57 2.35E-05 
222981_s_at 
RAB10, member RAS oncogene 
family 
1.79 1.29E-05 
205924_at 
RAB3B 
RAB3B, member RAS oncogene 
family 
2.36 6.54E-05 
239202_at 
RAB3B, member RAS oncogene 
family 
2.50 7.84E-05 
201047_x_at RAB6A 
RAB6A, member RAS oncogene 
family 
1.76 5.21E-05 
212561_at RAB6IP1 RAB6 interacting protein 1 1.86 4.77E-05 
210826_x_at RAD17 RAD17 homolog (S. pombe) 1.63 8.47E-06 
1556128_a_at RASGRF2 
Ras protein-specific guanine 
nucleotide-releasing factor 2 
1.76 4.19E-05 
211950_at RBAF600 retinoblastoma-associated factor 600 2.09 7.21E-05 
211686_s_at RBM13 
RNA binding motif protein 13 /// 
RNA binding motif protein 13 
2.10 3.09E-06 
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235004_at RBM24 RNA binding motif protein 24 3.04 9.33E-07 
201394_s_at RBM5 RNA binding motif protein 5 2.17 9.66E-05 
222666_s_at 
RCL1 
RNA terminal phosphate cyclase-like 
1 
2.82 6.56E-06 
209568_s_at 
ral guanine nucleotide dissociation 
stimulator-like 1 
2.16 9.27E-05 
219610_at RGNEF 
Rho-guanine nucleotide exchange 
factor 
1.53 6.97E-05 
212119_at RHOQ ras homolog gene family, member Q 1.71 8.23E-05 
202130_at RIOK3 
RIO kinase 3 (yeast) /// RIO kinase 3 
(yeast) 
2.77 6.33E-05 
209545_s_at RIPK2 
receptor-interacting serine-threonine 
kinase 2 
2.34 1.62E-06 
209882_at RIT1 Ras-like without CAAX 1 2.53 5.37E-05 
223886_s_at RNF146 ring finger protein 146 2.29 2.27E-05 
214023_x_at RP11-506K6.1 tubulin, beta polypeptide paralog 2.29 5.58E-05 
222514_at RRAGC Ras-related GTP binding C 2.30 9.12E-05 
208456_s_at 
RRAS2 
related RAS viral (r-ras) oncogene 
homolog 2 
2.94 2.04E-05 
212590_at 
related RAS viral (r-ras) oncogene 
homolog 2 
2.52 1.53E-05 
211509_s_at RTN4 reticulon 4 1.14 6.50E-05 
204268_at S100A2 S100 calcium binding protein A2 3.22 8.99E-05 
231894_at SARS Seryl-tRNA synthetase 4.41 1.63E-06 
209486_at SAS10 disrupter of silencing 10 1.50 5.17E-05 
222669_s_at SBDS 
Shwachman-Bodian-Diamond 
syndrome 
1.74 9.48E-05 
212589_at SCP2 Sterol carrier protein 2 2.47 7.91E-05 
202071_at SDC4 syndecan 4 (amphiglycan, ryudocan) 1.79 2.86E-05 
201583_s_at SEC23B Sec23 homolog B (S. cerevisiae) 1.42 5.98E-05 
201916_s_at SEC63 SEC63-like (S. cerevisiae) 1.43 6.52E-05 
202627_s_at 
SERPINE1 
serine (or cysteine) proteinase 
inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1 
2.04 4.35E-06 
202628_s_at 
serine (or cysteine) proteinase 
inhibitor, clade E (nexin, plasminogen 
activator inhibitor type 1), member 1 
2.53 8.62E-06 
224928_at SET7 SET domain-containing protein 7 1.94 4.01E-05 
33323_r_at SFN stratifin 2.11 2.82E-05 
223391_at SGPP1 
sphingosine-1-phosphate phosphatase 
1 
1.80 9.15E-05 
209091_s_at 
SH3GLB1 
SH3-domain GRB2-like endophilin 
B1 
1.82 8.15E-05 
210101_x_at 
SH3-domain GRB2-like endophilin 
B1 
1.87 3.31E-06 
227304_at SHMT1 
Serine hydroxymethyltransferase 1 
(soluble) 
1.74 6.99E-05 
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202777_at SHOC2 
soc-2 suppressor of clear homolog (C. 
elegans) 
1.85 3.05E-05 
212811_x_at SLC1A4 
solute carrier family 1 
(glutamate/neutral amino acid 
transporter), member 4 
2.17 9.78E-05 
225212_at SLC25A25 
solute carrier family 25 
(mitochondrial carrier; phosphate 
carrier), member 25 
1.91 7.96E-05 
203164_at SLC33A1 
solute carrier family 33 (acetyl-CoA 
transporter), member 1 
1.60 7.54E-05 
224579_at SLC38A1 Solute carrier family 38, member 1 2.08 9.28E-06 
224580_at SLC38A1 Solute carrier family 38, member 1 2.01 6.39E-05 
218041_x_at 
SLC38A2 
solute carrier family 38, member 2 1.70 7.26E-05 
220924_s_at solute carrier family 38, member 2 1.68 5.81E-05 
223044_at SLC40A1 
solute carrier family 40 (iron-
regulated transporter), member 1 
3.23 2.22E-05 
212290_at 
SLC7A1 
solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 
1 
3.25 3.38E-05 
212295_s_at 
solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 
1 
3.37 2.09E-06 
207528_s_at 
SLC7A11 
solute carrier family 7, (cationic 
amino acid transporter, y+ system) 
member 11 
5.61 8.12E-05 
209921_at 
solute carrier family 7, (cationic 
amino acid transporter, y+ system) 
member 11 
13.77 2.52E-05 
217678_at 
solute carrier family 7, (cationic 
amino acid transporter, y+ system) 
member 11 
9.88 2.66E-06 
241756_at SMARCA2 
SWI/SNF related, matrix associated, 
actin dependent regulator of 
chromatin, subfamily a, member 2 
1.99 7.15E-05 
210357_s_at SMOX spermine oxidase 3.65 1.73E-05 
212666_at SMURF1 
SMAD specific E3 ubiquitin protein 
ligase 1 
2.05 5.12E-06 
227489_at SMURF2 
SMAD specific E3 ubiquitin protein 
ligase 2 
2.36 4.11E-05 
223027_at SNX9 sorting nexin 9 2.63 3.86E-06 
203373_at SOCS2 suppressor of cytokine signaling 2 3.48 4.78E-05 
212777_at 
SOS1 
son of sevenless homolog 1 
(Drosophila) 
2.03 5.73E-05 
212780_at 
son of sevenless homolog 1 
(Drosophila) 
2.01 4.33E-05 
213668_s_at SOX4 
SRY (sex determining region Y)-box 
4 
4.85 3.66E-05 
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210117_at SPAG1 sperm associated antigen 1 2.38 7.44E-07 
1559517_a_at 
SPIRE1 
spire homolog 1 (Drosophila) 2.96 9.79E-05 
224995_at spire homolog 1 (Drosophila) 4.32 8.08E-05 
225018_at spire homolog 1 (Drosophila) 3.94 6.12E-07 
226342_at SPTBN1 Spectrin, beta, non-erythrocytic 1 3.51 7.74E-05 
217995_at SQRDL sulfide quinone reductase-like (yeast) 2.33 4.92E-05 
205335_s_at SRP19 signal recognition particle 19kDa 1.44 2.95E-05 
225252_at SRXN1 sulfiredoxin 1 homolog (S. cerevisiae) 3.63 1.29E-05 
226075_at SSB1 
SPRY domain-containing SOCS box 
protein SSB-1 
3.71 5.65E-05 
203544_s_at STAM 
signal transducing adaptor molecule 
(SH3 domain and ITAM motif) 1 
2.26 6.97E-06 
203438_at 
STC2 
stanniocalcin 2 5.99 1.78E-06 
203439_s_at stanniocalcin 2 2.78 4.60E-05 
202557_at 
STCH 
stress 70 protein chaperone, 
microsome-associated, 60kDa 
4.19 7.00E-05 
202558_s_at 
stress 70 protein chaperone, 
microsome-associated, 60kDa 
2.21 2.12E-05 
202693_s_at 
STK17A 
serine/threonine kinase 17a 
(apoptosis-inducing) 
3.76 5.65E-06 
202695_s_at 
serine/threonine kinase 17a 
(apoptosis-inducing) 
4.10 2.56E-05 
201061_s_at STOM stomatin 2.46 4.67E-07 
238462_at STS-1 Cbl-interacting protein Sts-1 2.76 2.95E-05 
216985_s_at STX3A syntaxin 3A 2.33 7.92E-06 
202021_x_at 
SUI1 
putative translation initiation factor 2.40 5.33E-05 
212130_x_at putative translation initiation factor 2.30 1.37E-05 
212227_x_at putative translation initiation factor 2.47 2.88E-05 
201837_s_at SUPT7L suppressor of Ty 7 (S. cerevisiae)-like 1.54 3.96E-05 
205691_at SYNGR3 synaptogyrin 3 2.87 5.22E-05 
226835_s_at 
TALDO1 /// 
HSUP1 
transaldolase 1 /// similar to RPE-
spondin 
1.64 1.19E-05 
219682_s_at TBX3 T-box 3 (ulnar mammary syndrome) 1.47 7.53E-05 
216241_s_at TCEA1 
transcription elongation factor A 
(SII), 1 
1.66 2.36E-05 
221471_at TDE1 tumor differentially expressed 1 1.59 3.49E-06 
202720_at TES 
testis derived transcript (3 LIM 
domains) 
3.07 1.06E-05 
219292_at THAP1 
THAP domain containing, apoptosis 
associated protein 1 
1.51 5.78E-05 
212665_at TIPARP 
TCDD-inducible poly(ADP-ribose) 
polymerase 
2.48 2.78E-06 
202011_at TJP1 
tight junction protein 1 (zona 
occludens 1) 
1.65 7.62E-05 
228284_at 
TLE1 /// 
LOC389863 
transducin-like enhancer of split 1 
(E(sp1) homolog, Drosophila) /// 
hypothetical gene supported by 
BC000228; NM_005077 
2.24 5.72E-05 
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209295_at 
TNFRSF10B 
tumor necrosis factor receptor 
superfamily, member 10b 
2.49 3.78E-05 
210405_x_at 
tumor necrosis factor receptor 
superfamily, member 10b 
2.52 5.89E-06 
218368_s_at TNFRSF12A 
tumor necrosis factor receptor 
superfamily, member 12A 
3.79 5.98E-05 
1558305_at TNRC15 Trinucleotide repeat containing 15 1.95 2.37E-05 
214774_x_at 
TNRC9 
trinucleotide repeat containing 9 2.43 9.83E-05 
215108_x_at trinucleotide repeat containing 9 1.98 8.11E-05 
216623_x_at trinucleotide repeat containing 9 2.45 8.34E-05 
200742_s_at 
TPP1 
tripeptidyl peptidase I 2.03 3.01E-05 
214196_s_at tripeptidyl peptidase I 2.07 7.48E-05 
202241_at TRIB1 tribbles homolog 1 (Drosophila) 2.40 2.45E-05 
1555788_a_at 
TRIB3 
tribbles homolog 3 (Drosophila) 5.80 5.50E-05 
218145_at tribbles homolog 3 (Drosophila) 4.03 6.86E-05 
204094_s_at TSC22D2 TSC22 domain family, member 2 1.93 1.88E-05 
201758_at TSG101 tumor susceptibility gene 101 2.11 4.51E-05 
226181_at TUBE1 tubulin, epsilon 1 4.52 4.16E-05 
201008_s_at 
TXNIP 
 
thioredoxin interacting protein 4.21 2.43E-06 
201009_s_at thioredoxin interacting protein 3.53 6.72E-07 
201010_s_at thioredoxin interacting protein 3.16 5.84E-06 
218794_s_at TXNL4B thioredoxin-like 4B 2.24 3.77E-05 
201266_at TXNRD1 thioredoxin reductase 1 3.62 8.74E-07 
217825_s_at UBE2J1 
ubiquitin-conjugating enzyme E2, J1 
(UBC6 homolog, yeast) 
1.30 9.34E-06 
201535_at UBL3 ubiquitin-like 3 2.07 6.06E-05 
222989_s_at 
UBQLN1 
ubiquilin 1 1.81 3.25E-05 
222991_s_at ubiquilin 1 1.77 1.97E-05 
212006_at UBXD2 UBX domain containing 2 1.76 9.34E-05 
204616_at UCHL3 
ubiquitin carboxyl-terminal esterase 
L3 (ubiquitin thiolesterase) 
1.50 5.56E-05 
202893_at UNC13B unc-13 homolog B (C. elegans) 1.46 2.44E-05 
232299_at UNQ830 ASCL830 1.45 8.69E-05 
220419_s_at USP25 ubiquitin specific protease 25 2.04 3.96E-05 
221654_s_at USP3 ubiquitin specific protease 3 1.27 1.53E-05 
223289_s_at USP38 ubiquitin specific protease 38 2.00 6.04E-05 
210513_s_at 
VEGF 
vascular endothelial growth factor 2.18 8.98E-05 
212171_x_at vascular endothelial growth factor 2.52 3.46E-05 
209822_s_at VLDLR very low density lipoprotein receptor 3.52 1.83E-05 
227815_at VPS33A Vacuolar protein sorting 33A (yeast) 1.47 5.21E-05 
200629_at WARS tryptophanyl-tRNA synthetase 2.60 4.33E-05 
210561_s_at WSB1 
WD repeat and SOCS box-containing 
1 
1.37 2.68E-06 
212342_at YIPF6 Yip1 domain family, member 6 1.31 5.43E-05 
217783_s_at 
YPEL5 
yippee-like 5 (Drosophila) 3.02 2.36E-05 
222408_s_at yippee-like 5 (Drosophila) 2.85 3.93E-06 
227436_at ZA20D1 Zinc finger, A20 domain containing 1 1.82 4.87E-07 
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213376_at ZBTB1 
zinc finger and BTB domain 
containing 1 
1.39 7.48E-05 
226962_at ZBTB41 
zinc finger and BTB domain 
containing 41 
1.89 2.86E-07 
223506_at ZC3H8 zinc finger CCCH-type containing 8 2.21 4.74E-05 
218478_s_at ZCCHC8 
zinc finger, CCHC domain containing 
8 
2.58 3.25E-05 
218919_at ZFAND1 zinc finger, AN1-type domain 1 2.42 9.50E-05 
37254_at ZNF133 
zinc finger protein 133 (clone pHZ-
13) 
1.37 3.81E-05 
206182_at ZNF134 
zinc finger protein 134 (clone pHZ-
15) 
2.78 4.74E-05 
1554433_a_at ZNF146 zinc finger protein 146 2.22 4.48E-05 
206683_at ZNF165 zinc finger protein 165 2.79 6.09E-05 
219376_at ZNF322B zinc finger protein 322B 1.76 1.64E-06 
225945_at ZNF655 zinc finger protein 655 1.84 7.81E-05 
227080_at ZNF697 zinc finger protein 697 2.57 8.93E-05 
226208_at ZSWIM6 zinc finger, SWIM-type containing 6 2.28 3.17E-05 
213567_at  Clone 23728 mRNA sequence 2.66 5.57E-05 
213685_at  
Gene from PAC 886K2, chromosome 
1 
1.79 3.03E-07 
213750_at  Full length insert cDNA YH77E09 1.90 9.50E-05 
224606_at  
Homo sapiens, clone 
IMAGE:4096273, mRNA 
3.92 9.07E-08 
224621_at  LOC440806 1.33 2.10E-05 
225522_at  Similar to BMP2 inducible kinase 2.58 1.85E-05 
225811_at  
Transcribed locus, weakly similar to 
XP_375099.1 PREDICTED: similar 
to hypothetical protein FLJ25224 
[Homo sapiens] 
1.43 7.40E-06 
226223_at  
CDNA FLJ14942 fis, A-
PLACE1011185 
2.02 8.23E-05 
226520_at  
Transcribed locus, weakly similar to 
XP_543946.1 PREDICTED: similar 
to chromosome 10 open reading 
frame 12 [Canis familiaris] 
2.26 2.43E-05 
226779_at  
CDNA FLJ37302 fis, clone 
BRAMY2016009 
1.57 3.87E-05 
227278_at  
Transcribed locus, moderately similar 
to XP_512541.1 PREDICTED: 
similar to hypothetical protein [Pan 
troglodytes] 
2.02 2.16E-05 
227452_at  
Hypothetical gene supported by 
AK000477 
2.63 8.62E-05 
227492_at  
Transcribed locus, weakly similar to 
XP_521389.1 PREDICTED: similar 
to UTY [Pan troglodytes] 
2.86 2.32E-05 
227747_at   2.81 6.15E-05 
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Probe ID Gene Symbol Gene Title Fold Difference 
P 
227755_at  
CDNA clone IMAGE:4077090, 
partial cds 
5.86 1.98E-06 
232297_at   1.62 5.41E-06 
241418_at  Hypothetical LOC344887 5.44 2.45E-06 
242005_at   4.38 5.69E-06 
243179_at  
CDNA FLJ33993 fis, clone 
DFNES2007757 
3.49 1.12E-05 
64488_at  
CDNA FLJ38849 fis, clone 
MESAN2008936 
1.43 6.20E-05 
1To be included in this table, differential gene expression had to meet a statistical cutoff of P<0.0001 
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Probe ID Gene Symbol Gene Title 
Fold 
Difference 
P 
202888_s_at ANPEP alanyl (membrane) aminopeptidase 
(aminopeptidase N, aminopeptidase M, 
microsomal aminopeptidase, CD13, p150) 
0.44 4.99E-05 
201301_s_at ANXA4 
 
annexin A4 0.58 3.40E-05 
201302_at annexin A4 0.55 3.32E-05 
218115_at ASF1B ASF1 anti-silencing function 1 homolog B 
(S. cerevisiae) 
0.29 9.32E-05 
218857_s_at ASRGL1 asparaginase like 1 0.34 7.21E-05 
244519_at ASXL1 additional sex combs like 1 (Drosophila) 0.70 7.23E-05 
218782_s_at ATAD2 ATPase family, AAA domain containing 2 0.42 7.61E-05 
222740_at ATPase family, AAA domain containing 2 0.46 7.12E-05 
203188_at B3GNT6 UDP-GlcNAc:betaGal beta-1,3-N-
acetylglucosaminyltransferase 6 
0.20 1.29E-05 
211715_s_at BDH 3-hydroxybutyrate dehydrogenase (heart, 
mitochondrial) /// 3-hydroxybutyrate 
dehydrogenase (heart, mitochondrial) 
0.51 7.56E-05 
202095_s_at BIRC5 baculoviral IAP repeat-containing 5 
(survivin) 
0.32 3.88E-05 
219555_s_at BM039 uncharacterized bone marrow protein 
BM039 
0.38 7.44E-06 
222118_at uncharacterized bone marrow protein 
BM039 
0.41 4.78E-05 
209642_at BUB1 BUB1 budding uninhibited by 
benzimidazoles 1 homolog (yeast) 
0.36 1.56E-05 
212121_at C10orf61 chromosome 10 open reading frame 61 0.52 7.55E-05 
212123_at chromosome 10 open reading frame 61 0.61 6.79E-05 
219067_s_at C10orf86 chromosome 10 open reading frame 86 0.50 2.23E-05 
202562_s_at C14orf1 chromosome 14 open reading frame 1 0.53 5.53E-05 
226597_at C19orf32 chromosome 19 open reading frame 32 0.31 5.40E-05 
218546_at C1orf115 chromosome 1 open reading frame 115 0.57 3.45E-05 
229381_at C1orf64 chromosome 1 open reading frame 64 0.45 5.16E-05 
225687_at C20orf129 chromosome 20 open reading frame 129 0.33 1.62E-05 
218709_s_at C20orf9 chromosome 20 open reading frame 9 0.77 2.89E-05 
218741_at C22orf18 chromosome 22 open reading frame 18 0.27 9.10E-05 
205654_at C4BPA complement component 4 binding protein, 
alpha 
0.41 2.86E-05 
201309_x_at C5orf13 chromosome 5 open reading frame 13 0.35 4.59E-06 
218233_s_at C6orf49 chromosome 6 open reading frame 49 0.48 9.84E-05 
223516_s_at chromosome 6 open reading frame 49 0.42 7.49E-05 
225777_at C9orf140 chromosome 9 open reading frame 140 0.43 1.21E-05 
200653_s_at CALM1 calmodulin 1 (phosphorylase kinase, delta) 0.54 2.36E-05 
64408_s_at CALML4 calmodulin-like 4 0.41 4.50E-05 
212669_at CAMK2G calcium/calmodulin-dependent protein 
kinase (CaM kinase) II gamma 
0.69 3.21E-05 
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203418_at CCNA2 cyclin A2 
 
0.27 1.28E-06 
213226_at 0.31 8.69E-06 
214710_s_at CCNB1 cyclin B1 
 
0.35 2.00E-05 
228729_at 0.33 1.21E-05 
208650_s_at CD24 CD24 antigen (small cell lung carcinoma 
cluster 4 antigen) 
0.50 9.75E-05 
216379_x_at CD24 antigen (small cell lung carcinoma 
cluster 4 antigen) 
0.52 8.20E-05 
203214_x_at CDC2 cell division cycle 2, G1 to S and G2 to M 0.32 2.34E-06 
210559_s_at cell division cycle 2, G1 to S and G2 to M 0.27 6.80E-06 
202870_s_at CDC20 CDC20 cell division cycle 20 homolog (S. 
cerevisiae) 
0.39 8.73E-05 
205167_s_at CDC25C cell division cycle 25C 0.27 2.26E-05 
204126_s_at CDC45L CDC45 cell division cycle 45-like (S. 
cerevisiae) 
0.33 3.74E-05 
203967_at CDC6 CDC6 cell division cycle 6 homolog (S. 
cerevisiae) 
0.19 6.98E-08 
203968_s_at CDC6 cell division cycle 6 homolog (S. 
cerevisiae) 
0.27 9.01E-06 
204510_at CDC7 CDC7 cell division cycle 7 (S. cerevisiae) 0.39 2.41E-06 
224753_at CDCA5 cell division cycle associated 5 0.28 8.44E-06 
224428_s_at CDCA7 cell division cycle associated 7 /// cell 
division cycle associated 7 
0.19 1.89E-06 
204159_at CDKN2C cyclin-dependent kinase inhibitor 2C (p18, 
inhibits CDK4) 
0.20 7.06E-05 
1555758_a_at CDKN3 cyclin-dependent kinase inhibitor 3 
(CDK2-associated dual specificity 
phosphatase) 
0.25 1.77E-05 
209714_s_at cyclin-dependent kinase inhibitor 3 
(CDK2-associated dual specificity 
phosphatase) 
0.28 1.66E-05 
204962_s_at CENPA centromere protein A, 17kDa 0.36 1.71E-05 
207828_s_at CENPF centromere protein F, 350/400ka (mitosin) 0.36 1.34E-05 
209194_at CETN2 centrin, EF-hand protein, 2 0.41 2.16E-05 
205394_at CHEK1 CHK1 checkpoint homolog (S. pombe) 0.23 5.02E-06 
210416_s_at CHEK2 CHK2 checkpoint homolog (S. pombe) 0.45 8.34E-05 
221675_s_at CHPT1 choline phosphotransferase 1 0.60 5.67E-05 
64900_at CHST5 /// 
MGC15429 
carbohydrate (N-acetylglucosamine 6-O) 
sulfotransferase 5 /// hypothetical protein 
MGC15429 
0.47 3.21E-05 
218267_at CINP cyclin-dependent kinase 2-interacting 
protein 
0.72 7.30E-05 
209357_at CITED2 Cbp/p300-interacting transactivator, with 
Glu/Asp-rich carboxy-terminal domain, 2 
0.59 6.42E-05 
228335_at CLDN11 claudin 11 (oligodendrocyte 
transmembrane protein) 
0.30 9.81E-06 
1554804_a_at CLDN19 claudin 19 0.29 1.44E-06 
201774_s_at CNAP1 chromosome condensation-related SMC-
associated protein 1 
0.31 1.84E-06 
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Probe ID Gene Symbol Gene Title 
Fold 
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211727_s_at COX11 COX11 homolog, cytochrome c oxidase 
assembly protein (yeast) /// COX11 
homolog, cytochrome c oxidase assembly 
protein (yeast) 
0.63 2.59E-05 
206651_s_at CPB2 carboxypeptidase B2 (plasma, 
carboxypeptidase U) 
0.07 2.50E-07 
204172_at CPOX coproporphyrinogen oxidase 0.39 3.85E-05 
1555889_a_at CRTAP cartilage associated protein 0.47 5.09E-05 
201111_at CSE1L CSE1 chromosome segregation 1-like 
(yeast) 
0.45 6.67E-05 
201112_s_at CSE1 chromosome segregation 1-like 
(yeast) 
0.55 7.44E-06 
201487_at CTSC cathepsin C 0.39 5.09E-05 
224516_s_at CXXC5 CXXC finger 5 /// CXXC finger 5 0.83 7.43E-05 
228906_at CXXC6 CXXC finger 6 0.35 5.53E-05 
209389_x_at DBI diazepam binding inhibitor (GABA 
receptor modulator, acyl-Coenzyme A 
binding protein) 
0.21 1.43E-05 
211070_x_at diazepam binding inhibitor (GABA 
receptor modulator, acyl-Coenzyme A 
binding protein) /// diazepam binding 
inhibitor (GABA receptor modulator, acyl-
Coenzyme A binding protein) 
0.23 8.75E-05 
222925_at DCDC2 doublecortin domain containing 2 0.87 3.54E-05 
203409_at DDB2 /// 
LHX3 
damage-specific DNA binding protein 2, 
48kDa /// LIM homeobox 3 
0.53 2.19E-05 
232278_s_at DEPDC1 DEP domain containing 1 0.38 1.06E-05 
235545_at DEP domain containing 1 0.59 2.82E-05 
226980_at DEPDC1B DEP domain containing 1B 0.28 3.18E-05 
201791_s_at DHCR7 7-dehydrocholesterol reductase 0.28 6.61E-05 
202533_s_at DHFR dihydrofolate reductase 0.34 2.89E-05 
202534_x_at dihydrofolate reductase 0.30 2.18E-05 
48808_at dihydrofolate reductase 0.29 2.31E-05 
204602_at DKK1 dickkopf homolog 1 (Xenopus laevis) 0.39 5.69E-05 
203764_at DLG7 discs, large homolog 7 (Drosophila) 0.31 6.39E-05 
209560_s_at DLK1 delta-like 1 homolog (Drosophila) 0.60 9.55E-05 
242138_at DLX1 distal-less homeo box 1 0.34 2.85E-05 
213647_at DNA2L DNA2 DNA replication helicase 2-like 
(yeast) 
0.31 5.42E-05 
201697_s_at DNMT1 DNA (cytosine-5-)-methyltransferase 1 0.54 2.34E-06 
221677_s_at DONSON downstream neighbor of SON 0.52 4.33E-05 
236055_at DQX1 DEAQ box polypeptide 1 (RNA-
dependent ATPase) 
0.50 1.11E-05 
218585_s_at DTL denticleless homolog (Drosophila) 0.17 1.17E-05 
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1553984_s_at DTYMK deoxythymidylate kinase (thymidylate 
kinase) 
0.24 9.57E-05 
203270_at deoxythymidylate kinase (thymidylate 
kinase) 
0.30 6.88E-06 
208956_x_at DUT dUTP pyrophosphatase 0.39 2.15E-07 
209932_s_at dUTP pyrophosphatase 0.35 4.92E-05 
228033_at E2F7 E2F transcription factor 7 0.41 8.56E-05 
219990_at E2F8 E2F transcription factor 8 0.26 1.73E-05 
202735_at EBP emopamil binding protein (sterol 
isomerase) 
0.38 2.50E-05 
213787_s_at emopamil binding protein (sterol 
isomerase) 
0.31 5.66E-06 
201984_s_at EGFR epidermal growth factor receptor 
(erythroblastic leukemia viral (v-erb-b) 
oncogene homolog, avian) 
0.44 9.83E-05 
208290_s_at EIF5 eukaryotic translation initiation factor 5 0.67 1.51E-05 
208708_x_at eukaryotic translation initiation factor 5 0.61 1.49E-06 
204256_at ELOVL6 ELOVL family member 6, elongation of 
long chain fatty acids (FEN1/Elo2, 
SUR4/Elo3-like, yeast) 
0.51 1.93E-05 
201341_at ENC1 ectodermal-neural cortex (with BTB-like 
domain) 
0.41 2.11E-05 
201719_s_at EPB41L2 erythrocyte membrane protein band 4.1-
like 2 
0.27 5.96E-05 
209368_at EPHX2 epoxide hydrolase 2, cytoplasmic 0.31 1.57E-06 
200043_at ERH enhancer of rudimentary homolog 
(Drosophila) /// enhancer of rudimentary 
homolog (Drosophila) 
0.72 3.04E-05 
203358_s_at EZH2 enhancer of zeste homolog 2 (Drosophila) 0.47 1.45E-05 
208962_s_at FADS1 fatty acid desaturase 1 0.39 5.15E-06 
208964_s_at fatty acid desaturase 1 0.42 3.46E-05 
222056_s_at FAHD2A fumarylacetoacetate hydrolase domain 
containing 2A 
0.61 2.45E-05 
225834_at FAM72A family with sequence similarity 72, 
member A 
0.49 8.83E-05 
203564_at FANCG Fanconi anemia, complementation group 
G 
0.35 3.02E-05 
211623_s_at FBL fibrillarin /// fibrillarin 0.60 4.08E-05 
234863_x_at FBXO5 F-box protein 5 0.49 8.99E-05 
210638_s_at FBXO9 F-box protein 9 0.60 7.98E-05 
210950_s_at FDFT1 farnesyl-diphosphate farnesyltransferase 1 0.24 1.18E-05 
205650_s_at FGA fibrinogen alpha chain 0.38 7.65E-05 
1552921_a_at FIGNL1 fidgetin-like 1 0.50 5.92E-06 
1562110_at FLJ10006 Hypothetical protein FLJ10006 0.81 3.34E-05 
213007_at FLJ10719 hypothetical protein FLJ10719 0.34 7.44E-06 
228273_at FLJ11029 Hypothetical protein FLJ11029 0.41 2.41E-05 
45633_at FLJ13912 hypothetical protein FLJ13912 0.50 3.05E-06 
1554102_a_at FLJ14624 hypothetical protein FLJ14624 0.74 5.18E-05 
215947_s_at FLJ14668 hypothetical protein FLJ14668 0.57 3.15E-05 
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14033_at ABCC6 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 6 
0.42 2.89E-06 
214274_s_at ACAA1 acetyl-Coenzyme A acyltransferase 1 
(peroxisomal 3-oxoacyl-Coenzyme A 
thiolase) 
0.38 3.77E-06 
209608_s_at ACAT2 acetyl-Coenzyme A acetyltransferase 2 
(acetoacetyl Coenzyme A thiolase) 
0.23 2.03E-05 
201128_s_at ACLY ATP citrate lyase 0.63 3.34E-06 
205364_at ACOX2 acyl-Coenzyme A oxidase 2, branched 
chain 
0.41 1.78E-05 
220675_s_at ADPN adiponutrin 0.33 3.66E-05 
211986_at AHNAK AHNAK nucleoprotein (desmoyokin) 0.71 4.56E-05 
201675_at AKAP1 A kinase (PRKA) anchor protein 1 0.68 9.04E-05 
201900_s_at AKR1A1 aldo-keto reductase family 1, member A1 
(aldehyde reductase) 
0.69 8.31E-05 
214259_s_at AKR7A2 aldo-keto reductase family 7, member A2 
(aflatoxin aldehyde reductase) 
0.57 8.21E-06 
217791_s_at ALDH18A1 
 
aldehyde dehydrogenase 18 family, 
member A1 
0.50 7.82E-06 
222416_at aldehyde dehydrogenase 18 family, 
member A1 
0.43 2.88E-06 
203608_at ALDH5A1 aldehyde dehydrogenase 5 family, member 
A1 (succinate-semialdehyde 
dehydrogenase) 
0.46 8.18E-05 
221589_s_at ALDH6A1 Aldehyde dehydrogenase 6 family, 
member A1 
0.43 2.74E-05 
208950_s_at ALDH7A1 aldehyde dehydrogenase 7 family, member 
A1 
0.22 2.48E-06 
208951_at aldehyde dehydrogenase 7 family, member 
A1 
0.18 6.95E-05 
201612_at ALDH9A1 aldehyde dehydrogenase 9 family, member 
A1 
0.47 6.77E-05 
219649_at ALG6 asparagine-linked glycosylation 6 
homolog (yeast, alpha-1,3-
glucosyltransferase) 
0.50 3.07E-05 
204294_at AMT aminomethyltransferase (glycine cleavage 
system protein T) 
0.48 2.31E-06 
208721_s_at ANAPC5 anaphase promoting complex subunit 5 0.46 7.59E-05 
208722_s_at anaphase promoting complex subunit 5 0.44 2.74E-05 
1552619_a_at ANLN anillin, actin binding protein (scraps 
homolog, Drosophila) 
0.40 1.72E-05 
222608_s_at anillin, actin binding protein (scraps 
homolog, Drosophila) 
0.33 7.04E-05 
201051_at ANP32A Acidic (leucine-rich) nuclear 
phosphoprotein 32 family, member A 
0.74 7.09E-05 
221505_at ANP32E acidic (leucine-rich) nuclear 
phosphoprotein 32 family, member E 
0.56 9.32E-05 
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219650_at FLJ20105 FLJ20105 protein 0.48 5.26E-05 
221685_s_at FLJ20364 hypothetical protein FLJ20364 0.35 6.93E-05 
220060_s_at FLJ20641 hypothetical protein FLJ20641 0.46 3.54E-05 
217872_at FLJ20643 hypothetical protein FLJ20643 0.82 2.03E-05 
234008_s_at FLJ21736 esterase 31 0.53 2.18E-05 
53071_s_at FLJ22222 hypothetical protein FLJ22222 0.45 4.79E-05 
213294_at FLJ38348 Hypothetical protein FLJ38348 0.70 3.81E-05 
218210_at FN3KRP fructosamine-3-kinase-related protein 0.52 8.55E-05 
1773_at FNTB farnesyltransferase, CAAX box, beta 0.50 6.83E-05 
225851_at farnesyltransferase, CAAX box, beta 0.39 4.34E-05 
202580_x_at FOXM1 forkhead box M1 0.45 9.49E-05 
223700_at GAJ GAJ protein 0.33 2.07E-05 
213133_s_at GCSH glycine cleavage system protein H 
(aminomethyl carrier) 
0.65 3.71E-05 
203560_at GGH gamma-glutamyl hydrolase (conjugase, 
folylpolygammaglutamyl hydrolase) 
0.34 1.40E-05 
218350_s_at GMNN geminin, DNA replication inhibitor 0.24 3.02E-06 
215690_x_at GPAA1 GPAA1P anchor attachment protein 1 
homolog (yeast) 
0.54 4.00E-05 
243193_at GPC3 Glypican 3 0.27 7.94E-05 
211829_s_at GPR30 G protein-coupled receptor 30 0.59 5.94E-06 
201348_at GPX3 glutathione peroxidase 3 (plasma) 0.48 7.07E-05 
214091_s_at glutathione peroxidase 3 (plasma) 0.51 9.15E-05 
201106_at GPX4 glutathione peroxidase 4 (phospholipid 
hydroperoxidase) 
0.62 8.94E-05 
203815_at GSTT1 glutathione S-transferase theta 1 0.52 3.89E-06 
202605_at GUSB glucuronidase, beta 0.57 5.20E-05 
200853_at H2AFZ H2A histone family, member Z 0.48 5.11E-05 
213911_s_at H2A histone family, member Z 0.55 6.31E-05 
201035_s_at HADHSC L-3-hydroxyacyl-Coenzyme A 
dehydrogenase, short chain 
0.35 9.73E-05 
201036_s_at L-3-hydroxyacyl-Coenzyme A 
dehydrogenase, short chain 
0.22 2.56E-05 
211569_s_at L-3-hydroxyacyl-Coenzyme A 
dehydrogenase, short chain 
0.29 8.96E-05 
212789_at hCAP-D3 KIAA0056 protein 0.44 4.27E-06 
218663_at HCAP-G chromosome condensation protein G 0.26 9.50E-05 
201209_at HDAC1 histone deacetylase 1 0.68 4.13E-05 
223556_at HELLS helicase, lymphoid-specific 0.29 3.69E-05 
204689_at HHEX hematopoietically expressed homeobox 0.53 8.51E-05 
213374_x_at HIBCH 3-hydroxyisobutyryl-Coenzyme A 
hydrolase 
0.61 6.65E-05 
204754_at HLF Hepatic leukemia factor 0.55 3.08E-05 
204755_x_at hepatic leukemia factor 0.59 1.21E-05 
208025_s_at HMGA2 high mobility group AT-hook 2 /// high 
mobility group AT-hook 2 
0.41 3.82E-06 
200680_x_at HMGB1 high-mobility group box 1 0.66 3.71E-05 
208808_s_at HMGB2 high-mobility group box 2 0.39 3.64E-05 
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208668_x_at HMGN2 high-mobility group nucleosomal binding 
domain 2 
0.48 2.79E-05 
209377_s_at HMGN3 high mobility group nucleosomal binding 
domain 3 
0.24 4.03E-06 
200014_s_at HNRPC heterogeneous nuclear ribonucleoprotein C 
(C1/C2) /// heterogeneous nuclear 
ribonucleoprotein C (C1/C2) 
0.75 9.85E-05 
200942_s_at HSBP1 heat shock factor binding protein 1 0.57 4.49E-05 
214434_at HSPA12A heat shock 70kDa protein 12A 0.48 4.79E-05 
200799_at HSPA1A heat shock 70kDa protein 1A 0.53 1.90E-05 
218026_at HSPC009 HSPC009 protein 0.41 1.04E-05 
210211_s_at HSPCA heat shock 90kDa protein 1, alpha 0.83 2.29E-05 
210619_s_at HYAL1 hyaluronoglucosaminidase 1 0.47 1.02E-05 
1555037_a_at IDH1 isocitrate dehydrogenase 1 (NADP+), 
soluble 
0.62 5.25E-05 
201193_at isocitrate dehydrogenase 1 (NADP+), 
soluble 
0.61 2.15E-06 
204615_x_at IDI1 isopentenyl-diphosphate delta isomerase 1 0.32 1.36E-05 
1555564_a_at IF I factor (complement) 0.39 2.88E-05 
203854_at I factor (complement) 0.36 6.22E-05 
214022_s_at IFITM1 interferon induced transmembrane protein 
1 (9-27) 
0.45 6.69E-05 
223807_at IGSF1 immunoglobulin superfamily, member 1 0.27 8.12E-05 
219255_x_at IL17RB interleukin 17 receptor B 0.42 9.02E-06 
224156_x_at interleukin 17 receptor B 0.42 2.24E-05 
203126_at IMPA2 inositol(myo)-1(or 4)-monophosphatase 2 0.50 4.70E-05 
204017_at KDELR3 KDEL (Lys-Asp-Glu-Leu) endoplasmic 
reticulum protein retention receptor 3 
0.47 5.21E-05 
202503_s_at KIAA0101 KIAA0101 0.14 2.33E-05 
211713_x_at KIAA0101 /// KIAA0101 0.25 9.42E-05 
224870_at KIAA0114 KIAA0114 gene product 0.61 9.17E-05 
213478_at KIAA1026 kazrin 0.62 6.09E-05 
221952_x_at KIAA1393 KIAA1393 0.38 7.35E-06 
218342_s_at KIAA1815 KIAA1815 0.46 9.52E-06 
218755_at KIF20A kinesin family member 20A 0.35 6.95E-06 
211519_s_at KIF2C kinesin family member 2C 0.38 2.11E-05 
228377_at KLHL14 kelch-like 14 (Drosophila) 0.38 8.42E-05 
201088_at KPNA2 karyopherin alpha 2 (RAG cohort 1, 
importin alpha 1) 
0.56 4.57E-05 
214039_s_at LAPTM4B lysosomal associated protein 
transmembrane 4 beta 
0.72 1.33E-05 
1552362_a_at LEAP-2 liver-expressed antimicrobial peptide 2 0.36 2.38E-05 
225614_at LOC113174 hypothetical protein BC012010 0.54 4.40E-05 
238554_at LOC283852 hypothetical protein LOC283852 0.41 5.04E-05 
231982_at LOC284422 similar to HSPC323 0.26 1.98E-05 
224637_at LOC400948 similar to RIKEN cDNA 2310016E02 0.39 9.17E-06 
224602_at LOC401152 HCV F-transactivated protein 1 0.39 5.77E-05 
226165_at LOC401466 hypothetical gene supported by BC055092 0.61 4.72E-05 
235898_at LOC440858 LOC440858 0.52 1.85E-06 
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209679_s_at LOC57228 hypothetical protein from clone 643 0.55 4.60E-05 
215215_s_at LOC81691 exonuclease NEF-sp 0.50 4.64E-05 
211596_s_at LRIG1 leucine-rich repeats and immunoglobulin-
like domains 1 /// leucine-rich repeats and 
immunoglobulin-like domains 1 
0.89 5.29E-09 
202904_s_at LSM5 LSM5 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 
0.61 9.56E-07 
211747_s_at LSM5 homolog, U6 small nuclear RNA 
associated (S. cerevisiae) /// LSM5 
homolog, U6 small nuclear RNA 
associated (S. cerevisiae) 
0.50 2.20E-05 
202245_at LSS lanosterol synthase (2,3-oxidosqualene-
lanosterol cyclase) 
0.36 7.97E-05 
219588_s_at LUZP5 leucine zipper protein 5 0.33 1.55E-05 
203007_x_at LYPLA1 lysophospholipase I 0.80 4.97E-05 
212279_at MAC30 hypothetical protein MAC30 0.17 2.25E-06 
212281_s_at hypothetical protein MAC30 0.16 2.31E-07 
212282_at hypothetical protein MAC30 0.13 4.88E-06 
1554768_a_at MAD2L1 MAD2 mitotic arrest deficient-like 1 
(yeast) 
0.22 1.45E-05 
203362_s_at MAD2 mitotic arrest deficient-like 1 
(yeast) 
0.23 6.42E-05 
209014_at MAGED1 melanoma antigen family D, 1 0.35 4.66E-05 
210018_x_at MALT1 mucosa associated lymphoid tissue 
lymphoma translocation gene 1 
0.66 8.66E-05 
228468_at MASTL microtubule associated serine/threonine 
kinase-like 
0.40 5.16E-06 
207256_at MBL2 mannose-binding lectin (protein C) 2, 
soluble (opsonic defect) 
0.43 4.47E-05 
209624_s_at MCCC2 methylcrotonoyl-Coenzyme A carboxylase 
2 (beta) 
0.52 9.41E-05 
220651_s_at MCM10 MCM10 minichromosome maintenance 
deficient 10 (S. cerevisiae) 
0.15 1.98E-05 
202107_s_at MCM2 MCM2 minichromosome maintenance 
deficient 2, mitotin (S. cerevisiae) 
0.21 3.73E-05 
201555_at MCM3 MCM3 minichromosome maintenance 
deficient 3 (S. cerevisiae) 
0.19 1.70E-06 
212141_at MCM4 MCM4 minichromosome maintenance 
deficient 4 (S. cerevisiae) 
0.29 9.85E-05 
216237_s_at MCM5 MCM5 minichromosome maintenance 
deficient 5, cell division cycle 46 (S. 
cerevisiae) 
0.16 2.75E-06 
201930_at MCM6 MCM6 minichromosome maintenance 
deficient 6 (MIS5 homolog, S. pombe) (S. 
cerevisiae) 
0.31 4.44E-06 
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208795_s_at MCM7 MCM7 minichromosome maintenance 
deficient 7 (S. cerevisiae) 
0.42 2.59E-05 
210983_s_at  MCM7 minichromosome maintenance 
deficient 7 (S. cerevisiae) 
0.30 7.70E-05 
202645_s_at MEN1 multiple endocrine neoplasia I 0.75 6.49E-05 
226118_at MGC11266 hypothetical protein MGC11266 0.52 4.43E-05 
227055_at MGC17301 hypothetical protein MGC17301 0.53 9.63E-05 
226456_at MGC24665 hypothetical protein MGC24665 0.21 2.60E-07 
238465_at MGC33648 hypothetical protein MGC33648 0.85 1.04E-05 
226499_at MGC61598 Similar to ankyrin-repeat protein Nrarp 0.51 2.88E-05 
205904_at MICA MHC class I polypeptide-related sequence 
A 
0.73 5.30E-05 
206247_at MICB MHC class I polypeptide-related sequence 
B 
0.31 1.59E-05 
209585_s_at MINPP1 multiple inositol polyphosphate histidine 
phosphatase, 1 
0.53 4.59E-05 
231746_at MIXL1 Mix1 homeobox-like 1 (Xenopus laevis) 0.19 3.70E-05 
212020_s_at MKI67 antigen identified by monoclonal antibody 
Ki-67 
0.59 2.63E-05 
218883_s_at MLF1IP MLF1 interacting protein 0.32 4.46E-05 
217909_s_at MLX MAX-like protein X 0.59 4.60E-05 
218865_at MOSC1 MOCO sulphurase C-terminal domain 
containing 1 
0.29 3.14E-05 
202472_at MPI mannose phosphate isomerase 0.44 2.43E-05 
202911_at MSH6 mutS homolog 6 (E. coli) 0.32 5.06E-06 
211450_s_at mutS homolog 6 (E. coli) 0.35 6.02E-05 
222403_at MTCH2 mitochondrial carrier homolog 2 (C. 
elegans) 
0.82 6.54E-05 
223172_s_at MTP18 mitochondrial protein 18 kDa 0.54 9.12E-05 
201710_at MYBL2 v-myb myeloblastosis viral oncogene 
homolog (avian)-like 2 
0.15 4.50E-06 
203359_s_at MYCBP c-myc binding protein 0.47 4.24E-05 
201970_s_at NASP nuclear autoantigenic sperm protein 
(histone-binding) 
0.34 2.39E-05 
210289_at NAT8 N-acetyltransferase 8 (camello like) 0.46 1.26E-05 
210774_s_at NCOA4 nuclear receptor coactivator 4 0.66 7.21E-05 
214279_s_at NDRG2 NDRG family member 2 0.45 4.74E-05 
209224_s_at NDUFA2 NADH dehydrogenase (ubiquinone) 1 
alpha subcomplex, 2, 8kDa 
0.51 2.68E-06 
203606_at NDUFS6 NADH dehydrogenase (ubiquinone) Fe-S 
protein 6, 13kDa (NADH-coenzyme Q 
reductase) 
0.41 1.49E-05 
211080_s_at NEK2 NIMA (never in mitosis gene a)-related 
kinase 2 /// NIMA (never in mitosis gene 
a)-related kinase 2 
0.58 5.00E-05 
202007_at NID1 nidogen 1 0.42 2.93E-05 
225592_at NRM nurim (nuclear envelope membrane 
protein) 
0.38 7.51E-05 
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215093_at NSDHL NAD(P) dependent steroid 
dehydrogenase-like 
0.45 4.18E-05 
209731_at NTHL1 nth endonuclease III-like 1 (E. coli) 0.42 7.67E-05 
224581_s_at NUCKS Nuclear ubiquitous casein kinase and 
cyclin-dependent kinase substrate 
0.54 1.64E-05 
218768_at NUP107 nucleoporin 107kDa 0.57 2.01E-05 
219978_s_at NUSAP1 nucleolar and spindle associated protein 1 0.34 4.49E-05 
200077_s_at OAZ1 ornithine decarboxylase antizyme 1 /// 
ornithine decarboxylase antizyme 1 
0.69 3.81E-06 
215952_s_at ornithine decarboxylase antizyme 1 0.63 7.25E-05 
213599_at OIP5 Opa interacting protein 5 0.26 1.11E-05 
219105_x_at ORC6L origin recognition complex, subunit 6 
homolog-like (yeast) 
0.44 9.24E-06 
218589_at P2RY5 purinergic receptor P2Y, G-protein 
coupled, 5 
0.42 6.30E-05 
205719_s_at PAH phenylalanine hydroxylase 0.59 9.54E-05 
217583_at phenylalanine hydroxylase 0.45 6.65E-05 
201014_s_at PAICS phosphoribosylaminoimidazole 
carboxylase, 
phosphoribosylaminoimidazole 
succinocarboxamide synthetase 
0.67 1.09E-05 
226649_at PANK1 pantothenate kinase 1 0.40 7.53E-05 
228717_at Pantothenate kinase 1 0.43 1.60E-05 
227626_at PAQR8 progestin and adipoQ receptor family 
member VIII 
0.45 9.13E-05 
219148_at PBK PDZ binding kinase 0.21 6.79E-05 
205353_s_at PBP prostatic binding protein 0.33 1.12E-05 
211941_s_at prostatic binding protein 0.40 4.85E-05 
212857_x_at PC4 activated RNA polymerase II transcription 
cofactor 4 
0.85 9.48E-05 
201202_at PCNA proliferating cell nuclear antigen 0.31 5.75E-06 
218014_at PCNT1 pericentrin 1 0.37 1.32E-06 
203857_s_at PDIA5 protein disulfide isomerase family A, 
member 5 
0.45 4.39E-05 
207668_x_at PDIA6 protein disulfide isomerase family A, 
member 6 
0.52 3.66E-05 
208638_at protein disulfide isomerase family A, 
member 6 
0.59 9.74E-05 
221142_s_at PECR peroxisomal trans-2-enoyl-CoA reductase 0.43 4.09E-05 
212092_at PEG10 paternally expressed 10 0.35 1.35E-05 
209242_at PEG3 paternally expressed 3 0.42 5.01E-05 
207132_x_at PFDN5 prefoldin 5 0.72 3.29E-06 
221521_s_at Pfs2 DNA replication complex GINS protein 
PSF2 
0.14 1.23E-05 
200886_s_at PGAM1 phosphoglycerate mutase 1 (brain) 0.59 8.91E-06 
226623_at PHYHIPL phytanoyl-CoA hydroxylase interacting 
protein-like 
0.51 1.61E-05 
1559156_at PIAS1 Protein inhibitor of activated STAT, 1 0.52 1.42E-05 
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1563111_a_at PIGX phosphatidylinositol glycan, class X 0.62 3.43E-05 
203649_s_at PLA2G2A phospholipase A2, group IIA (platelets, 
synovial fluid) 
0.29 2.85E-05 
202240_at PLK1 polo-like kinase 1 (Drosophila) 0.36 8.56E-05 
204886_at PLK4 polo-like kinase 4 (Drosophila) 0.35 5.33E-05 
204887_s_at polo-like kinase 4 (Drosophila) 0.30 2.52E-05 
204519_s_at PLLP plasma membrane proteolipid 
(plasmolipin) 
0.26 5.06E-07 
204441_s_at POLA2 polymerase (DNA directed), alpha 2 
(70kD subunit) 
0.48 5.48E-05 
205909_at POLE2 polymerase (DNA directed), epsilon 2 
(p59 subunit) 
0.29 6.33E-05 
210830_s_at PON2 paraoxonase 2 0.78 5.20E-05 
213695_at PON3 paraoxonase 3 0.77 5.56E-06 
209482_at POP7 processing of precursor 7, ribonuclease P 
subunit (S. cerevisiae) 
0.38 2.78E-05 
235113_at PPIL5 peptidylprolyl isomerase (cyclophilin)-like 
5 
0.34 6.76E-05 
225203_at PPP1R16A protein phosphatase 1, regulatory 
(inhibitor) subunit 16A 
0.40 3.53E-05 
228010_at PPP2R2C protein phosphatase 2 (formerly 2A), 
regulatory subunit B (PR 52), gamma 
isoform 
0.34 4.48E-05 
39729_at PRDX2 peroxiredoxin 2 0.51 1.15E-05 
205053_at PRIM1 primase, polypeptide 1, 49kDa 0.34 5.45E-05 
226611_s_at PRR6 proline rich 6 0.48 9.49E-05 
206102_at PSF1 DNA replication complex GINS protein 
PSF1 
0.14 2.66E-06 
223808_s_at PTPMT1 protein tyrosine phosphatase, 
mitochondrial 1 
0.63 3.57E-05 
203554_x_at PTTG1 pituitary tumor-transforming 1 0.26 2.44E-05 
232037_at PUNC putative neuronal cell adhesion molecule 0.36 1.62E-05 
223032_x_at PX19 px19-like protein 0.49 6.65E-05 
222077_s_at RACGAP1 Rac GTPase activating protein 1 0.43 9.29E-05 
210216_x_at RAD1 RAD1 homolog (S. pombe) 0.50 6.28E-05 
204146_at RAD51AP1 RAD51 associated protein 1 0.25 1.61E-05 
213762_x_at RBMX RNA binding motif protein, X-linked 0.58 4.68E-05 
225310_at RNA binding motif protein, X-linked 0.63 6.29E-05 
201485_s_at RCN2 reticulocalbin 2, EF-hand calcium binding 
domain 
0.62 1.62E-05 
201486_at reticulocalbin 2, EF-hand calcium binding 
domain 
0.55 6.55E-06 
209085_x_at RFC1 replication factor C (activator 1) 1, 
145kDa 
0.67 9.39E-05 
1053_at RFC2 replication factor C (activator 1) 2, 40kDa 0.45 7.93E-05 
203696_s_at replication factor C (activator 1) 2, 40kDa 0.34 7.92E-06 
204127_at RFC3 replication factor C (activator 1) 3, 38kDa 0.21 3.79E-05 
204128_s_at replication factor C (activator 1) 3, 38kDa 0.19 6.17E-05 
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204023_at RFC4 replication factor C (activator 1) 4, 37kDa 0.25 9.36E-05 
203210_s_at RFC5 replication factor C (activator 1) 5, 
36.5kDa 
0.32 1.23E-05 
202963_at RFX5 regulatory factor X, 5 (influences HLA 
class II expression) 
0.48 4.23E-05 
212651_at RHOBTB1 Rho-related BTB domain containing 1 0.48 3.17E-06 
209507_at RPA3 replication protein A3, 14kDa 0.22 6.46E-05 
216505_x_at RPS10 /// 
LOC388885 
ribosomal protein S10 /// hypothetical 
LOC388885 
0.85 6.85E-05 
201476_s_at RRM1 ribonucleotide reductase M1 polypeptide 0.33 6.34E-05 
201890_at RRM2 ribonucleotide reductase M2 polypeptide 0.16 1.21E-05 
209773_s_at ribonucleotide reductase M2 polypeptide 0.10 6.98E-08 
1559946_s_at RUVBL2 RuvB-like 2 (E. coli) 0.65 8.70E-05 
234987_at SAMHD1 SAM domain and HD domain 1 0.47 4.83E-05 
209146_at SC4MOL sterol-C4-methyl oxidase-like 0.31 5.64E-05 
200832_s_at SCD stearoyl-CoA desaturase (delta-9-
desaturase) 
0.38 2.76E-05 
203453_at SCNN1A sodium channel, nonvoltage-gated 1 alpha 0.41 1.66E-06 
201339_s_at SCP2 sterol carrier protein 2 0.61 2.12E-05 
201286_at SDC1 syndecan 1 0.45 1.78E-05 
222021_x_at SDHA /// 
SDHAL2 
succinate dehydrogenase complex, subunit 
A, flavoprotein (Fp) /// succinate 
dehydrogenase complex, subunit A, 
flavoprotein-like 2 
0.57 4.64E-05 
244163_at SEMA3A Sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3A 
0.42 3.17E-05 
219194_at SEMA4G sema domain, immunoglobulin domain 
(Ig), transmembrane domain (TM) and 
short cytoplasmic domain, (semaphorin) 
4G 
0.42 6.66E-06 
1555851_s_at SEPW1 selenoprotein W, 1 0.45 1.88E-05 
230318_at SERPINA1 Serine (or cysteine) proteinase inhibitor, 
clade A (alpha-1 antiproteinase, 
antitrypsin), member 1 
0.50 5.46E-05 
220626_at SERPINA10 serine (or cysteine) proteinase inhibitor, 
clade A (alpha-1 antiproteinase, 
antitrypsin), member 10 
0.46 7.46E-05 
209443_at SERPINA5 serine (or cysteine) proteinase inhibitor, 
clade A (alpha-1 antiproteinase, 
antitrypsin), member 5 
0.38 7.06E-05 
206325_at SERPINA6 serine (or cysteine) proteinase inhibitor, 
clade A (alpha-1 antiproteinase, 
antitrypsin), member 6 
0.23 4.97E-07 
206386_at SERPINA7 serine (or cysteine) proteinase inhibitor, 
clade A (alpha-1 antiproteinase, 
antitrypsin), member 7 
0.17 9.35E-08 
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205576_at SERPIND1 serine (or cysteine) proteinase inhibitor, 
clade D (heparin cofactor), member 1 
0.55 5.83E-05 
235339_at SETDB2 SET domain, bifurcated 2 0.74 7.90E-05 
200753_x_at SFRS2 splicing factor, arginine/serine-rich 2 0.44 3.84E-07 
200754_x_at splicing factor, arginine/serine-rich 2 0.47 3.48E-06 
214882_s_at splicing factor, arginine/serine-rich 2 0.44 6.77E-05 
201739_at SGK serum/glucocorticoid regulated kinase 0.46 9.48E-05 
209980_s_at SHMT1 serine hydroxymethyltransferase 1 
(soluble) 
0.26 6.34E-05 
205339_at SIL TAL1 (SCL) interrupting locus 0.35 1.83E-05 
207974_s_at SKP1A S-phase kinase-associated protein 1A 
(p19A) 
0.68 7.32E-05 
203124_s_at SLC11A2 solute carrier family 11 (proton-coupled 
divalent metal ion transporters), member 2 
0.65 1.70E-05 
230687_at SLC13A3 solute carrier family 13 (sodium-
dependent dicarboxylate transporter), 
member 3 
0.25 3.11E-05 
227506_at SLC16A9 solute carrier family 16 (monocarboxylic 
acid transporters), member 9 
0.44 7.58E-05 
226728_at SLC27A1 solute carrier family 27 (fatty acid 
transporter), member 1 
0.61 7.82E-06 
202499_s_at SLC2A3 solute carrier family 2 (facilitated glucose 
transporter), member 3 
0.36 1.82E-05 
218494_s_at SLC2A4RG SLC2A4 regulator 0.28 3.53E-05 
202830_s_at SLC37A4 solute carrier family 37 (glycerol-6-
phosphate transporter), member 4 
0.41 3.29E-06 
219795_at SLC6A14 solute carrier family 6 (amino acid 
transporter), member 14 
0.33 3.82E-07 
202219_at SLC6A8 solute carrier family 6 (neurotransmitter 
transporter, creatine), member 8 
0.38 1.58E-05 
204240_s_at SMC2L1 SMC2 structural maintenance of 
chromosomes 2-like 1 (yeast) 
0.37 1.66E-05 
201770_at SNRPA small nuclear ribonucleoprotein 
polypeptide A 
0.48 6.59E-05 
206055_s_at SNRPA1 small nuclear ribonucleoprotein 
polypeptide A' 
0.55 2.05E-05 
203832_at SNRPF small nuclear ribonucleoprotein 
polypeptide F 
0.33 2.23E-05 
209891_at SPBC25 spindle pole body component 25 homolog 
(S. cerevisiae) 
0.24 8.99E-05 
212558_at SPRY1 sprouty homolog 1, antagonist of FGF 
signaling (Drosophila) 
0.52 3.19E-06 
227752_at SPTLC2L serine palmitoyltransferase, long chain 
base subunit 2-like (aminotransferase 2) 
0.25 1.98E-05 
213562_s_at SQLE squalene epoxidase 0.32 9.73E-05 
200652_at SSR2 signal sequence receptor, beta (translocon-
associated protein beta) 
0.62 1.19E-05 
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203015_s_at SSX2IP synovial sarcoma, X breakpoint 2 
interacting protein 
0.58 6.98E-05 
204092_s_at STK6 serine/threonine kinase 6 0.54 5.75E-05 
200783_s_at STMN1 stathmin 1/oncoprotein 18 0.29 3.12E-06 
213881_x_at SUMO2 SMT3 suppressor of mif two 3 homolog 2 
(yeast) 
0.70 6.22E-05 
41037_at TEAD4 TEA domain family member 4 0.56 2.84E-05 
214063_s_at TF transferrin 0.65 7.67E-05 
204731_at TGFBR3 transforming growth factor, beta receptor 
III (betaglycan, 300kDa) 
0.59 4.36E-05 
203046_s_at TIMELESS timeless homolog (Drosophila) 0.44 6.21E-05 
1554408_a_at TK1 thymidine kinase 1, soluble 0.27 1.87E-05 
202338_at thymidine kinase 1, soluble 0.23 3.58E-05 
222477_s_at TM7SF3 transmembrane 7 superfamily member 3 0.62 7.20E-06 
213352_at TMCC1 transmembrane and coiled-coil domain 
family 1 
0.56 6.84E-06 
1554483_at TMEM37 transmembrane protein 37 0.22 7.39E-05 
1554485_s_at transmembrane protein 37 0.20 1.92E-05 
234672_s_at TMEM48 transmembrane protein 48 0.42 8.72E-05 
203432_at TMPO thymopoietin 0.39 9.58E-05 
218467_at TNFSF5IP1 tumor necrosis factor superfamily, 
member 5-induced protein 1 
0.60 5.39E-05 
1552977_a_at TNRC5 trinucleotide repeat containing 5 0.41 8.94E-05 
201292_at TOP2A topoisomerase (DNA) II alpha 170kDa 0.32 2.41E-05 
210052_s_at TPX2 TPX2, microtubule-associated, homolog 
(Xenopus laevis) 
0.49 3.64E-06 
204033_at TRIP13 thyroid hormone receptor interactor 13 0.32 2.60E-07 
209108_at TSPAN6 tetraspanin 6 0.38 3.63E-05 
209109_s_at tetraspanin 6 0.33 2.03E-05 
203824_at TSPAN8 tetraspanin 8 0.17 4.56E-05 
212320_at TUBB tubulin, beta polypeptide 0.34 3.69E-06 
213726_x_at TUBB2 tubulin, beta, 2 0.51 4.74E-05 
201714_at TUBG1 tubulin, gamma 1 0.62 9.41E-06 
209077_at TXN2 thioredoxin 2 0.63 9.26E-06 
202589_at TYMS thymidylate synthetase 0.33 7.93E-06 
202954_at UBE2C ubiquitin-conjugating enzyme E2C 0.32 9.95E-05 
223229_at UBE2T ubiquitin-conjugating enzyme E2T 
(putative) 
0.33 4.53E-05 
202706_s_at UMPS uridine monophosphate synthetase (orotate 
phosphoribosyl transferase and orotidine-
5'-decarboxylase) 
0.72 5.63E-05 
202330_s_at UNG uracil-DNA glycosylase 0.19 5.91E-07 
206771_at UPK3A uroplakin 3A 0.22 7.78E-05 
203856_at VRK1 vaccinia related kinase 1 0.35 4.39E-05 
203797_at VSNL1 visinin-like 1 0.18 1.78E-05 
203798_s_at visinin-like 1 0.17 4.27E-05 
229551_x_at ZNF367 zinc finger protein 367 0.34 2.42E-05 
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1To be included in this table, differential gene expression had to meet a statistical cutoff of P<0.0001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table S4 (Continued) 
Probe ID Gene Symbol Gene Title 
Fold 
Difference 
P 
204026_s_at ZWINT ZW10 interactor 0.17 1.27E-05 
205675_at   0.46 7.01E-05 
215528_at  MRNA; cDNA DKFZp586O1318 (from 
clone DKFZp586O1318) 
0.63 5.34E-05 
221588_x_at   0.36 1.46E-05 
222044_at   0.64 7.44E-05 
227349_at  CDNA FLJ11381 fis, clone 
HEMBA1000501 
0.37 9.98E-05 
227350_at  CDNA FLJ11381 fis, clone 
HEMBA1000501 
0.20 1.95E-05 
228143_at   0.63 9.89E-05 
229500_at   0.75 2.55E-05 
230960_at  Transcribed locus 0.37 1.60E-06 
231007_at 1 Transcribed locus, weakly similar to 
XP_375099.1 PREDICTED: similar to 
hypothetical protein FLJ25224 [Homo 
sapiens] 
0.40 1.02E-06 
236201_at 1 Transcribed locus 0.30 3.45E-05 
238075_at 1 Transcribed locus 0.32 4.22E-05 
240422_at 1 Transcribed locus 0.38 6.43E-05 
241607_at 1 LOC440702 0.38 5.54E-05 
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